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Abstract 
Chronic obstructive pulmonary disease (COPD) patients who suffer recurrent 
exacerbations are a recognised clinical phenotype. Pulmonary rehabilitation is 
considered a cornerstone treatment in the management of COPD. The aim of this 
thesis was to investigate how frequent exacerbators respond to pulmonary 
rehabilitation in terms of clinical outcomes and inflammation. Study 1 suggested 
that frequent exacerbators were less likely to complete pulmonary rehabilitation 
(44% vs 69%; p=0.025), but those who completed experienced clinically important 
improvements in outcomes. Study 2 demonstrated that fibrinogen concentrations 
were significantly reduced in both frequent and infrequent exacerbators (p=0.033), 
and total leukocyte (p=0.018) and neutrophil (p=0.018) counts reduced in frequent 
exacerbators only upon completion of pulmonary rehabilitation. Study 3 suggested 
a tendency towards an increase in MKP-1 anti-inflammatory gene expression in 
response to corticosteroid treatment (2hr, p=0.060) in both frequent and infrequent 
exacerbators upon completion of pulmonary rehabilitation. Study 4 showed that an 
acute bout of exercise at the beginning of pulmonary rehabilitation induced 
increases in leukocyte counts (p=0.002) and immature neutrophils (p=0.002) in 
both groups. No differences in inflammatory responses to acute exercise were 
observed with an acute bout of exercise at the end of pulmonary rehabilitation in 
both groups. Study 5 suggested that frequent exacerbators recorded fewer daily 
steps (d=0.3) and spent less time in light (d=0.8) and moderate-to-vigorous 
activities (d=0.3). There were no definitive differences in inflammation between 
frequent and infrequent exacerbators. Overall, this thesis shows that pulmonary 
rehabilitation should be encouraged in frequent exacerbators as they stand to have 
significant improvements in clinical outcomes and resolution of inflammation.   
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1 Chapter ONE 
Literature Review 
 Definition and burden of COPD 
Chronic Obstructive Pulmonary Disease (COPD) is a common, preventable and 
treatable disease characterised by persistent respiratory symptoms and largely 
irreversible and progressive airflow limitation that is due to airway and/or alveolar 
abnormalities induced by exposure to noxious stimuli (Global Initiative for Chronic 
Obstructive Lung Disease (GOLD), 2019).  
COPD is a leading cause of morbidity and mortality worldwide that triggers an 
economic and social burden that is both substantial and increasing (Lozano et al., 
2012). There are estimated to be 1.2 million diagnosed COPD patients in the United 
Kingdom (UK), however, estimates believe that there are over 3 million people living 
with the condition (National Institute for Health and Care Excellence (NICE), 2018). 
COPD results in approximately 23,000 deaths a year in the UK (Department of 
Health, 2012a), and represents a significant expense (annual cost to the National 
Health Service (NHS) of £1.9 billion) as the second largest cause of emergency 
hospital admissions (British Lung Foundation, 2017).  
 COPD disease development  
1.2.1 Risk factors 
Historically, the most common risk factor for COPD has been tobacco smoking 
(Quint & Wedzicha, 2007). Prevalence of COPD is higher in smokers and ex-
smokers when compared to non-smokers (Fukuchi et al., 2004; Halbert et al., 2006; 
Menezes et al., 2005). Chronic exposure to an irritant, such as tobacco smoke, 
amplifies the normal inflammatory response in the lung (Rabe et al., 2007), causing 
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a progressive decline in lung function and increase in airflow limitation (de Godoy 
et al., 1996; Fabbri & Rabe, 2007; Hoenderdos & Condliffe, 2013). 
It has been estimated that at least 25% of smokers will develop clinically significant 
COPD (Lokke et al., 2006). However, research has shown that 25-45% of patients 
with chronic airflow limitation have never smoked highlighting other potential causal 
components (Eisner et al., 2010; Salvi & Barnes, 2009). Causal components such 
as; indoor air pollution, passive smoking, exposure to occupational dusts and/or 
chemicals have been identified and are increasingly considered to be important 
contributors to the pathogenesis of COPD (GOLD, 2019). Nevertheless, due to the 
nature of COPD development in smokers and non-smokers, it has long been 
advocated that genetic components are also important factors in COPD 
development (Smith & Harrison, 1997). A key risk factor in patients who have never 
smoked is a severe hereditary deficiency of α1-antitrypsin (Stoller & Aboussouan, 
2005). α1-antitrypsin has a primary role of protecting tissues (e.g. lung and the 
airways) from the damaging effects of proteases derived from inflammatory cells, 
in particular neutrophil elastase, which is considered to be actively involved in 
destruction of lung tissue (e.g. elastin breakdown) and disease pathophysiology 
(Hoenderdos & Condliffe, 2012). Recent evidence has proposed a further 97 
genetic signals which may be involved in the pathogenesis of COPD, reflecting a 
complex genetic component which stems beyond α1-antitrypsin alone (Wain et al., 
2017). Such genetic components may become targets of future therapies to prevent 
chronic airflow limitation (Wain et al., 2017).  
1.2.2 Pathology 
To be able to produce therapies that target the management of COPD, it is 
important to understand the underlying pathophysiology. Chronic airflow limitation 
in COPD is caused by a mixture of small airways disease (obstructive bronchiolitis), 
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mucus hypersecretion (chronic bronchitis) and parenchymal destruction 
(emphysema) (GOLD, 2019). These pathological changes are underpinned by 
chronic inflammatory processes including increased number of inflammatory cells 
within the lung and structural changes due to exposure to inhaled tobacco smoke 
and/or irritants (Lee, Taneja & Vassallo, 2012). One identified progressive process 
is airway remodelling causing a loss of elasticity in lung tissue, especially the 
recoiling component, due to emphysematous destruction (Decramer, Janssens & 
Miravitlles, 2012). This emphysematous destruction and repeated tissue damage 
can lead to the development of fibrotic tissue reducing the expansion capacity of 
the lungs and the ability of the lungs to fully clear on exhalation (Ferguson, 2006). 
The risk of dynamic hyperinflation, a severe form of breathlessness for COPD 
patients, increases as a result of gas trapping that follows the combination of loss 
of elasticity within the alveoli tissue and narrowing of the airways (Ferguson, 2006). 
Furthermore, structural changes including the loss of; respiratory alveoli, 
bronchioles and alveolar ducts have been seen to occur in COPD leading to 
mucociliary dysfunction and reduced mucous clearance (Quint & Wedzicha, 2007). 
Typically, the inflammation and structural changes increase with COPD severity 
and appear to persist within the lung even in the absence of further exposure to risk 
factors.  
1.2.3 Inflammatory cells and mediators 
COPD is underpinned by chronic inflammation in both the systemic and airway 
compartments (Rovina, Koutsoukou & Koulouris, 2013; Stockley, Mannino & 
Barnes, 2009). A complex network of immune pathways, including cells and 
signalling proteins are involved in the inflammatory processes resulting in disease 
pathogenesis and progression.  
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1.2.3.1 Macrophages 
Macrophages are important cells in the immune response as they are involved in 
the process of efferocytosis whereby apoptotic cells are removed (Mosser & 
Edwards, 2008). In COPD, macrophage numbers are increased in the lungs and 
are believed to orchestrate inflammation through the release of chemokines that 
attract many other immune cells including neutrophils (Barnes, 2004; Barnes, 
2008). The continued elevated presence of macrophages in the lungs may be partly 
explained by the defective nature of these cells in COPD populations to engulf 
apoptotic cells, and hence failure to adequately resolve inflammation (Hodge et al., 
2003).  
1.2.3.2 Epithelial cells  
Epithelial cells play an important role in protecting the body from noxious 
substances as they act as a defensive barrier between the external environment 
and the internal milieu (Gao et al., 2015). Airway epithelial cells are important in the 
defence of the airways as they produce mucus from goblet cells and secrete 
antioxidants (Barnes, 2016). Epithelial cells are important in the pathogenesis of 
COPD as exposure to cigarette smoke, or other irritants, triggers these cells to 
release inflammatory cytokines and chemotactic factors attracting inflammatory 
cells to the lungs (Barnes 2008). Epithelial cells also play a role in the fibrosis of 
small airways due to this pro-inflammatory response to noxious stimuli combined 
with a loss of cilia resulting in irreversible narrowing of the airways (Hogg et al., 
2004). Alongside macrophages, epithelial cells can release proteases such as 
matrix metalloproteinase-9 (MMP-9), which causes elastin degradation contributing 
towards emphysema (Barnes, 2008). Acute and/or chronic exposure of these cells 
to noxious material increases the pro-inflammatory response (e.g. increases in 
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MMP-9) shifting the balance between pro- and anti-inflammatory in favour of pro-
inflammatory mediators (Barnes, 2016).  
1.2.3.3 Neutrophils  
Neutrophils are the most dominant leukocyte in the circulation, accounting for 50-
60% of blood leukocytes and are a part of the granulocyte family. They play a key 
role in the innate immune response, acting as the first line of defence against 
microbial invasion or tissue debris removal (Bouman et al., 2004; Malm, Lenkei & 
Sjodin, 1999; Nieman, 2001). Neutrophil recruitment to sites of inflammation is 
usually central to bacterial clearance and inflammation resolution (Hoenderdos & 
Condliffe, 2013).  
Whilst recruitment of neutrophils can be seen to occur in healthy lungs, this is 
amplified in COPD whereby neutrophils are recognised to be the major immune cell 
type in pathogenesis of the disease (Quint & Wedzicha, 2007). Elevated levels of 
neutrophils have been observed in both the lung and systemic compartments in 
patients with COPD (Hoenderdos & Condliffe, 2013). Evidence has supported the 
importance of neutrophils in COPD as elevated neutrophil counts in the lung have 
been linked to the: degree of airway obstruction (Pilette et al., 2007), development 
and severity of emphysema (Parr et al., 2006), and rate of lung function decline 
(Donaldson et al., 2005a). The amplified neutrophil response in COPD shifts the 
balance between protease/antiprotease in favour of lung tissue destruction (Quint 
& Wedzicha, 2007). Neutrophils are prominent in COPD due to the chronic 
inflammatory responses characterised by elevated macrophage numbers in the 
lung releasing chemokines to recruit neutrophils (Barnes, 2004; Barnes, 2008). 
Exposure to airway irritants also triggers an inflammatory response attracting 
neutrophils to the lungs (Barnes, 2016). The chronic accumulation of neutrophils in 
the airways can also lead to tissue damage due to production of reactive oxygen 
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species (ROS) exceeding antioxidant defences (Barnes, 2016). This state of 
oxidative stress has also been proposed to impair antiprotease defences (Cavarra 
et al., 2001), further accelerating the breakdown of elastin in the lung parenchyma 
(Barnes, 2016).  
1.2.3.4 Eosinophils 
Eosinophils, like neutrophils, are part of the granulocyte family. Eosinophils are 
responsible for triggering inflammatory responses in allergic disorders such as 
asthma (Walford & Doherty, 2014). Eosinophilic inflammation is more apparent in 
asthma compared to the neutrophilic inflammation observed in COPD (Barnes, 
2008). However, eosinophils can be observed to be elevated in COPD and are seen 
to play an increasing role in disease progression and treatment, particularly in 
patients with asthmatic features  (Tashkin & Wechsler, 2018).  
1.2.3.5 T cells 
T cells are another important cell type which have been shown to play a role in 
airway remodelling (Kim & Criner, 2013). T cells have been observed to be elevated 
in patients with COPD, especially patients with more severe airflow limitation 
(Saetta et al., 1998). T cells have also been shown to orchestrate inflammatory 
processes and accumulate in the lung of COPD patients resulting in structural 
damage (Barnes, 2008).  
1.2.3.6 Cytokines and chemokines 
Inflammatory mediators including cytokines and chemokines have also been 
implicated in the development of COPD (Donnelly & Barnes, 2006). Cytokines and 
chemokines derived from inflammatory cells in the lung interact with each other in 
a complex manner to perpetuate the chronic inflammatory response, via the 
recruitment of further inflammatory cells (Barnes, 2014). 
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Cytokines are small secreted proteins released by cells which interact with other 
cells (e.g. signalling) (Zhang & An, 2007). Several cytokines have been implicated 
in COPD as mediators of chronic inflammation (Barnes, 2008; Barnes, 2009). 
Tumour necrosis factor alpha (TNF-α) is one of these cytokines increased in the 
airways of COPD patients (Mukhopadhyay, Hoidal & Mukherjee, 2006), and is 
commonly produced by macrophages and monocytes during acute inflammation 
causing a diverse range of signalling events (Idriss & Naismith, 2000). Interleukin-
6 (IL-6) is another cytokine which stimulates the acute phase response in the event 
of tissue injury or infection (Tanaka, Narazaki & Kishimoto, 2014). IL-6 levels are 
significantly elevated in the airways and circulation of COPD patients playing a role 
in the amplification of inflammation underpinning the disease (de Moraes et al., 
2014).  
Chemokines are proteins with the ability to stimulate the recruitment and activation 
of leukocytes (Groves & Jiang, 1995). Several chemokines have also been 
implicated in the development of COPD (Barnes, 2014). Chemokine ligand-8 
(CXCL8), also known as IL-8, is one of the chemokines implicated in COPD as 
characterised by increased concentrations in sputum (Aaron et al., 2001; Keatings 
et al., 1996), and is secreted from macrophages, T cells, epithelial cells, and 
neutrophils (Barnes, 2014). CXCL8  induces chemotaxis of neutrophils towards 
sites of inflammation (Russo et al., 2014). CXCL8 is believed to be a key chemokine 
in the self-perpetuating notion of chronic persistent inflammation in both the airways 
and circulation of COPD (Traves et al., 2002). CXCL8 plays a role in neutrophil 
activation via chemokine receptor-1 (CXCR1) and is chemotactic for neutrophils via 
CXCR2, which can also be activated by CXCL1 (Barnes, 2014). Like CXCL8, 
concentrations of CXCL1 have been also observed to be increased in the airways 
of COPD patients (Traves et al., 2002).  
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Overall, the aforementioned cells and mediators underpin the integral role chronic 
inflammation, both systemically and in the airways, plays in the pathophysiology of 
COPD (Di Stefano et al., 1998; Hogg et al., 2004). Current understanding 
demonstrates that inflammatory cells and mediators play a key role in the 
development of airflow limitation and increasingly in disease symptomology 
(Rennard, 2007). 
 COPD disease activity 
1.3.1 Symptoms 
A clinical diagnosis of COPD is considered in any individual who has dyspnoea, 
chronic cough or frequent sputum production, and an underlying history of chronic 
exposure to risk factors for COPD (NICE, 2018).  
1.3.1.1 Dyspnoea 
The most common symptom in COPD is chronic and progressive dyspnoea. 
Chronic dyspnoea is a major cause of disability and anxiety (Miravitlles et al., 2014), 
whereby patients have often described the sensation of dyspnoea as a starvation 
of air, periods of gasping, chest heaviness, and an increased effort required to 
breathe (Elliott et al., 1991). The progressive nature of dyspnoea in COPD occurs 
because of structural changes with disease progression, e.g. narrowing of the 
airways (Quint & Wedzicha 2007). Muscle deconditioning, commonly observed in 
COPD, also contributes to the increased requirement of ventilation during exertion 
leading to heightened symptoms of dyspnoea (Roig et al., 2011). However, there 
are other neural and perceptual factors which can influence the sensation of 
dyspnoea in COPD (O’Donnell et al., 2007). For example, disruption of the 
respiratory feedback pathways to the brain (O’Donnell et al., 2007). This illustrates 
the multicomponent factors associated with assessing dyspnoea in COPD.  
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1.3.1.2 Cough  
Persistent coughing is also a characteristic of COPD and is often the first symptom 
to present. Coughing can often be disregarded as a symptom as it is often 
perceived as an expected consequence of exposure to noxious material (GOLD, 
2019). During the early stages of COPD, coughing may be intermittent, but with 
development, coughing can be present every day in varying degrees. The causes 
of cough in COPD are poorly understood but are in part believed to be as a result 
of airway inflammation (Smith & Woodcock, 2006). It has also been suggested that 
mucus secretion is also a component in coughing in COPD (Joos et al., 2003). 
Chronic coughing in COPD can be productive or unproductive in terms of sputum 
production (Cho et al., 2016). Although cough is a major symptom of COPD, airflow 
limitation can develop in the absence of a cough and sputum production.  
1.3.1.3 Sputum 
Frequent sputum production is present in up to 30% of COPD patients (GOLD, 
2019). Sputum production is common in COPD due to the mucus hypersecretion 
that comes with disease development (GOLD, 2019). Production of sputum can be 
intermittent in periods of bacterial infections with expectorated sputum used by 
clinicians to identify causative pathogens and guide treatment (Allinson et al., 
2016).  
1.3.1.4 Chest  
Chest tightness and wheezing are also symptoms commonly experienced by COPD 
patients. These symptoms can vary across the timespan of a single day, and 
severity is sensitive to change across days. However, when considering respiratory 
symptoms such as chest tightness and wheezing, it is important to consider that 
other factors such as comorbidities can contribute to the severity of these symptoms 
(Lee et al., 2017).  
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1.3.2 Systemic manifestations and co-morbidities  
Although thorough assessment of pulmonary manifestations and respiratory 
symptoms are essential for diagnosis, the disease stems beyond the pulmonary 
compartment with systemic effects associated with the lung disease triggering the 
development of comorbidities (Decramer et al., 2008; Fabbri et al., 2008). These 
comorbidities can independently affect health status and outcomes, increasing the 
risk of health care resource use (Mannino et al., 2008; Sin et al., 2006).  
Evidence has found that up to 50-60% of COPD patients can present with at least 
one comorbidity (Crisafulli et al., 2008; Crisafulli et al., 2010). Some of the most 
common comorbidities in COPD include: heart failure, diabetes, osteoporosis, 
malnutrition and anxiety disorders (Cavailles et al., 2013). However, such is the 
diversity of comorbidities being presented with COPD; it is important to assess for 
appropriate individualised treatment plans (Cavailles et al., 2013). Comorbidities 
alongside COPD can have a negative impact on clinical outcomes and may 
contribute to disease progression and morbidity (Cavailles et al., 2013).  
However, whether comorbidities are a direct result of COPD progression remains 
unclear. Some comorbidities have been suggested to be directly caused by COPD, 
for example, pulmonary artery disease and malnutrition. Other comorbidities such 
as anxiety, depression, obesity, osteoporosis, diabetes and sleep disturbance have 
not been directly identified to be a result of COPD (Cavailles et al., 2013). The fact 
that smoking is also a risk factor for many of these comorbidities makes it difficult 
to draw conclusions about relationships (Chatila et al., 2008). However, the majority 
of these extrapulmonary manifestations have a common ground of chronic systemic 
inflammation (Cavailles et al., 2013), and may contribute towards the exacerbation 
of respiratory symptoms (Hyeon Jeong et al., 2016).  
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1.3.2.1 Systemic inflammation  
Systemic inflammation has been suggested to play a key role in the development 
of systemic manifestations of COPD (Vestbo, 2007). The presence of systemic 
inflammation in COPD has previously been confirmed by elevated levels of markers 
of inflammation including C-reactive protein (CRP), IL-6, fibrinogen, and leukocytes 
(Gan et al., 2004).  
Fibrinogen and CRP are acute phase proteins found in circulating plasma which 
increase in response to inflammation (Jain, Gautam & Naseem, 2011). The acute 
phase response is a systemic response to local or systemic disorders affecting 
homeostasis commonly caused by infection or tissue injury (Gordon & Koy, 1985; 
Grus et al., 1999). As part of the acute phase response, pro-inflammatory cytokines 
are released and inflammatory cells are activated leading to further production of 
cytokines and other inflammatory mediators (Gruys et al., 2005; Jain, Gautam & 
Naseem, 2011). Fibrinogen is an acute phase protein which is converted into fibrin 
via the action of thrombin which forms a fibrous mesh that impedes blood flow 
during the clotting process (Duvoix et al., 2013). Fibrinogen concentration increases 
in response to increased IL-6 production and plays an important role in maintaining 
haemostasis (Gabay & Kushner, 1999; Mackiewicz et al., 1991). Fibrinogen is a 
commonly used marker to assess for cardiovascular disease risk (Stec et al., 2000), 
but is becoming a more prominent marker in COPD. In COPD, fibrinogen levels are 
elevated and considered to be an ‘ideal’ blood biomarker for the existence of 
systemic inflammation (Duvoix et al., 2013). CRP is also an acute phase protein 
which is increased in the plasma in response to infection via the action of IL-6 
(Ridker, 2016). CRP is believed to play a key role in the innate immune system by 
binding to Fc receptors resulting in the production of proinflammatory cytokines to 
amplify the inflammatory response (du Clos, 2000). CRP levels are raised in COPD 
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patients and are associated with poorer lung function and exercise capacity (Aksu 
et al., 2013). Elevated CRP levels have also been suggested to be indicative of low-
grade systemic inflammation in COPD (Mannino, Ford & Redd, 2003; Sin & Man, 
2003).  
The identification of these biomarkers in COPD have been associated with negative 
outcomes. For example, heightened persistent systemic inflammation has been 
associated with a higher incidence of exacerbations and an accelerated decline in 
lung function demonstrating the importance of assessing these biomarkers in 
COPD (Agusti et al., 2012; Hurst et al., 2006).  
1.3.3 Exacerbations of COPD 
1.3.3.1 Defining exacerbations 
Exacerbations are defined as events in the natural course of COPD, characterised 
by an acute worsening of respiratory symptoms beyond that of day-to-day variation 
that results in additional therapy (GOLD, 2019). Exacerbations of COPD are 
important events in COPD as they: accelerate lung function decline (Donaldson et 
al., 2002; Kanner, Anthonisen & Connett, 2001), negatively impact on quality of life 
(Kessler et al., 2006 Spencer et al., 2004), accelerate physical activity decline 
(Demeyer et al., 2018), and increase respiratory symptoms (Seemungal et al., 
2000).   
The severity of exacerbations is variable. Some patients present with mild to 
moderate COPD exacerbations explained by worsening daily symptoms requiring 
treatment with antibiotics and oral corticosteroids, whilst others may display with 
more severe exacerbations requiring hospitalisation and in some instances 
prolonged ventilator support as a consequence of acute respiratory failure 
(Bafadhel et al., 2011; Seemungal et al., 2000; Spruit et al., 2016a). Anthonisen et 
al. (1987) have previously defined acute exacerbations based on the following 
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clinical criteria: increased sputum volume, increased sputum purulence, and 
increased dyspnoea. Using these criteria, Anthonisen et al. (1987) categorised 
exacerbations into 3 categories: mild (one symptom present plus one of the 
following: upper respiratory tract infection (URTI) within 5 days, increased wheezing 
or cough, fever without an obvious source, 20% increase in respiratory rate, heart 
rate raised above baseline), moderate (any two symptoms present), and severe (all 
three symptoms present). COPD patients usually recover from exacerbations within 
7-10 days of onset, but in some cases, this can be prolonged with approximately 
20% of exacerbations not reaching a recovered pre-exacerbation state 8 weeks 
after onset (Seemungal et al., 2000).  
The Anthionsen et al. (1987) definition of exacerbations has been developed over 
the years. The categorisation of exacerbations as mild, moderate or severe are still 
used but have been adapted based on treatments required (e.g. use of short-acting 
beta2-adrenoceptor agonist (SABA), oral corticosteroids/antibiotics, 
hospitalisation). This is considered to provide a more tailored categorisation of 
exacerbations with the severity of exacerbations also being found to relate to a 
cause (GOLD, 2019). 
1.3.3.2 Causes of exacerbations 
Exacerbations are the most prominent cause of hospitalisation in COPD accounting 
for 50-75% of healthcare costs related to COPD (Donaire-Gonzalez et al., 2015), 
with 60% of these exacerbations caused by respiratory (viral or bacterial) infection 
(Barnes, 2000).  
Bacterial exacerbations account for a substantial amount of COPD exacerbations 
with increased colonisation by pathogenic strains being a suggested cause of an 
exacerbation (Sethi, 2004). One of the main characteristics of bacterial 
exacerbations is the presence of purulent sputum reflecting an increase in 
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inflammatory mediators which can be seen in mild, moderate and severe 
exacerbations (Brusse-Keizer et al., 2009; Soler et al., 2012). In bacterial infections, 
H. influenza, S. pneumoniae, and M. catarrhalis are the most prominent pathogens 
in the lower airways of patients with exacerbations of COPD (Blasi et al., 2002; 
Monso et al., 1995; Pela et al., 1998; Woodhead et al., 2011).  
Viral exacerbations also account for a significant total of exacerbations of COPD 
(Wedzicha & Donaldson, 2003). Viral exacerbations are more likely to lead to 
severe exacerbations (e.g. hospitalisation) and greater level of airway inflammation 
(Wedzicha & Donaldson, 2003). Common viruses resulting in respiratory tract 
infections in COPD include; rhinovirus, coronavirus, influenza A and B (Wedzicha 
& Donaldson, 2003).  
It is also important to note that changes in the environment can cause 
exacerbations including exposure to outdoor pollution/dusts and changes in 
temperature (sudden changes from hot to cold or vice versa) (Sapey & Stockley, 
2006). There are also several non-physical causes of hospital admissions for 
exacerbations of COPD to consider. Heightened levels of anxiety and depression 
have been shown to be a mainstay during exacerbations and are often an 
underlying cause of hospital admission (Kessler et al., 2006; Laurin et al., 2011; Ng 
et al., 2007; Spruit et al., 2016a). Other non-physical factors such as poor coping 
skills, social isolation and poor resilience have been suggested to be other 
underlying causal factors for hospitalised exacerbations (Fitzgerald & Poureslami, 
2014; Kessler et al., 2006; Spruit et al., 2016a).  
1.3.3.3 Exacerbations and Inflammation 
Exacerbations are usually inflammatory events with increases in several markers 
of inflammation being seen within the airways and systemically (Perera et al., 2007). 
Inflammatory markers such as CRP, fibrinogen, IL-6, TNF-α, and leukocytes have 
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been seen to be increased in the event of an exacerbation (Johansson et al., 2014; 
Markoulaki et al., 2011).  
CRP, fibrinogen, and neutrophil counts are observed to be elevated in a stable state 
in COPD (Aksu et al., 2013; Duvoix et al., 2013; Hoenderdos & Condliffe, 2013), 
but during exacerbations, these markers of systemic inflammation are elevated 
further (Hurst et al., 2006; Wedzicha et al., 2000). Evidence has suggested that 
during exacerbations circulating neutrophils: are dysregulated through up-regulated 
expression of pro-inflammatory related genes, produce more ROS and elastase, 
and have an enhanced expression of cellular adhesion molecules (Fujimoto et al., 
2005; Noguera et al., 1998; Oudijk et al., 2005; Vaitkus et al., 2013). This 
recruitment of neutrophils to sites of inflammation is mediated by intra- and extra-
cellular signalling. Blood neutrophils are identified by cell surface expression of 
CD16 & CD45  and undergo adhesion, mediated by CD62L, to the endothelial cells 
before rolling down the endothelium. During this rolling process cell activation 
occurs, characterised by increased CD11b and CD66b expression, before arresting 
on the endothelium and strengthening adhesion. This stronger adhesion leads to 
cell spreading before neutrophil extravasation into tissue (Ley et al., 2007) (Figure 
1.1). 
 
Figure 1.1 Process of neutrophil adhesion and activation cascade. Neutrophils are 
identified by high expression of CD16 (FcγRIIIb) and CD45. Adhesion cascade 
comprises of three steps: rolling (mediated by selectins (e.g. CD62L)), activation 
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(mediated by chemokines), and arrest (mediated by integrins). CD62L (L-selectin) 
is shed during the process of neutrophil activation, with an upregulation in CD11b 
(MAC-1) and CD66b as the process of activation progresses during migration. 
Adapted from Ley et al., (2007). 
 
Following exacerbation, blood parameters as well as lung function are expected to 
eventually return to pre-exacerbation levels, however, on rare occasions, persistent 
changes can be seen (Donaldson et al., 2015; Donaldson & Wedzicha, 2017). 
Measuring these cellular responses is important as patients who present with 
persistent inflammation tend to have more severe COPD and are more at risk of 
mortality and suffering future exacerbations compared to those without systemic 
inflammation (Agusti et al., 2012). However, it is not yet known whether persistent 
systemic inflammation is a cause or effect of increased exacerbation risk (Agusti et 
al., 2012).   
 COPD disease severity 
1.4.1 Airflow limitation 
In order to confirm the presence and severity of airflow limitation (and hence make 
the diagnosis of COPD) spirometry is performed in individuals with dyspnoea, 
chronic cough or sputum production and a history of exposure to risk factors. A 
clinical diagnosis of COPD in such patients is based on a post-bronchodilator 
spirometry reading of Forced Expiratory Volume in one second (FEV1)/Forced Vital 
Capacity (FVC) <0.70 confirming the presence of airflow limitation (Gruffydd-Jones, 
2012). The GOLD consensus report on the global strategy for the diagnosis, 
management and prevention of COPD in 2001 (GOLD, 2001), categorised COPD 
in four stages based on severity of airflow obstruction: stage 1 (mild, FEV1 ≥ 80% 
of predicted), stage 2 (moderate, FEV1 50-80% of predicted), stage 3 (severe, FEV1 
30-50% of predicted), and stage 4 (very severe, FEV1 <30% of predicted).  
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Despite the widespread use of spirometry for the diagnosis of COPD, there are 
limitations with this method. There is a weak correlation between FEV1, symptom 
severity, and patient health status (Jones, 2009), and spirometry provides little 
information on disease activity (Paone et al., 2016). With this in mind, more recent 
international guidelines have incorporated symptom measurements and 
exacerbation history to provide a better overview of disease severity (GOLD, 2019). 
1.4.2 Symptoms monitoring and assessment 
The assessment of respiratory symptoms is important in COPD management. 
Respiratory symptoms are often associated with functional capacity and infectious 
events (Sethi, 2010; Troosters et al., 2013).  
In practice, the modified Medical Research Council (mMRC) scale, Chronic 
Respiratory Questionnaire (CRQ), St. Georges Respiratory Questionnaire (SGRQ), 
or the COPD Assessment Tool (CAT) are commonly used pre- and post-
intervention to assess symptomatic changes (Lacasse et al., 2006). These 
assessments of symptoms can be broadly used to carry out a measurement of 
overall health status in response to treatment or with an aim to monitor exacerbation 
risk.  
The mMRC scale is a classical measure of breathlessness which grades patients 
from 0-4 depending on the self-reporting of functional limitation due to 
breathlessness (Fletcher, 1960). This tool has been shown to correlate well with 
other measures of health status (Bestall et al., 1999).  The CRQ, SGRQ and CAT 
are widely used and cover specific domains including: dyspnoea, emotion, fatigue, 
mastery, activity, impact, cough, sputum, chest tightness, and sleep (Dodd et al., 
2011; Ferrer et al., 2002; Williams et al., 2001). These tools build on the previous 
use of the mMRC scale to understand overall symptoms rather than focussing on 
dyspnoea alone. However, these tools are limited to measuring symptoms at 
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selected timepoints providing a general overview failing to capture daily symptoms 
which have been seen to fluctuate in COPD (Roche, Chavannes & Miravitlles, 
2013).  
The large and increasing burden of COPD exacerbations has led to interest in 
identifying fluctuations in symptoms, specifically capturing clinically relevant acute 
worsening of respiratory symptoms by daily monitoring/symptom diaries. Such 
diaries can provide important clinical information as COPD patients with higher daily 
respiratory symptoms have been seen to be more susceptible to sudden onset of 
exacerbations (Aaron et al., 2012). Also, these diaries have the capability to pick 
up unreported exacerbations (identified by elevated respiratory symptoms) which 
can result in later severe exacerbations if left untreated (Donaldson et al., 2002; 
Calverley et al., 2005; Seemungal et al., 1998; Seemungal et al., 2000).  
Despite the benefits of monitoring daily respiratory symptoms via daily diary cards, 
it is important to acknowledge there are limitations with the use of these tools. For 
example, daily diary cards do not have established thresholds or minimally clinically 
important differences (MCID) to counter for the heterogeneity of 
symptoms/exacerbations, making it challenging to establish clinically relevant 
changes in respiratory symptoms. The EXAcerbation of COPD Tool (EXACT®) has 
been developed and used in clinical studies to detect, monitor and assess the 
severity of exacerbations. The EXACT® is a daily quantitative patient reported 
measure assessing symptoms and functional capabilities (Jones et al., 2011). The 
overall score has been validated for detection of exacerbations and the severity of 
such events in clinical research by assessing the relationship among; EXACT® 
scores, medication use, SGRQ, stable-state FEV1, GOLD stage and mMRC over 
time between acute and stable states (Leidy et al., 2011; Leidy & Murray, 2013). 
Within this measurement tool, there is a subscale (E-RS™) which focusses on 
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specific domains of respiratory symptoms; breathlessness, chest, and 
cough/sputum. This enables respiratory symptoms to be monitored prior to and 
during exacerbations to assess severity of and recovery from such events (Leidy & 
Murray, 2013). This tool is relatively new and thus far has been limited to the 
assessment of pharmacological treatments to prevent or treat COPD exacerbations 
(Beier et al., 2017; Papi et al., 2017; Wedzicha et al., 2014). However, there has 
been a lack of studies utilising this tool for the assessment of changes in symptoms 
in response to non-pharmacological interventions.  
1.4.3 Exacerbation risk  
Exacerbations have a hospital admission mortality rate of 10% (Steer, Gibson & 
Bourke, 2012), with up to 43% of patients dying within 1 year of admission (Connors 
et al., 1996). 
Until recently, clinical measures to identify and predict the risk of future 
exacerbations had proved difficult. Relationships were also unable to be identified 
between clinical factors such as: FEV1%, smoking history, body mass index (BMI), 
oxygen use, or mMRC dyspnoea score with patients who have recurrent 
exacerbations (Hurst et al., 2010; Moy et al., 2013). However, the large-scale 
Evaluation of COPD Longitudinally to Identify Predictive Surrogate Endpoints 
(ECLIPSE) study outlined that the single best predictor of future exacerbations is a 
previous history of exacerbations (Hurst et al., 2010).  
1.4.3.1 Frequent exacerbator phenotype  
Exacerbations can be cluster events, whereby when a patient experiences an 
exacerbation, increased susceptibility to another event can be seen shortly after 
(Hurst et al., 2009). Patients who are more susceptible to, and experience, frequent 
exacerbations have been characterised as a distinct phenotype of COPD. A COPD 
phenotype is referred to as “a single or combination of disease attributes that 
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describe differences between individuals with COPD as they relate to clinically 
meaningful outcomes (symptoms, exacerbations, response to treatment, speed of 
progression of the disease or death)” (Han et al., 2010).  
Frequent exacerbators are defined as COPD patients who have had 2 or more 
exacerbations in the last year (hospitalisations or treatment with antibiotics or 
corticosteroids), whereas infrequent exacerbators are COPD patients who have 
had none or 1 exacerbation in the last year (Hurst et al., 2010). The frequent 
exacerbator is considered to be a stable phenotype; however, the ECLIPSE study 
found that a significant proportion of COPD patients can see fluctuations in terms 
of exacerbation frequency (Donaldson et al., 2013).  
The underlying mechanisms as to why a subset of patients experience recurrent 
exacerbations remains unclear. It has been proposed that patients who experience 
frequent exacerbations have an altered immune profile increasing susceptibility to 
recurrent infections (Wedzicha, Mackay & Singh, 2013). For example, airways of 
frequent exacerbators appear to be more inflamed with higher levels of IL-6 and IL-
8 (Bhowmik et al., 2000). Furthermore, systemic biomarkers such as fibrinogen and 
CRP have also been seen to be elevated in frequent exacerbators (Donaldson et 
al., 2005a; Perera et al., 2007). This is further supported by evidence suggesting 
that patients with elevated levels of fibrinogen, CRP and leukocytes in a stable state 
have been suggested to be more at risk of having an exacerbation (Thomsen et al., 
2013). The following mechanisms have been proposed to explain this underlying 
systemic inflammation in COPD: spill over of inflammatory mediators from the 
pulmonary compartment, inflammatory responses to tissue hypoxia, and a reaction 
induced by the pro-inflammatory bacterial product lipopolysaccharide (Wouters, 
2005).  Fibrinogen, CRP, and IL-6 are now recognised biomarkers of exacerbations 
playing prominent roles in the inflammatory processes in COPD; however, there is 
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still a need for clarity of the role of these biomarkers in the frequent exacerbator 
phenotype in relation to prediction of exacerbations (Chen, Leung & Sin, 2016).  
Inflammation is heavily implicated in the frequent exacerbator phenotype and is 
regarded as a treatable trait of COPD, but currently the best treatment for 
inflammation is unclear (Agusti et al., 2016). In order to better understand the 
underlying biology, there have been calls for comparisons between frequent and 
infrequent exacerbators (Agusti & Vestbo, 2011). Much of the evidence so far has 
assessed changes in biological markers between patients in a stable state and 
when presenting with an exacerbation which has had limited use in informing 
treatments. The ECLIPSE study however, has assessed retrospective data and 
identified that frequent exacerbators of COPD present with elevated leukocyte 
counts, CRP and fibrinogen identifying potential surrogate markers of the treatable 
trait of inflammation (Hurst et al., 2010; Agusti et al., 2016). This has led to 
suggestions that measurements of inflammatory markers in the systemic 
compartment maybe more insightful moving forwards (Singh et al., 2014).  
The frequent exacerbator phenotype is a recognised major phenotype across all 
severities of airflow limitation, however its prevalence does increase with COPD 
severity. The ECLIPSE study showed that frequent exacerbators were present in 
22% of GOLD stage 2 COPD patients, 33% of stage 3, and 47% of stage 4 (Hurst 
et al., 2010), highlighting the importance of assessing exacerbation risk based on 
previous history in all COPD stages.  
1.4.4 Combined COPD assessment 
A revised assessment for COPD patients proposed in the GOLD, (2011), report and 
again updated in 2017 (GOLD, 2017), recognised the impact of exacerbations and 
has been a major step forward from using spirometry alone to diagnose and assess 
COPD to guide treatment. This combined assessment, through the categorising of 
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COPD patients through the GOLD stages (A, B, C, D), provides a more 
individualised treatment pathway by stratifying COPD patients based on 
assessment of symptoms and exacerbation risk following confirmed diagnosis via 
spirometry (Figure 1.2) (GOLD, 2017).  
 
Figure 1.2. Adapted GOLD, (2017) combined ABCD assessment tool for COPD. 
GOLD stage A – COPD patients with low exacerbation risk and less symptoms. 
GOLD stage B – COPD patients with low exacerbation risk but more symptoms. 
GOLD stage C – COPD patients with high exacerbation risk with less symptoms. 
GOLD stage D – COPD patients with high exacerbation risk and more symptoms.  
 
Further assessments (e.g. exercise tolerance) can also be undertaken to 
understand the capabilities of a patient and the functional impairment induced by 
COPD and/or comorbidities. An example of an exercise tolerance test is the 
incremental shuttle walk test (ISWT) which is a walking bleep test which gradually 
increases in speed until symptom limitation and is indicative of maximal exercise 
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capacity (Holland et al., 2014). However, the ISWT is not always suitable for 
patients with differing impairments meaning the 6-minute walk test (6MWT) can be 
performed instead. The 6MWT requires patients to walk as far as possible at their 
own pace in 6 minutes with rest periods permitted (Holland et al., 2014).  
These assessment tools help to inform clinicians about treatment pathways on an 
individualised basis.  
 Treatment of COPD symptoms and exacerbations 
COPD is a complex heterogeneous disease with many different options for 
treatment. The main therapeutic goals in the treatment of COPD are to reduce 
symptoms and the frequency of exacerbations (Vestbo et al., 2013).  
1.5.1 Pharmacological therapy 
Pharmacological therapies for the treatment of COPD fall under the two main 
categories of bronchodilators and anti-inflammatory treatments. Prescription of 
these pharmacological therapies depend on disease activity and severity. This is 
well characterised by the stepwise approach (Figure 1.3) (GOLD, 2019). The 
stepwise approach provides guidance on the implementation of pharmacological 
therapies as COPD progresses. For example, the use of bronchodilators in mild to 
moderate COPD to manage dyspnoea before introducing corticosteroids with more 
severe disease. Anti-inflammatory treatments such as corticosteroids are especially 
important for preventing and/or reducing the risk of exacerbations, hence often 
prescribed for frequent exacerbators (GOLD, 2019). 
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I: Mild II: Moderate III: Severe IV: Very Severe 
• FEV1/FVC < 0.70 
• FEV1 ≥ 80% 
predicted 
• FEV1/FVC < 0.70 
• 50% ≤ FEV1 < 80% 
predicted 
• FEV1/FVC < 0.70 
• 30% ≤ FEV1 < 50% 
predicted 
• FEV1/FVC < 0.70 
• FEV1 < 30% 
predicted or FEV1 
< 50% predicted 
plus chronic 
respiratory failure 
Active reduction of risk factor(s); influenza vaccination 
Add short-acting bronchodilator (when needed) 
 Add regular treatment with one or more long-acting bronchodilators 
(when needed); add pulmonary rehabilitation 
  Add inhaled glucocorticosteroids if repeated 
exacerbations 
   Add long-term 
oxygen if chronic 
respiratory failure. 
Consider surgical 
treatments 
 
Figure 1.3. Stepwise approach to the treatment of COPD patients (GOLD, 2019). 
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1.5.1.1   Bronchodilators 
Bronchodilators are a cornerstone of pharmacological therapy in COPD. 
Bronchodilators fall under two major classes, beta2-adrenoceptor agonists (SABA 
and long-acting beta2-adrenoceptor agonists (LABA)) and anti-muscarinic/anti-
cholinergics (short-acting muscarinic antagonists (SAMA) and long-acting 
muscarinic antagonists (LAMA)) which are used as rescue medication  and 
maintenance therapy in COPD (GOLD, 2019).  
1.5.1.1.1 Beta2-adrenoceptor agonists 
Beta2-adrenoceptor agonists, also known as beta-agonists, function via activation 
of the beta2-adrenoceptors located on airway smooth muscle resulting in airway 
relaxation (Billington, Penn & Hall, 2017). SABA’s play a key role in immediate relief 
of symptoms through accelerated bronchodilation and can be seen to reduce 
dynamic hyperinflation at rest and during exercise (O’Donnell et al., 2004; 
O’Donnell et al., 2006). SABA’s are recommended to be prescribed upon diagnosis 
of COPD and can be used as a rapid ‘reliever’ across all disease severities (Figure 
1.3). This inhaled medication can be seen to be effective within 3 min reaching peak 
bronchodilation after 2.5 hr to alleviate symptoms of dyspnoea (Ejiofor & Turner, 
2013). SABA’s can be seen to effectively act for between 4-6 hrs following intake 
(Vathenen et al., 1988).  
LABA’s function in a similar way to SABA’s but provide a more prolonged response 
lasting 12 hrs or more (Cazzola et al., 2013). The prescription of a LABA is 
recommended for patients with moderate to very severe COPD (Figure 1.3). 
LABA’s do not preclude any additional benefit from SABA’s therapy as needed 
(Cazzola et al., 2013), and do not act as fast in terms of providing immediate relief 
of symptoms, but they have been seen to reduce exacerbations by 10-20% (GOLD, 
2019; Wedzicha, Decramer & Seemungal, 2012).  
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The role bronchodilators play in prevention of exacerbations is believed to be 
attributed to a reduction in dynamic hyperinflation, a known mechanism 
underpinning increased breathlessness in COPD (Wedzicha, Decramer & 
Seemungal, 2012). Combining two LABA’s can also induce significant 
improvements in lung function, but exacerbation risk is only marginally reduced 
(Wedzicha, Mackay & Singh, 2013). It is not believed that LABA’s impact on the 
underlying causes of exacerbations, but plausibly increase the symptom threshold 
of COPD patients resulting in decreased exacerbations via reducing 
breathlessness (Vestbo & Lange, 2015) (Figure 1.4). 
1.5.1.1.2 Anti-muscarinic/anti-cholinergics 
Short-acting muscarinic antagonists are another form of bronchodilator which 
provide accelerated short-term bronchodilation via a different pathway to beta2-
agonists by blocking the activity of the muscarinic acetylcholine receptor, mainly M1 
and M3-receptors, resulting in airway smooth muscle relaxation and reduced mucus 
secretion (Barnes, 1993). SAMA’s can be utilised across all severities of COPD as 
a fast acting ‘reliever’ inhaler. LAMA’s, such as Tiotropium, have been seen to have 
similar benefits to LABA’s in terms of symptom relief, prolonged bronchodilation, 
and improvements in exercise tolerance but act via different mechanisms (Karner, 
Chong & Poole, 2012; Kesten et al., 2008). LAMA’s should be prescribed in patients 
with moderate to very severe COPD (Figure 1.3). Reduced time to first exacerbation 
has also been seen when using tiotropium (LAMA) once-daily compared to 
salmeterol twice-daily (LABA) (Vogelmeier et al., 2011). LABA’s are unlikely to have 
major anti-inflammatory effects (Powrie et al., 2007), whereas LAMA’s could have 
a potentially beneficial effect by reducing mucus hypersecretion associated with 
exacerbations, although the data to support this mechanism are inconclusive 
(Vestbo & Lange, 2015).  
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A combination of these therapies can be implemented to optimise therapeutic 
response. It is becoming common place to prescribe LABA/LAMA combination 
therapy, with benefits such as short-term improvements in lung function and quality 
of life previously observed (Cazzola & Molimard, 2010; Martinez et al., 2017).  
There are several inhalers available which include both LABA’s and LAMA’s which 
have been shown to reduce the risk of exacerbations (Wedzicha et al., 2016). 
However, this effect has been questioned as a recent trial has found that the 
LABA/LAMA combination was no more effective than LAMA alone for reducing the 
risk of exacerbations (Calverley et al., 2018). This suggests that bronchodilators 
may need to be combined with anti-inflammatory therapies (e.g. corticosteroids) 
which are specifically designed to target inflammation to prove more effective in 
reducing exacerbations (Putman et al., 2016).  
1.5.1.2 Anti-inflammatory agents 
1.5.1.2.1 Corticosteroids 
Inhaled corticosteroids (ICS) act to alleviate symptoms by reducing inflammation in 
the airways of COPD patients. Corticosteroids are targets for suppressing 
inflammation by activating transcription of anti-inflammatory and suppressing 
transcription of proinflammatory genes (Barnes, 2010). Mitogen kinase 
phosphatase-1 (MKP-1) and glucocorticoid-induced leucine zipper (GILZ) are both 
corticosteroid-inducible genes which are transcribed in response to corticosteroid 
treatment to prevent the release of pro-inflammatory mediators (Kelly et al., 2012; 
King et al., 2009; Newton & Holden, 2007). The main mechanism of MKP-1 is to 
inactivate pro-inflammatory mitogen-activated protein kinases (MAPK’s) resulting 
in a reduced production of cytokines (Barnes, 2008). GILZ also targets key 
inflammatory transcription factors resulting in a suppression of inflammatory gene 
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expression (Berrebi et al., 2003; Eddleston et al., 2007; Godot et al., 2006; 
Mittelstadt & Ashwell, 2001). 
Corticosteroids have largely been introduced as a treatment in COPD given the 
positive effects seen in the treatment of asthma. ICS treatment in COPD has been 
seen to be ineffective at arresting long-term FEV1 decline (Burge et al., 2000; 
Pauwels et al., 1999; Vestbo et al., 1999; Wise et al., 2000), but has been seen to 
reduce exacerbation frequency (Spencer et al., 2004). Alone, corticosteroids have 
been shown to be effective in treating acute exacerbations and reducing 
exacerbation frequency by 25% (Burge et al., 2000; Calverley et al., 2007). The 
clinical benefits of corticosteroids have been established in COPD for reducing 
exacerbation events, but evidence does not always support a reduction in 
symptoms or of controlled inflammation (Barnes, 2000). This is believed to be as a 
result of decreased activity and expression of histone deacetylase 2 (HDAC2) in 
the inflammatory cells of COPD patients (Ito et al., 2005). This decreased HDAC2 
activity is believed to be due to oxidative stress (Ito et al., 2005; Barnes, 2006). 
These proposals are considered to be a key factor in why COPD patients with 
neutrophilic inflammation are resistant to the effects of corticosteroids whereas 
COPD patients with eosinophilic inflammation, aligning with the inflammatory profile 
of asthma patients, respond better (Brightling et al., 2000; Chanez et al., 1997; 
Pizzichini et al., 1998; Pavord et al., 2016).  
Systemic corticosteroids, as opposed to inhaled, are usually used to treat 
exacerbations and have been seen to induce improvements in lung function and 
dyspnoea whilst decreasing relapse rate in the treatment of exacerbations (Albert, 
Martin & Lewis; 1980; Niewoehner et al., 1999). However, the use of systemic 
corticosteroids is not associated with long-term benefits in stable COPD (Walters, 
Walters & Wood-Baker, 2005), and may increase the risk of mortality (Sin & Tu, 
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2001). The use of systemic corticosteroids has also been associated with side 
effects including weight gain and depression (Wood-Baker et al., 2005). Questions 
still arise over the effectiveness of both systemic and inhaled corticosteroid 
treatment as COPD patients have been suggested to develop a corticosteroid 
insensitivity as a result of chronic use, meaning that high doses fail to suppress 
inflammation (Lo Tam Loi et al., 2013).  
Historically, corticosteroids have been targeted at patients who have frequent 
exacerbations despite treatment with LABA and/or LAMA (GOLD, 2019). The 
addition of ICS to the treatment regimen of LABA/LAMA has been recommended 
given the positive effect observed with a reduced risk of exacerbation (GOLD, 
2019). However, there is an increasing presence of ICS withdrawal in COPD 
patients due to wide reports of pneumonia with long-term use (Fernandes et al., 
2017), but the withdrawal of ICS has been seen to be associated with an increased 
rate of exacerbations of COPD (Magnussen et al., 2014; Watz et al., 2016; Wouters 
et al., 2005). Research has assessed the possibility of combination therapy (ICS & 
beta2-agonists) to facilitate sensitivity to corticosteroids in COPD with suggestions 
of beneficial effects (Barnes, 2013; Boardman et al., 2014). Anti-inflammatory drugs 
(e.g. ICS) have different mechanisms in reducing the risk of exacerbations 
compared to LABA’s. Anti-inflammatory drugs are assumed to modify the 
inflammatory response to airway irritants or bronchial infection accompanying an 
exacerbation (Vestbo & Lange, 2015). Anti-inflammatory drugs have a lesser effect 
on lung function compared to bronchodilators and have been suggested to only be 
effective in certain exacerbations depending on inflammatory profile (Vestbo & 
Lange, 2015). Furthermore, anti-inflammatory drugs target inflammation as a way 
of reducing symptomatic changes as opposed to bronchodilators which act to 
increase symptom thresholds for exacerbations (Figure 1.4).   
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Figure 1.4. Symptomatic threshold for exacerbations and how pharmacological 
treatments can reduce exacerbation rate. a) Solid line dictates standard symptom 
variations over time with symptoms exceeding the exacerbation threshold as 
depicted by the dotted line. b) LABA’s increase the symptom threshold line and 
exacerbation perception potentially reducing the amount of exacerbations 
experienced. c) Anti-inflammatory drugs do not alter the symptom threshold, but 
they: modulate inflammation, reduce symptoms, and reduce the amplitude of 
symptomatic changes, leading to fewer exacerbations (Vestbo & Lange, 2015). 
 
1.5.1.2.2 PDE4 Inhibitors 
Phosphodiesterase type 4 (PDE4) inhibitors (e.g. roflumilast) are a newer 
pharmacological therapy option for the treatment of COPD. This new therapy has 
been introduced following efforts to establish pharmacological regimens that 
specifically target inflammation and reduce exacerbations of COPD (Calverley et 
al., 2009). This is particularly relevant in the case of individuals who experience 
frequent exacerbations of COPD as there is a poor availability of treatments that 
specifically target inflammation in an effective manner (Han et al., 2014; Rabe & 
Watz, 2017). PDE inhibitors act by increasing levels of cyclic adenosine 
monophosphate (cAMP) and cyclic guanosine monophosphate (cGMP) to relax the 
airway smooth muscle causing bronchodilation and inhibit production of 
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inflammatory cell activation (Bryson & Rodger, 1987; Cortijo et al., 1993; Holgate 
et al., 1987; Kotlikoff & Kamm, 1996; Schramm & Grunstein, 1992; Spina, 2003). 
Specifically, PDE4 inhibitors have been seen to reduce matrix metalloproteinase 
(MMP) activity, a protease capable of degrading extracellular matrix proteins, in the 
lung (Lagente et al., 2005). PDE4 inhibitors have also been shown to drive the 
resolution of neutrophilic inflammation (Sousa et al., 2010). As a result of these 
various anti-inflammatory mechanisms, PDE4 inhibitors have been seen to reduce 
the risk of exacerbations in COPD (Cowan, 2005; Rabe et al., 2005).  
Ultimately, PDE4 inhibitors have found a place in the pharmacological management 
of COPD due to the lack of available anti-inflammatory treatments and the burden 
of recurrent exacerbations, but this therapy does come with severe side effects. 
These side effects include; nausea, vomiting and increased gastric acid secretion 
(Dyke & Montana, 2002), and use of this therapy should be undertaken with caution 
(GOLD, 2019).  
1.5.1.3 Pharmacological issues 
Large sums of money are spent on pharmacological therapies to treat COPD (World 
Health Statistics, 2011), however, the benefits of these therapies on exacerbations, 
hospitalisations or mortality are modest at best and/or at the expense of the 
incidence of adverse effects (Sin, 2014). The pharmacological options currently 
appear to be insufficient in suppressing inflammation, which is considered to be a 
treatable trait in COPD (Agusti et al., 2016). With this in mind, the importance of 
non-pharmacological treatment options are on the rise. Vestbo et al. (2013) have 
emphasised the multi-component nature of non-pharmacological interventions 
suggesting that interventions such as; smoking cessation, pulmonary rehabilitation 
and physical activity could play an important role in the management of symptoms 
and exacerbations.    
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1.5.2 Non-Pharmacological therapy 
1.5.2.1 Smoking cessation 
Despite a depth of pharmacological and non-pharmacological treatment options, 
smoking cessation is still considered the intervention with greatest potential to 
influence the management of COPD patients and is strongly recommended by 
health services and government bodies (Hopkinson & Polkey, 2010). However, 
damage as a result of chronic smoking has already occurred and smoking cessation 
cannot reverse these effects, so it is important to also seek supporting treatments 
to limit the progression of COPD (Hopkinson & Polkey, 2010).  
Smoking is believed to be a major contributing factor to COPD exacerbations, with 
a high prevalence of COPD exacerbations in patients who continue to smoke 
(Badaran et al., 2012). Smokers with respiratory symptoms may also be more 
susceptible to the effects of smoking than those who do not present with symptoms 
(Kohansal et al., 2009). However, smoking cessation is believed to improve 
respiratory symptoms and prevent excessive lung function decline in smokers with 
COPD as well as among smokers without chronic symptoms (Willemse et al., 
2004).  
1.5.2.2 Flu vaccination 
Another cost-effective non-pharmacological treatment in COPD is influenza 
vaccination (Lall et al., 2016). Influenza represents a key cause of COPD 
exacerbations which have a significant burden on healthcare utilisation (Seemungal 
et al., 2001). Influenza vaccinations have been seen to reduce lower respiratory 
tract infections requiring hospitalisation (Wongsurakiat et al., 2004), and death in 
COPD patients (Nichol et al., 1994; Poole et al., 2006), meaning they are strongly 
recommended for patients with COPD (Bekkat-Berkani et al., 2017).  
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1.5.2.3 Education 
Patient education has been suggested to be an independently effective treatment 
pathway for COPD, despite the inability of education to independently alter lung 
function or exercise capacity (Celli, 1995). Education is intended to support long-
term behaviour change and has been seen to play a role in; improving skills, 
instilling confidence in self-management options, improving ability to handle 
disease complications, enhancing smoking cessation, and health status if used 
effectively (Celli, 1995; GOLD, 2019).  
1.5.2.4 Physical activity  
Reduction in physical activity levels during the course of COPD increases the risk 
of comorbidity development and disease progression (Garcia-Aymerich et al., 
2007). COPD patients are commonly seen to be less physically active than healthy 
individuals with further decline in physical activity levels and larger portions of the 
day being spent in a sedentary state as COPD severity worsens (Pitta et al., 2005; 
Watz et al., 2009). As a result, COPD patients who have lower physical activity 
levels are likely to have a poorer survival rate and increased risk of hospitalisation 
compared to COPD patients who are physically active (e.g. 2 or more hours of 
physical activity per week) (Garcia-Aymerich et al., 2006).  
In COPD, a vicious cycle involving breathlessness, inactivity and reduced exercise 
capacity resulting in poorer quality of life has been proposed (Troosters et al., 
2013). This vicious cycle illustrates the negative effects of continued inactivity in 
COPD, but this cycle can be reversed with an increase in physical activity. COPD 
patients who maintain increased physical activity levels are associated with 
improved lung function or slower lung function decline, improved functional status, 
and when physical activity is undertaken at a low intensity can experience a lower 
frequency of exacerbations and hospitalisations (Donaire-Gonzalez et al., 2015; 
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Garcia-Aymerich et al., 2007; Garcia-Aymerich et al., 2009). Despite this, there is 
still a clear lack of understanding of the mechanisms underpinning these changes.  
The norm for promoting physical activity in COPD is to deliver structured physical 
activity in the form of an exercise programme to help with disease management 
(Troosters et al, 2013).   
1.5.2.5 Pulmonary rehabilitation 
Exercise training, most often as part of pulmonary rehabilitation, is considered a 
cornerstone treatment in the management of COPD. Pulmonary rehabilitation has 
been defined as “a comprehensive intervention based on a thorough patient 
assessment followed by patient-tailored therapies that include, but are not limited 
to, exercise training, education, and behaviour change, designed to improve the 
physical and psychological condition of people with chronic respiratory disease and 
to promote the long-term adherence to health-enhancing behaviours” (Spruit et al., 
2013).  
The NICE, (2018) guidelines recommend that patients with stable COPD who are 
functionally impaired due to breathlessness should be referred for ‘conventional’ 
pulmonary rehabilitation. NICE guidance also recommends that patients admitted 
to hospital for an acute exacerbation of COPD should be referred for and 
commence ‘early’ pulmonary rehabilitation within 4 weeks of discharge (NICE, 
2018). This quality standard has been released as NICE suggest the 
commencement of early pulmonary rehabilitation post-discharge for acute 
exacerbation of COPD reduces the short-term risk of hospital readmission whilst 
improving quality of life and exercise capacity (NICE, 2018).  
UK recommendations for conventional and early pulmonary rehabilitation 
programmes include a programme of 6-12 weeks, with 2 or 3 sessions per week, to 
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achieve noticeable improvements in quality of life and exercise capacity (Bolton et 
al., 2013). Pulmonary rehabilitation can take place in a variety of settings including; 
community settings, hospital, and patients’ homes with clinical benefits 
demonstrated in all settings if delivered in line with national guidelines (Bolton et 
al., 2013). Pulmonary rehabilitation has been shown to have moderate to large 
clinically significant improvements on the management of dyspnoea, increasing 
exercise capacity, and improving quality of life for patients with COPD (McCarthy 
et al., 2015; Nici et al., 2006). Given the in-depth evidence around the benefits of 
pulmonary rehabilitation on outcomes such as exercise capacity and quality of life, 
McCarthy et al. (2015) concluded that there was no need for further randomised 
controlled trials comparing the effect of pulmonary rehabilitation to usual care in 
COPD on these outcomes (McCarthy et al., 2015). However, this was concluded 
based on the average COPD patient, whereby due to the inherent heterogeneity in 
COPD, some patients respond better than others, underlying the importance of 
looking into comorbidity and phenotype subsets and how these patients respond to 
rehabilitation (Spruit et al., 2015a).   
The aforementioned study by Spruit et al. (2015a) categorised patients as ‘very 
good responders’, ‘good responders’, ‘moderate responders’, and ‘poor 
responders’. Key factors underpinning ‘very good responders’ included COPD 
patients with; higher symptoms of dyspnoea, higher number of hospitalisations in 
the previous 12 months, poorer exercise performance, and more symptoms of 
anxiety and depression. This paper demonstrated the importance of considering 
subgroups of COPD patients in the context of pulmonary rehabilitation. However, a 
subsequent study has followed on from this to suggest that pulmonary rehabilitation 
stood to benefit all COPD patients regardless of the presence, number, or nature 
of comorbidities (Kallianos et al., 2016). Interestingly, many of the listed 
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characteristics of ‘very good responders’ align with characteristics of the frequent 
exacerbator phenotype (Le Rouzic et al., 2018), yet there is still a poor 
understanding of where pulmonary rehabilitation sits in the treatment of this 
phenotype, and other clinical phenotypes, especially given the poor efficacy of 
pharmacological options.  
Despite the benefits of using pulmonary rehabilitation as a treatment, the funding 
provided is far less than that provided to lesser effective treatments (Griffiths et al., 
2001; Hak et al., 1998; Hoogendoorn et al., 2010; Mayers et al., 2007; Oba, 2007). 
Pulmonary rehabilitation has routinely not been considered to impact on outcomes 
such as reduced health care use and disease progression which may, in part, 
explain this shortfall in funding from healthcare services burdened by COPD 
exacerbations. Another major issue identified with pulmonary rehabilitation is the 
low rates of referral and poor patient uptake (Brooks et al., 2007; Garvey, Fullwood, 
& Rigler, 2013; Hayton et al., 2013; Jones et al., 2014b; Jones et al., 2017; Keating, 
Lee, & Holland, 2011; Marciniuk et al., 2010). Numerous qualitative studies have 
identified common patient reported barriers linked to this poor uptake including a 
lack of perceived benefit or a fear that exercise (pulmonary rehabilitation) may 
exacerbate symptoms (Fischer et al., 2007; Harris, Hayter & Allender, 2008; Taylor 
et al., 2007; Young et al., 1999).  
Even when enrolled, completion of pulmonary rehabilitation is another significant 
issue for providers with attrition rates as high as 60% (Boutou et al., 2014; Hayton 
et al., 2013; Hogg et al., 2012). One factor that often has been proposed to be 
related to poor adherence is incidence of exacerbations during pulmonary 
rehabilitation programmes (Hayton et al., 2013). Up to one third of dropouts from 
pulmonary rehabilitation have been attributed to acute exacerbations of COPD 
(Steele et al., 2010). However, a recent study has suggested that this is limited to 
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severe exacerbations whereas mild-to-moderate exacerbations do not affect 
dropout or response to pulmonary rehabilitation (Braeken et al., 2017). Such 
evidence is important to consider when referring COPD patients with a history of 
exacerbations to pulmonary rehabilitation but it remains unclear to what extent the 
frequent exacerbator phenotype impacts on programme compliance and outcomes 
across all pulmonary rehabilitation settings (e.g. home, community and hospital). 
 Exercise in the management of COPD exacerbations 
1.6.1 Pulmonary rehabilitation & exacerbations 
More recently, interest has grown in assessing whether pulmonary rehabilitation 
has impact beyond exercise capacity and health status (McCarthy et al., 2015). 
There has been  increasing numbers of reports of pulmonary rehabilitation reducing 
the risk of health-care use (Griffiths et al., 2000; Moore et al., 2016; van Ranst et 
al., 2014). A recent systematic review by Moore et al. (2016) found that pulmonary 
rehabilitation groups had lower overall rates of hospital admissions compared to 
those in control groups in randomised controlled trials. Five of the studies included 
in this review were pooled and found that pulmonary rehabilitation reduced hospital 
admissions in the 12 months post-rehabilitation compared to the 12 months prior to 
rehabilitation (Moore et al., 2016). However, this review also considered pooled 
data from observational cohort studies where findings were in contrast with 
randomised trials and did not support a beneficial effect of pulmonary rehabilitation 
on hospitalisations over control groups (Moore et al., 2016). The same authors also 
performed an historical cohort study using electronic health records and suggested 
that patients referred for pulmonary rehabilitation (but did not necessarily complete) 
did not have fewer GP visits and hospitalisations for acute exacerbations of COPD 
in the year following pulmonary rehabilitation compared to those not referred to 
pulmonary rehabilitation (Moore et al., 2017). However, ‘real-world’ data in the form 
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of the UK National COPD Pulmonary Rehabilitation Audit has highlighted a 
reduction in the risk of hospitalisation and length of stay following completion of 
pulmonary rehabilitation (Steiner et al., 2017a). These findings highlight the lack of 
clarity and interest in assessing health-care use outcomes in response to exercise 
interventions especially following pulmonary rehabilitation to identify if the duration 
of benefits from a pulmonary rehabilitation programme alone can be prolonged, or 
rather, enhanced during the post-rehabilitation period (Moore et al., 2016).  
Early pulmonary rehabilitation (1-month post-hospital discharge for acute 
exacerbation) has also been shown in clinical trials to reduce hospital readmissions 
in COPD patients (Puhan et al., 2011). A recent update in the synthesis of evidence  
in this area has downgraded the quality of the evidence due to inconsistencies in 
the estimates of effect across randomised controlled trials to date (Puhan et al., 
2016). However, the authors felt that the extensiveness of the programmes 
delivered, i.e. the amount of exercise undertaken, was key in explaining the 
variance in intervention effect suggesting more research is required in this area 
(Puhan et al., 2016). 
The benefits outlined have seen pulmonary rehabilitation labelled as one of the 
most cost-effective methods of treating COPD (California Pulmonary Rehabilitation 
Collaborative Group, 2004; Griffiths et al., 2000; Griffiths et al., 2001; Puhan et al., 
2011; Raskin et al., 2006; Zoumot, Jordan, & Hopkinson, 2014). Therefore, any 
patients who have the potential to benefit from pulmonary rehabilitation are strongly 
recommended to be offered this therapy (Rochester et al., 2015). It is also important 
to note that pulmonary rehabilitation was not designed or intended to impact health 
care use but the mounting evidence linking the positive interaction cannot be 
ignored.  
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Isolating the component of pulmonary rehabilitation largely responsible for this 
reduction in exacerbations is difficult. It is unclear whether the observed effect is 
due to the exercise alone, or whether other factors (e.g. education) are having a 
sole or additive effect. For example, Evans & Steiner (2018) proposed that the role 
pulmonary rehabilitation plays in increasing disease knowledge may contribute to 
this reduction in exacerbations. Further investigation of the efficacy and 
mechanisms of the impact of exercise interventions on exacerbations would help to 
answer this.  
1.6.2 Exercise maintenance and exacerbations 
Given the numerous benefits identified with pulmonary rehabilitation, there are still 
issues surrounding long-term sustainability of improvements gained from 
pulmonary rehabilitation, with patients returning to baseline levels 12 months 
following rehabilitation (Mador, Patel & Nadler, 2011; McCarthy et al., 2015). 
Therefore, there is interest in exercise programmes which can maintain the initial 
benefits of pulmonary rehabilitation (Alison et al., 2017; Beauchamp et al., 2013).  
Supervised maintenance exercise programmes after pulmonary rehabilitation in 
COPD appear to be more effective in preserving the improvements in exercise 
capacity up to 6 months but show no effects with respect to health-related quality 
of life post-rehabilitation (Beauchamp et al., 2013; Busby, Reese & Simon, 2014). 
Exacerbations and hospital admissions are key events in the management of 
COPD but the effects of exercise, particularly supervised maintenance programmes 
following pulmonary rehabilitation, on these outcomes have received little attention.  
As maintenance programmes are usually exercise only programmes, it provides a 
model by which to further assess the effects of exercise alone on exacerbations 
and other health care use outcomes.  
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Therefore, a systematic review was undertaken (Jenkins et al., 2018), using a pre-
registered protocol (Appendix A) to collate and synthesise all of the available 
evidence from randomised controlled trials in order to estimate the size of the effect 
of supervised maintenance exercise programmes compared to usual care following 
pulmonary rehabilitation on health-care use (Table 1.1).  
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Table 1.1. Characteristics of included studies 
Study 
(Country)  
Sample size, 
Gender, Age 
FEV1% predicted 
(spirometry), 
Smoking history 
Inclusion/ 
Exclusion criteria 
Study aim, 
Design, Unit 
of allocation 
Pulmonary 
rehabilitation 
programme 
(setting, 
components, 
duration, 
frequency) 
Maintenance 
programme 
(setting, 
components, 
duration, 
frequency) 
Primary 
outcome (1) 
Other 
outcomes and 
follow up (2) 
Ries et al., 
2003 (USA) 
164 participants 
Int: n = 83 
Con: n = 81 
 
Males: n = 89  
Females: n = 75 
 
Age, mean ± SD  
All: 67 ± 8  
FEV1 %pred, mean 
All: 45% 
 
No data available for 
smoking status 
Inclusion: Clinical diagnosis of 
chronic lung disease; Chronic 
symptoms and perceived disability 
from disease; Stable state; No 
other significant medical or 
psychiatric conditions that would 
interfere with programme 
participation; Commitment to 
abstain from smoking. 
Assess a 
telephone-based 
maintenance 
intervention for 
retaining 
benefits 
following 
pulmonary 
rehabilitation 
 
RCT, cluster 
Exercise and 
education 
combined with 
psychosocial 
support. 
 
Twelve, 2 h 
sessions over 8 
weeks.  
Weekly semi-
structured phone 
calls and monthly 
supervised 
reinforcement 
sessions (1.5 h 
supervised 
exercise, 1.0 h 
topic review, 0.5 h 
social time) for 12 
months. 
(1) Pulmonary 
function, exercise 
tolerance, 
dyspnoea, 
depression. 
(2) QoL, health 
status, health-care 
use. 
Brooks et al., 
2002 
(Canada) 
85 participants 
Int: n = 37 
Con: n = 48 
 
Males: n = 50 
Females: n = 35 
 
Age, mean ± SD 
Int: 68 ± 1 
Con: 68 ± 1 
FEV1 %pred, mean ± 
SD 
Int: 32 ± 2 
Con: 32 ± 2 
 
All non-smokers for at 
least 6 months 
Inclusion: Severe stable COPD 
(FEV1 <40% predicted, FEV1/FVC 
<0.70); Completion of inpatient or 
outpatient rehabilitation; Non-
smoker for a minimum of 6 
months; Aged 49-85 years.  
Exclusion: Coexisting conditions 
that might limit exercise tolerance 
or cognitive functioning; Non-
compliance with respiratory 
rehabilitation; Mechanical 
ventilatory support for any part of 
the day; Inability to communicate 
in English; Living too far away to 
participate.  
Compare the 
effects of two 
post-
rehabilitation 
programmes on 
functional 
exercise 
capacity and 
health-related 
QoL in patients 
with COPD.  
 
RCT, individual  
Exercises – 
Breathing, 
treadmill or cycle 
exercises, interval 
and upper 
extremity training, 
leisure walking. 
Patient education 
and psychosocial 
support included 
(relaxation and 
occupational 
therapy). 
 
Inpatient – 5 times 
a week for 6 
weeks. Outpatient 
– 3 times a week 
at the centre and 
at home for 8 
weeks. 
Monthly 2 h group 
sessions 
supervised by a 
physical therapist 
for 12 months. 
First hour for 
discussion around 
home exercise 
programme, 
second hour for 
performing 
components of the 
home exercise 
programme under 
supervision. 
Phone calls made 
between visits with 
standardised 
questions 
regarding 
(1) 6MWT, CRQ.  
(2) Medical 
outcomes survey: 
short-form 36, 
SGRQ, subject 
compliance, 
pulmonary function.  
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adherence to 
home exercises.  
Spencer et al., 
2010 
(Australia) 
48 participants 
Int: n = 24 
Con: n = 24 
 
Males: n = 22 
Females: n = 26  
 
Age, mean ± SD  
Int: 65 ± 8 
Con: 67 ± 7 
FEV1 %pred, mean ± 
SD 
Int:  57 ± 21% 
Con:  60 ± 16% 
 
Current smokers 
Int: n = 6   
Con: n = 5  
Inclusion: COPD diagnosis; 
Completed 8-week pulmonary 
rehabilitation programme; 
FEV1/FVC < 70% and FEV1 < 
80% predicted. 
Exclusion: Exacerbation in 
previous month; Supplemental 
oxygen; Comorbidities that would 
prevent performing exercises; 
Clinic patients (pulmonary 
rehabilitation). 
Determine if 
weekly-
supervised 
exercise 
following 
pulmonary 
rehabilitation 
would maintain 
functional 
exercise 
capacity and 
QoL. 
 
RCT, individual 
Exercises – 20 
min walking, 20 
min cycling, 10 
min arm cycling, 
upper and lower 
limb strength 
training.  
 
8 weeks in a 
pulmonary 
rehabilitation gym. 
 
Pulmonary 
rehabilitation gym 
for 12 months. 
Supervised 
exercise 1 day per 
week with 
unsupervised 
exercise 4 days 
per week. 
Exercises 
prescribed in line 
with exercise 
undertaken during 
pulmonary 
rehabilitation. 
(1) 6MWT, SGRQ. 
(2) Lung function 
tests, ISWT + 
ESWT, HADS, 
hospital admissions, 
length of stay and 
exacerbations. 
Ringbaek et 
al., 2010 
(Denmark) 
96 participants 
Int: n = 55 
Con: n = 41 
 
Males: n = 31 
Females: n = 63 
 
Age, mean ± SD 
Int: 67 ± 1 
Con: 69 ± 9  
FEV1 %pred, mean ± 
SD 
Int: 36 ± 14%  
Con: 37 ± 16%  
 
Current smokers 
Int: n = 13  
Con: n = 7  
Inclusion: Stable COPD (FEV1 
<80%, FEV1/FVC <70%); 
Motivation for pulmonary 
rehabilitation; Completion of 7 
weeks of pulmonary rehabilitation.  
Exclusion: Musculoskeletal, 
cardiac or cognitive problems.  
 
Examine 
whether 
maintenance 
training 
improved long-
term effect of 
pulmonary 
rehabilitation. 
 
RCT, individual 
Supervised 
walking and 
cycling both at 
85% of predicted 
VO2 peak + 
unsupervised 
exercise at home.  
 
Twice a week for 7 
weeks with 
supplementary 
education once a 
week. 
Weekly supervised 
exercise for first 6 
months, every 
second week for 
the next 6 months 
and no supervised 
exercise for the 
last 6 months. 
Unsupervised 
exercise at home 
encouraged. 
(1) ESWT, SGRQ. 
(2) Hospitalisation 
(time to first 
admission, 
admission rates, 
days in hospital), 
exercise adherence, 
attendance at 
evaluation visits. 
Wilson et al., 
2015 and 
Burns et al., 
2016 
(United 
Kingdom) 
148 participants 
Int: n = 73 
Con: n = 75 
 
Males: n = 91 
Females: n = 57 
 
Age, mean ± SD  
Int: 67 ± 15  
Con: 69 ± 9 
FEV1 %pred, mean ± 
SD 
All: 41 ± 16% 
 
>20 pack-year 
smoking history 
 
No data available on 
current smoking status 
Inclusion: Over 35 years of age; 
COPD diagnosis (FEV1<80%); 
>20 pack-year smoking history; 
Completed at least 60% of 
pulmonary rehabilitation sessions. 
Exclusion: Cardiac or pulmonary 
disease (other than COPD); 
Myocardial infarction within 6 
months or unstable angina; 
Respiratory infection within last 4 
weeks; Uncontrolled or severe 
comorbidities; Cognitive 
complications. 
Evaluate long-
term effect of 
maintenance 
exercise on 
health-related 
QoL. 
Assess the cost-
effectiveness of 
maintenance 
exercise 
following 
pulmonary 
rehabilitation on 
Exercises - 
Walking, cycling, 
sit to stand, step-
ups, arm exercises 
with dumbbells. 
High intensity 
(85% of maximum 
capacity). 
Once a week for 8 
weeks (1 hour for 
exercise + 1 hour 
for education). 
Endurance 
exercise everyday 
Individually 
tailored strength + 
endurance 
exercises 
including walking, 
cycling, sit-to-
stand, step-ups 
and arm exercises 
with dumbbells.  
One 2 h (1 h 
exercise + 1 h 
education) session 
every 3 months for 
12 months. Same 
(1)  CRQ 
(dyspnoea). 
(2) CRQ (other 
domains), ESWT, 
BMI, Body fat, 
HADS, EQ5D. 
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health-related 
QoL. 
 
RCT, individual 
+ strength 
exercise two more 
times a week at 
home.  
group of patients 
from original 
pulmonary 
rehabilitation. 
Home exercise 
programme 
review. 
Roman et al., 
2013 (Spain) 
71 participants 
Con: n = 23 
RHB: n = 22 
RHBM: n = 26 
 
Males: n = 58 
Females: n = 13 
 
Age, mean (95% CI)  
RHBM: 65 (62 - 68) 
RHB: 64 (60– 68) 
Con: 63 (60 - 66) 
FEV1 %pred, mean 
(95% CI) 
Con: 60 (56 - 64)  
RHB: 60 (55 - 65)  
RHBM: 61 (56 - 66) 
 
Current smokers  
Con: n = 8  
RHB: n = 7  
RHBM: n = 9  
Inclusion: 35 – 74 years old; 
Moderate COPD diagnosis; 
Smokers or non-smokers. 
Exclusion: Musculoskeletal 
conditions affecting ability to 
exercise; Terminal illness/other 
severe disease.   
Use 
maintenance 
post-pulmonary 
rehabilitation to 
improve QoL in 
COPD 
 
RCT, individual 
Exercises - Low 
intensity peripheral 
muscle training. 
Abdominal, upper 
and lower limb 
exercises, 
shoulder and full 
arm circling, 
weight-lifting and 
other exercises. 
Each exercise 
repeated 8 -10 
times over 45 min.  
Three 1 h 
sessions a week 
for 12 weeks with 
15 min of 
respiratory 
physiotherapy 
every session and 
45 min of 
education during 
weeks 1, 6 + 12.  
Low intensity 
peripheral muscle 
training. One 
session a week for 
9 months.  
(1) CRQ. 
(2) Pulmonary 
function, 6MWT, 
hospital admissions, 
GP visits, 
exacerbations. 
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Moullec et al., 
2008, 2010 
(France) 
40 participants 
Int: n = 14 
Con: n = 26 
 
Males: n = 31 
Females: n = 9 
 
Age, mean ± SD 
Int: 63 ± 7 
Con: 60 ± 10 
FEV1 %pred, mean ± 
SD 
Int: 53 ± 16 
Con: 47 ± 19 
 
No data available on 
smoking status 
Inclusion: FEV1/FVC <0.7, FEV1 
30-79% predicted; No indication 
for home oxygen therapy; Stable 
state for the previous 2 months; 
No change in medication and 
symptoms for the previous 4 
weeks; >40 years of age; No 
previous pulmonary rehabilitation 
experience.  
Exclusion: Medical or psychiatric 
disturbances that would hinder 
programme participation; 
Diagnosis of asthma; Congestive 
left heart failure; Terminal 
disease.  
 
 
Determine 
changes in the 
emotional and 
functional 
dimensions of 
QoL in COPD 
one year after a 
pulmonary 
rehabilitation 
programme with 
or without a 
follow-up 
intervention.  
 
Quasi-RCT, 
individual 
Twenty inpatient 
sessions over 4-
weeks. 
Community 
gymnasium.  
Individualised 
strength, interval, 
breathing, and 
endurance training 
with nature 
walking at 
ventilatory 
threshold.  
96 sessions 
across 12 months.  
Exercise training 
(3.5 h per week; 
72 sessions); 
health education 
(2 h per month; 12 
sessions); and 
psychosocial 
support (with 
discussion group 1 
h per month; 12 
sessions).  
(1) 6MWT, QoL 
(SGRQ and 
WHOQoL-Brief). 
(2) Six-item 
questionnaire with a 
VAS, maximal 
exercise capacity, 
physical activity, 
health-care 
utilisation, 
attendance, 
pulmonary function. 
Guell et al., 
2017 (Spain) 
138 participants 
Int: n = 68 
Con: n = 70 
 
Males: n = 123 
Females: n = 15 
 
Age, mean ± SD 
Int: 64 ± 9 
Con: 64 ± 8 
 
FEV1 %pred, mean ± 
SD 
Int: 34 ± 11 
Con: 34 ± 9  
 
No data available on 
smoking status 
Inclusion: COPD diagnosis (grade 
II-IV severity); Clinically stable 
during previous 4 weeks; 18-75 
years old; Ex-smokers or with 
intention to quit; BODE index 
value between 3-10. 
Exclusion: Bronchodilator 
response (FEV1 increment >15% 
of the baseline value after 200mcg 
of inhaled bronchodilator); Other 
respiratory diagnosis; Severe 
coronary artery disease; 
Orthopaedic diseases limiting 
mobility; Life expectancy lower 
than 2 years; Inability to co-
operate. 
Assess the 
efficacy of a 
supervised 
maintenance 
programme after 
pulmonary 
rehabilitation on 
improving 
symptoms, 
exercise 
capacity and 
health-related 
QoL compared 
with just 
pulmonary 
rehabilitation on 
its own. 
 
RCT, individual 
Three hospital-
based 2 h 
sessions a week 
for 8 weeks. 
Supplemented 
with 4 education 
sessions and 
chest 
physiotherapy. 
30 min weight-
lifting (0.5 kg in 
each hand, 
increased by 1 kg 
a week until peak 
tolerance), 30 min 
leg cycling (start at 
50% maximum 
load achieved 
during initial 
exercise test, load 
increased by 10 
Watts if heart rate 
Supervised 
exercise on 
alternate weeks at 
hospital for 36 
months. 
Unsupervised 
home exercise 
programme (3 
days a week) 
similar to hospital 
programme (15 
min chest 
physiotherapy, 30 
min arm training, 
30 min leg 
training). 
Supplemented by 
structured phone 
calls from 
physiotherapists 
every 15 days.  
(1) BODE index. 
(2) 6MWT, Health-
related QoL and 
CRQ. 
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and oxygen 
saturation are 
stable and 
exercise is 
tolerated). 
Exercise similar to 
pulmonary 
rehabilitation. 
Exercises, if well 
tolerated, were 
progressed at 
hospital visits.  
Con = control group, Int = intervention group, RHB = pulmonary rehabilitation with no maintenance, RHBM = pulmonary rehabilitation with maintenance, RCT = randomised controlled trial, FEV1 %pred = forced 
expiratory volume in 1 second % of predicted, FVC = forced vital capacity, QoL = quality of life, 6MWT = 6 minute walk test, SGRQ = St. Georges respiratory questionnaire, ISWT = incremental shuttle walk test, 
ESWT = endurance shuttle walk test, HADS = hospital anxiety and depression scale, CRQ = chronic respiratory disease questionnaire, BMI = body mass index, EQ5D = euro quality of life five dimensions 
questionnaire, WHOQoL = world health organisation quality of life brief questionnaire, VAS = visual analogue scale, BODE = body mass index, airflow obstruction, dyspnoea, and exercise index. 
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Data synthesis of five trials (Guell et al., 2017; Moullec et al., 2008 & 2010; Roman 
et al., 2013; Spencer, Alison & McKeough, 2010; Wilson et al., 2015) suggests that, 
on average, supervised maintenance exercise following pulmonary rehabilitation 
compared to pulmonary rehabilitation alone significantly reduces the risk of 
experiencing at least one respiratory-cause hospital admission by 38% (Figure 
1.5A). Synthesized data from three trials (Guell et al., 2017; Spencer, Alison & 
McKeough, 2010; Wilson et al., 2015), suggest that, on average, supervised 
maintenance exercise may also influence multiple admissions by reducing the rate 
of respiratory-cause admissions by 28% (Figure 1.5B).  
 
Figure 1.5. Trial-level data, effect estimates and forest plot of comparison for the 
overall risk (of experiencing at least one event) (A) and incidence rates (B) of 
respiratory-cause hospitalisation.  
 
Whilst pooling of studies for other primary measures in this review (relative risk-
reduction in exacerbations requiring treatment with antibiotics and/or systemic 
corticosteroids and all-cause mortality of 21% and 43% respectively) did not 
translate to statistically significant changes, the point estimates of effect do surpass 
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proposed thresholds of clinical significance (Jones et al., 2014a; Wedzicha et al., 
2017) (Figure 1.6 & Figure 1.7).  
 
Figure 1.6. Trial-level data, effect estimates and forest plot of comparison for the 
overall risk of experiencing at least one exacerbation requiring treatment with 
medication. 
 
Figure 1.7. Trial-level data, effect estimates and forest plot of comparison for the 
risk of mortality.  
 
Similarities, with regards to the benefits of exercise on COPD hospitalisation, can 
be seen with Moore et al. (2016) where data from randomised controlled trials on 
health-care use following pulmonary rehabilitation alone compared to no treatment 
were synthesised. However, the Moore et al. (2016) review did not focus on 
interventions aiming to maintain exercise regimens following pulmonary 
rehabilitation, but instead evaluated the short- and long-term benefits of initial 
pulmonary rehabilitation programmes on exacerbations compared to no treatment. 
It was concluded that the delivery of pulmonary rehabilitation to stable COPD 
patients or patients following acute exacerbations results in reduced rates of 
hospitalisations compared with usual care. The findings presented above suggest 
that continuing maintenance exercise in a supervised manner following pulmonary 
rehabilitation may further enhance the benefit on hospitalisations, supporting 
proposals  for an independent effect of exercise on health-care use in COPD. Such 
evidence of the efficacy of exercise alone on incidence of exacerbations further 
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strengthens the potential value of non-pharmacological therapies in the 
management of COPD patients with a history of frequent exacerbations. It also 
suggests that the underlying mechanism of the impact of such interventions (e.g. 
pulmonary rehabilitation) on exacerbations are linked, in part, to effects beyond 
improvements in disease knowledge/management (Evans & Steiner, 2018), and 
may in fact be immune-regulatory or anti-inflammatory effects of exercise (Jenkins, 
Holden & Jones, 2018). To investigate this further, it would be important to compare 
inflammatory responses to pulmonary rehabilitation and/or physical activity 
according to COPD exacerbation phenotypes to determine any potential anti-
inflammatory mechanisms with exercise.  
1.6.3 Exercise & mechanisms of exacerbation & symptom management  
Despite reports of the benefits of exercise-based programmes (pulmonary 
rehabilitation (Moore et al., 2016), and supervised maintenance exercise following 
rehabilitation (Jenkins et al., 2018)), on health-care use outcomes such as COPD 
exacerbations, there is still a paucity of evidence examining the underpinning 
mechanisms (Jenkins, Holden & Jones, 2018). However, in healthy populations, 
there is a body of research demonstrating the effects of exercise on relevant 
mechanistic pathways seen in COPD exacerbations (inflammation, respiratory 
symptoms/infections and immunity). These will be explored in this section and 
subsequently discussed to what extent they have been transferred to COPD 
populations yet.  
 Exercise as an anti-inflammatory intervention in healthy 
It is well established that exercise induces transient changes on immune and 
inflammatory responses that are dependent on exercise intensity, duration and 
frequency (Woods et al., 2012). In healthy populations, moderate exercise intensity 
and frequency has been suggested to enhance immunity with prolonged strenuous 
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exercise suggested to decrease immunity (Walsh et al., 2011). The immune 
response to exercise involves transient changes in several markers of host defence 
and inflammation depending on whether assessments are based on chronic or 
acute effects of exercise (Kruger & Mooren, 2007; McCarthy & Dale, 1988).  
1.7.1 Inflammatory cells 
1.7.1.1 Chronic responses  
Leukocytes and neutrophils play a key role in the innate immune response as a first 
line of defence against invading pathogens (Bouman et al., 2004; Malm, Lenkei & 
Sjodin, 1999; Nieman, 2001). Regular exercise training has been suggested to have 
little impact on blood total leukocyte and neutrophil counts in healthy populations 
(Gleeson & Bishop, 2005). However, there is little understanding on the role 
exercise training may play in neutrophil function (Walsh et al., 2011). Walking 
interventions, in the form of ~30-60 min 2 days a week for 12 weeks, has been 
observed to provide immunological benefits and attenuate oxidative stress when 
compared to a control group (Takahashi et al., 2013). In terms of neutrophil 
activation, this study reported increased expression of the adhesion marker CD62L, 
which is commonly shed (i.e. reduced) upon neutrophil activation, with a 
concomitant decrease in the activation marker CD66b, both findings indicative of a 
protective effect against inflammation (Takahashi et al., 2013). This proposes that 
exercise training in a healthy population, where leukocyte and neutrophil counts are 
at normal levels, may play more of a role in reducing basal neutrophil activation 
marker expression as opposed to decreasing inflammatory cell numbers. However, 
the effects of exercise training in populations characterised by inflammation (i.e. 
increased leukocyte and neutrophil counts) are unclear. 
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1.7.1.2 Acute responses  
It is widely accepted that an acute bout of exercise in a healthy population induces 
an inflammatory response as characterised by an increase in leukocyte and 
neutrophil counts (Petersen & Pedersen, 2005; Walsh et al., 2011). The initial 
response of increased activation and numbers in circulation is an evolutionary 
response to physical stress, and the preparing of the body for immune responses 
to prevent injury or infection (Pedersen & Hoffman-Goetz, 2000). A second delayed 
increase in neutrophil count is also seen in the hours following exercise which is 
related to the intensity and duration of the acute bout of exercise (Peake, 2002; 
Robson et al., 1999). This delayed neutrophilia following more strenuous exercise 
is a temporary immune response with circulating neutrophil levels returning to 
baseline levels within 24 hours of exercise cessation depending on the type of 
exercise undertaken (Mooren et al., 2012).  
Mature neutrophils are mobilised from the marginated pool during exercise (Walsh 
et al., 2011), with immature neutrophils sourced from the bone marrow if acute 
exercise is strenuous (Risoy et al., 2003). Not only does exercise alter neutrophil 
mobilisation, but exercise can also be seen to alter the function of these 
inflammatory cells. An acute bout of exercise has been suggested to result in an 
enhanced neutrophil activation as characterised by increases in neutrophil 
activation markers (CD11b & CD66b) (Gray et al., 1993; Pizza et al., 1996; Smith 
et al., 1996; van Eeden et al., 1999), with decreases also observed in the neutrophil 
adhesion marker CD62L following acute exercise (Kurokawa et al., 1995; van 
Eeden et al., 1999). This demonstrates the short-lived pro-inflammatory nature of 
acute exercise, but regular exercise has been shown to favour an anti-inflammatory 
environment at rest in healthy individuals. 
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1.7.2 Inflammatory mediators   
1.7.2.1 Chronic responses 
It is well established in a healthy population that regular exercise training and being 
physically active reduces systemic inflammation (Jankord & Jemiolo, 2004; Woods 
et al., 2012). This decrease in systemic inflammation is often characterised by 
reductions in circulating IL-6, IL-8, CRP, TNF-α, and fibrinogen concentrations 
following regular moderate aerobic exercise training (Beavers et al., 2010; Ernst, 
1993; Johannsen et al., 2012; Nicklas et al., 2008; Febbraio, 2007; Gleeson, 2007; 
Handschin & Spiegelman, 2008; Pedersen & Febbraio, 2012), demonstrating the 
anti-inflammatory nature of exercise in healthy populations. The mechanisms 
underpinning these anti-inflammatory effects of exercise are not yet well 
established, but have been proposed to be a result of a reduction in cytokine 
production in fat and muscle tissue as part of the ‘adaptive’ response to exercise 
(Kasapis & Thompson, 2005; Ahmadizad, El-Sayed & Maclaren, 2006; Bodary et 
al., 2003; El-Sayed, Ali & El-Sayed, 2005; El-Sayed, Jones & Sale, 1999). Despite 
a lack of clarity around the capacity of exercise training to decrease basal 
inflammatory cell counts in healthy individuals, it is apparent that exercise training 
can provide anti-inflammatory benefits as demonstrated by a reduction of several 
markers of systemic inflammation. 
1.7.2.2 Acute responses 
In a healthy population, the acute inflammatory response to exercise is well 
established with an increase in inflammatory mediators post-exercise before 
returning to baseline levels 24 hours post-exercise (Peake et al., 2017; Woods et 
al., 2012). Strenuous acute exercise in healthy individuals has been seen to induce 
an increase in inflammatory mediators such as IL-6, IL-8, fibrinogen, CRP, TNF-α 
and markers for oxidative stress (e.g. increased ROS production contributing to 
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inflammation and muscular damage following maximal exercise) (Bizheh & Jaafari, 
2011; Montgomery et al., 1996; Petersen & Pedersen, 2005). In particular, these 
responses can be seen during strenuous exercise (Ostrowski et al., 1999), and is 
characterised as an acute inflammatory response to exercise (Alessio, 1993; 
Pedersen & Hoffman-Goetz, 2000). However, there is still a lack of clarity with 
regards to CRP responses to acute exercise as a recent review categorised 
responses as ‘inconclusive’ (Brown et al., 2015). This mainly pro-inflammatory 
response is balanced by the increased release of anti-inflammatory cytokines (e.g. 
IL-10) which act to restrict the magnitude and duration of the inflammatory response 
(Northoff, Weinstock & Berg, 1994, Ostrowski et al., 1999; Pedersen & Hoffman-
Goetz, 2000; Petersen & Pedersen, 2005). The extent of the increase in these 
factors yet again depends on both the intensity and duration of exercise (Reihmane 
et al., 2013).  
When assessing these acute responses, it is important to consider a couple of 
factors. For example, it is believed that exercise training can blunt this acute 
response (Kasapis & Thompson, 2005; Mattusch et al., 2000; Montgomery et al., 
1996), and training state needs to be considered as it is not yet clear whether 
sedentary individuals are more susceptible to an amplified inflammatory response 
when compared to trained individuals (Brown et al., 2015). 
1.7.3 Respiratory symptoms 
Whilst monitoring of respiratory symptoms are not characteristic of healthy adults 
there has been interest in the role of inflammatory parameters in reported 
symptoms following exercise. In healthy populations, exercise-induced changes in 
inflammatory parameters have been suggested to impact upon respiratory 
symptoms linked to infection. For example, heavy exercise training loads 
undertaken in a frequent manner have been linked with an acute increase in 
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respiratory symptoms (Nieman et al., 1990; Peters & Bateman, 1983). There have 
been proposals that increases in pro-inflammatory parameters and exercise-
induced suppression of the immune system provides a mechanistic link for this 
increase in symptoms (Walsh et al., 2011). However, there is an underlying 
uncertainty as to whether these symptoms are a result of infection or rather 
inflammatory stimuli mimicking an URTI (e.g. exercise induced asthma/allergic 
airway inflammation) (Cox et al., 2010; Helenius, Lumme & Haahtela, 2005; Spence 
et al., 2007). There is little available evidence to link mechanisms with increased 
symptoms, but one proposal suggests that an enhanced migration of inflammatory 
cytokines into the airways as a result of exercise induced muscle damage may 
provide a potential mechanism (Peake, Nosaka & Suzuki, 2005; Pedersen et al., 
2001). 
 Exercise as an anti-inflammatory intervention in COPD  
Due to the established evidence in healthy populations, exercise immunology has 
progressed as a field to the stage where exercise can be considered as a potential 
form of anti-inflammatory therapy (Petersen & Pedersen, 2005; Timmons, 2005). 
Given the anti-inflammatory effects seen in healthy individuals, there is a strong 
rationale for assessing the immune response to exercise in individuals with 
inflammatory disease, especially COPD given the increasing evidence of the 
benefits of exercise on relevant clinical endpoints (i.e. exacerbations). An 
international respiratory statement previously highlighted the need to investigate 
the mechanisms behind exercise and inflammation in COPD to understand pro- 
and anti-inflammatory responses (Watz et al., 2014). This is of importance given 
that inflammation is considered a treatable trait in COPD and pharmacological 
therapies to date have been insufficient at tackling inflammation in COPD (Agusti 
et al., 2016).  
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1.8.1 Inflammatory cells 
1.8.1.1 Chronic responses 
There is limited evidence assessing inflammatory cell responses to chronic exercise 
training programmes in patients with COPD. Of the available evidence, previous 
research has suggested that a pulmonary rehabilitation programme does not 
induce significant reductions in blood total leukocyte and neutrophil counts (El 
Gammal et al., 2015; Mercken et al., 2005; Sciriha et al., 2017). However, these 
studies did not assess any markers of neutrophil function which have been shown 
in healthy individuals to be more sensitive to change with chronic exercise training 
programmes than counts alone. Mercken et al. (2005) demonstrated that 8 weeks 
of pulmonary rehabilitation was associated with reduced exercise-induced oxidative 
stress following an acute bout of exercise. This suggests that there is a chronic anti-
inflammatory response to exercise in COPD. Therefore, the ability of exercise 
training to reduce oxidative stress in COPD whilst not enhancing inflammatory cell 
counts can be interpreted as a positive effect (Mercken et al., 2005). Further 
research is required to assess inflammatory cell counts and functional changes in 
response to pulmonary rehabilitation, especially in those susceptible to recurrent 
exacerbations to identify whether a cohort of patients experience an enhanced pro- 
or anti-inflammatory response with exercise training.  
1.8.1.2 Acute responses 
Leukocyte and neutrophil count response to acute exercise is well documented in 
healthy individuals with an acute mobilisation followed by a further delayed 
mobilisation, if the exercise is strenuous enough, in the hours following exercise 
before returning to resting levels 24 hours post-exercise (McCarthy & Dale, 1988; 
McCarthy et al., 1991). A similar inflammatory response to acute exercise has also 
recently been observed in COPD patients following an acute bout of interval walking 
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(Jenkins et al., 2015). Further evidence supports this by demonstrating that 
incremental exercise to symptom limitation in COPD patients induces short-term 
increases in blood neutrophils, lymphocytes and monocytes (Davidson et al., 2012; 
van Helvoort et al., 2005). In COPD, leukocytosis is observed at rest with maximal 
and submaximal exercise workloads inducing further elevations in circulating 
leukocytes, however the relative increase in leukocytes is not classified as 
exaggerated when compared to the inflammatory response seen in healthy 
individuals with exercise (Jenkins et al., 2015; van Helvoort et al., 2005; van 
Helvoort et al., 2006).  It has, however, been suggested, that it is the activation state 
of neutrophils that  requires further investigation in COPD and not the increased 
number, whereby neutrophils have been seen to have greater basal activation in 
COPD (Oudijk et al., 2005; Hoenderdos & Condliffe, 2013). Unfortunately, to date 
there is no available evidence assessing the range of neutrophil activation 
responses to exercise in patients with COPD. There remains a paucity of evidence 
examining leukcotye and neutrophil responses to acute exercise in COPD.  
1.8.2 Inflammatory mediators 
1.8.2.1 Chronic responses 
Of the available evidence assessing changes in inflammatory mediators with 
exercise training in patients with COPD, utilising resistance or endurance training 
of moderate intensity for 8 weeks, research has suggested that the levels of plasma 
IL-6, IL-8, and CRP are not decreased following training (Ryrso et al., 2018). This 
is further supported by previous studies suggesting that 7-8 weeks of pulmonary 
rehabilitation does not modify the circulating levels of IL-6 and CRP (Canavan et 
al., 2007; El Gammal et al., 2015). However, recent evidence has cast doubt over 
this lack of an anti-inflammatory effect of exercise in COPD by showing that a 
moderate intensity exercise training programme is effective in reducing circulating 
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concentrations of CRP and IL-6 (Abd El-Kader, Al-Jiffri & Al-Shreef, 2016; de 
Alencar Silva et al., 2018).   
In terms of physical activity levels, evidence suggests that COPD patients who are 
physically active have lower levels of circulating CRP and IL-6 (Moy et al., 2014). 
This is backed by further studies finding that physical inactivity is independently 
associated with elevated fibrinogen, CRP and TNF-α in COPD (Garcia-Aymerich et 
al., 2009; Waschki et al., 2012; Watz et al., 2008). Some have suggested that the 
mechanisms behind this have been proposed to be due to the lack of skeletal 
muscle use conferring  systemic inflammation in inactive patients as opposed to the 
anti-inflammatory benefits of regular physical activity observed in active patients 
(Handschin & Spiegelman, 2008).  
Despite conflicting findings, all the aforementioned studies do at least propose that 
exercise training and being physically active does not have any pro-inflammatory 
effects in COPD. For example, Canavan et al. (2007) concluded that pulmonary 
rehabilitation is unlikely to enhance systemic inflammation in non-muscle wasted 
COPD patients. This conclusion was also supported by studies of El Gammal et al. 
(2015) and Sciriha et al. (2017) who found that pulmonary rehabilitation did not 
mediate any pro-inflammatory markers in the average COPD patient. Further 
research is required to assess inflammatory responses to exercise training in 
patients in COPD, placing emphasis on patients with higher systemic inflammation 
(e.g. frequent exacerbators), and utilising established biomarkers for exacerbations 
(e.g. fibrinogen).  
1.8.2.2 Acute responses 
It has been proposed that markers such as IL-6 and CRP, which have been seen 
to be elevated in COPD (Gan et al., 2004; Wouters et al., 2007), could be key 
biomarkers to assess in response to exercise (de Alencar Silva et al., 2018; Garrod 
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et al., 2007; van der Vlist & Janssen, 2010). In terms of acute responses in COPD, 
studies have shown that acute exercise to symptom limitation does not induce 
significant changes in the concentrations of IL-6 or CRP (Canavan et al., 2007;  
Spruit et al., 2007; van Helvoort et al., 2005), whereas others have shown  an 
increase in the concentration of IL-6 post-exercise in COPD patients (de Alencar 
Silva et al., 2018).  
Taking this evidence, combined with that seen in healthy populations, it is important 
to assess the implications of pro-inflammatory responses traditionally observed with 
acute exercise, to determine whether this pro-inflammatory response could be 
detrimental in patients with higher systemic inflammation and increased 
susceptibility to infection (e.g. frequent exacerbators). For example, research has 
proposed that an exhaustive acute exercise bout could be detrimental for COPD 
patients due to increased exposure to ROS leading to bursts of acute inflammatory 
responses (van Helvoort et al., 2006). It is also important to examine the role 
exercise training could have on reducing this pro-inflammatory response as 
previous evidence has suggested that acute inflammatory responses to a 
single/acute bout of exercise have been seen to be blunted with exercise training 
(Gokhale, Chandrashekara, & Vasanthakumar, 2007). Further research is required 
to assess and interpret these inflammatory responses to acute exercise in patients 
with COPD, utilising markers of systemic inflammation (e.g. fibrinogen) which are 
heavily implicated in the prognosis of patients (e.g. exacerbation frequency) and 
have been left relatively unexplored.  
1.8.3 Respiratory symptoms  
In COPD, respiratory symptoms are elevated compared to healthy individuals with 
exercise training shown to reduce the burden of these symptoms (Spruit et al., 
2016b). Exercise (pulmonary rehabilitation) has been shown to influence clinical 
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endpoints (risk of exacerbations (Moore et al., 2016)) but, like the evidence 
presented in healthy populations (e.g. respiratory infection), conclusive evidence of 
the mechanisms are not apparent yet. The anti-inflammatory nature of exercise 
training in COPD populations may play a role in this reduced reporting of respiratory 
symptoms (Jenkins, Holden & Jones, 2018). This evidence is based on chronic 
responses to exercise training but it is currently unclear to what extent respiratory 
symptoms may relate to responses to acute exercise. There have been calls for 
ongoing monitoring of respiratory symptoms in COPD patients undergoing exercise 
training (Franssen & Rochester, 2014). Further research is required to develop links 
between exercise and respiratory symptoms in COPD, especially in an acute setting 
whereby acute bouts of strenuous exercise may result in short bursts of 
inflammation which conceivably may increase (perception or incidence of) 
respiratory symptoms and/or exacerbation risk in COPD patients.  
The effects of acute and/or chronic exercise on immune response in COPD are 
heavily understudied and the pro- and anti-inflammatory responses warrant 
investigation (Watz et al., 2014). It is also unclear how immune responses to 
exercise in COPD impact on disease activity (e.g. symptoms and exacerbations) 
and whether important clinical phenotypes display altered immune profiles in 
response to exercise.  
 Summary and Aims 
COPD is a common, preventable and treatable disease characterised by persistent 
respiratory symptoms and largely irreversible and progressive airflow limitation that 
is due to airway and/or alveolar abnormalities induced by exposure to noxious 
stimuli. A distinct subset (phenotype) of patients are more susceptible to frequent 
exacerbations of COPD (a change in dyspnoea, cough and/or sputum production 
that is acute in onset and may warrant a change in regular medication) (Hurst et al., 
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2010). Frequent exacerbators of COPD have heightened levels of local and 
systemic inflammation, which is considered a treatable trait (Agusti et al., 2016), 
and have been key targets of pharmacological approaches in this phenotype, with 
results so far proving unsuccessful. 
Exercise, as part of pulmonary rehabilitation, is considered to be a cornerstone in 
the management of COPD, through improvements in dyspnoea, quality of life and 
exercise capacity (McCarthy et al., 2015). Research to date, has focussed on how 
exercise in COPD affects the overall population, not recognising potential 
differences between phenotypes, especially in terms of compliance to pulmonary 
rehabilitation. Research has also not addressed the mechanisms behind a 
reduction in exacerbations with pulmonary rehabilitation (Moore et al., 2016), and 
exercise alone in COPD (Jenkins et al., 2018). In a healthy population, it is well 
accepted that exercise confers anti-inflammatory and immune-modulatory 
properties which can also been seen in other chronic diseases associated with low-
grade systemic inflammation (Petersen & Pedersen, 2005). There is limited 
research available addressing the effects of pulmonary rehabilitation, and exercise 
in general, on inflammation in frequent and infrequent exacerbators of COPD. 
Research is required to identify if anti-inflammatory effects of exercise are 
demonstrable in COPD patients, and whether such responses differ among clinical 
phenotypes, in order to inform whether non-pharmacological therapies such as 
pulmonary rehabilitation could also be used to target the treatable trait of systemic 
inflammation in frequent exacerbators of COPD.  
The overall aim of this thesis is to assess the effects of exercise on clinical 
outcomes and inflammation and in frequent and infrequent exacerbators of COPD.  
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To do this, this thesis aims to address the following areas: 
• Examine differences in pulmonary rehabilitation completion, clinical 
outcomes, and daily respiratory symptoms between frequent and infrequent 
exacerbators (Study 1) 
• Assess resting inflammation following chronic exercise training as part of 
pulmonary rehabilitation in frequent and infrequent exacerbators (Study 2) 
• Assess changes in corticosteroid inducible anti-inflammatory gene 
expression following pulmonary rehabilitation in frequent and infrequent 
exacerbators (Study 3) 
• Assess inflammatory responses to acute exercise at the start and end of 
pulmonary rehabilitation in frequent and infrequent exacerbators (Study 4) 
• Examine physical activity levels and inflammation in frequent and infrequent 
exacerbators of COPD following pulmonary rehabilitation (Study 5) 
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2 Chapter TWO 
General Methods 
 Ethical Approval 
The experimental procedures in this thesis received National Health Service (NHS) 
& Health Research Authority (HRA) approval via the London-Bromley (Research 
Ethics Committee (REC) Reference – 16/LO/0865) and West Midlands-Edgbaston 
(REC Reference – 18/WM/0081) REC’s. Following NHS & HRA approval, 
procedures were locally approved through the College of Science REC (CoSREC), 
University of Lincoln (CoSREC Reference – CoSREC178; CoSREC Reference – 
CoSREC440). The procedures were fully compliant with; Declaration of Helsinki - 
Recommendations Guiding Physicians in Biomedical Research Involving Human 
Subjects, Lincolnshire Community Health Services (LCHS) Countywide Community 
Respiratory Service (CCRS) Standard Operating Procedures, University of Lincoln 
College of Science Standard Operating Procedures, and University of Lincoln 
College of Science Risk Assessments. All patients & participants provided both 
verbal and written consent prior to involvement.  
 Inclusion Criteria  
2.2.1 COPD patients (Studies 1 - 4) 
COPD patients were included if they had been clinically diagnosed with any severity 
of COPD and had been referred to pulmonary rehabilitation.  
2.2.2 Healthy comparators (Studies 2 & 3) 
Healthy comparators were included if they had not been diagnosed with COPD or 
any other respiratory condition and were characteristically matched (age (between 
45-85 years old) & smoking status (based on exhaled carbon monoxide content)) 
to the COPD patients. 
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 Exclusion Criteria (Studies 1 - 4) 
The exclusion criteria for COPD patients & healthy comparators were; inability or 
unwillingness to sign informed consent, any unstable ongoing cardiovascular 
events which may be exacerbated by exercise, inability to complete walk tests due 
to physical or mental impairment, other active inflammatory conditions e.g. 
rheumatoid arthritis or cancer, and confirmed asthma, allergic rhinitis or other 
respiratory disease (bronchiectasis, pulmonary fibrosis) as a primary or secondary 
diagnosis.  
 Recruitment  
2.4.1 COPD patients (Studies 1 - 4) 
COPD patients were first approached (as part of usual care) by the CCRS of the 
LCHS NHS Trust. Patients were contacted by an appropriate clinician (external to 
this study) to enrol onto pulmonary rehabilitation as part of standard procedures. At 
this point, potential participants received written and verbal information about study 
procedures. Patients consented or declined to being approached by the Chief 
Investigator at the initial assessment for pulmonary rehabilitation.  
At initial assessment, patients were assessed by an appropriately qualified clinician 
(external to the study) for suitability to enrol onto pulmonary rehabilitation based on 
health status (supported by a health-screening questionnaire) and medical history. 
Clinicians also reviewed patient medications, mMRC dyspnoea score, 
comorbidities, and exacerbation history in the previous 12 months. Exacerbation 
events were based on patient recall with verification by medical records and defined 
as a respiratory event that led to a hospitalisation or the prescription of antibiotics 
and/or oral corticosteroids (Calverley et al., 2003). Spirometry measurements were 
obtained from patient records as part of a yearly GP review (in accordance with 
usual screening procedures of pulmonary rehabilitation). All of this information was 
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screened against study inclusion and exclusion criteria. These data were shared 
between LCHS NHS Trust and the University of Lincoln in linked anonymised form.  
If screened patients were deemed eligible and consented to being approached 
about taking part in the research study, they were referred onto the Chief 
Investigator at initial assessment for pulmonary rehabilitation. Procedures for each 
study were explained and further verification of inclusion and exclusion criteria was 
undertaken prior to obtaining written consent. Patients were made aware of their 
right to withdraw at any point without impacting upon the level of care they received. 
Following obtaining consent, patients provided information on age, smoking 
status/history, and comorbidities (presented using the Charlson Comorbidity Index 
(Charlson et al., 1987)) before providing measurements of: height, body mass and 
exhaled carbon monoxide (MicroCO Meter, CareFusion). Patients were then 
defined as either a frequent exacerbator or infrequent exacerbator based on 
reported exacerbation history in the previous 12 months. Frequent exacerbators 
were defined as having 2 or more exacerbations within the previous 12 months 
whilst infrequent exacerbators were defined as having no more than 1 exacerbation 
(Hurst et al., 2010). A flow diagram illustrating the recruitment of COPD patients for 
studies is detailed below (Figure 2.1).  
2.4.2 Healthy comparators (Studies 2 & 3) 
Healthy participants were screened in accordance with the inclusion/exclusion 
criteria and characteristics of pre-existing COPD recruits (e.g. age, gender and 
smoking status). The screening was undertaken by a nurse or General Practitioner 
(GP) based within the relevant GP Medical Practices (Nettleham Medical Practice 
& Lindum Medical Practice). Eligible participants were sent a study information pack 
(containing a cover letter, participant information sheet, consent form, declaration 
of interest form, and pre-paid envelope) by the nurse or GP. Participants who were 
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interested in taking part in the study completed and returned the declaration of 
interest form detailing their preferred method of contact (telephone or email) which 
was used by the Chief Investigator for recruiting participants. The initial contact 
between the Chief Investigator and participant involved the detailed explanation of 
study procedures and booking a visit time at their local GP practice. At the initial 
visit, participants had the opportunity to ask questions before providing verbal and 
written consent prior to study enrolment. During the visit, healthy participants were 
further screened in line with inclusion/exclusion criteria. Eligible healthy participants 
then provided verbal and written consent before collection of height, body mass, 
exhaled carbon monoxide reading (MicroCO Meter, CareFusion), current 
comorbidities (presented using the Charlson Comorbidity Index (Charlson et al., 
1987)), spirometry (MicroLab Spirometer, MicroMedical), medications, and medical 
history. Healthy control participants then provided a single venous blood sample 
(section 2.7) before study participation was completed. The healthy comparator 
group did not partake in any intervention and were used for baseline comparisons 
in inflammation. The recruitment of healthy comparators for studies is detailed 
below (Figure 2.1). 
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Figure 2.1. Flow diagram of COPD patients and healthy comparators throughout 
the studies comprising the thesis 
 
 Pulmonary Rehabilitation 
Pulmonary rehabilitation was delivered by LCHS at two community venues 
(Sudbrooke Drive Community Centre & Bracebridge Community Centre) based in 
Lincoln. The pulmonary rehabilitation programme in Lincolnshire is delivered in 
accordance with NICE accredited BTS pulmonary rehabilitation guidelines (Bolton 
et al., 2013) and adheres to several quality standards as outlined in the UK National 
COPD Pulmonary Rehabilitation Audit in terms of programme content and length 
(Steiner et al., 2016). The pulmonary rehabilitation course, consisting of both 
exercise and education, was 8 weeks in duration with sessions taking place twice 
a week (16 sessions in total). Each session was 2 hr long with 1 hr devoted to 
exercise and 1 hr devoted to education in accordance with BTS guidelines (Bolton 
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et al., 2013). Patients were encouraged to partake in 1 further exercise session a 
week at home as part of the ongoing programme. Sessions were delivered by a 
fully qualified respiratory physiotherapist with the support of a respiratory 
physiotherapy assistant. These classes were specifically designed to improve 
exercise capacity and disease knowledge to help patients improve their 
management of COPD. 
The exercise component of each session consisted of exercises aimed at improving 
cardiorespiratory fitness and muscle strength. Exercises aimed at improving 
cardiorespiratory fitness involved: walking, get up and go, and step-up exercises. 
Exercises aimed at improving muscular strength included: bicep curls, wall press, 
bent arm lateral raise, and cross and reach. Measurement of performance and 
perceived rating of exertion (modified Borg scale (Mahler & Horowitz, 1994)) on 
each exercise was assessed following each session to determine exercise targets 
for the next class in line with clinical judgement. 
The accompanying education component included discussions of the following 
topics: introduction to COPD, nature of the disease, medications in COPD, 
bronchodilators & oxygen, managing exacerbations, chest clearance, breathing 
control, coping strategies 1 (physically), coping strategies 2 (psychologically), 
energy conservation, roles & benefits of exercise, diet & nutrition, relaxation 
therapy, benefits & allowances, previous patient perspective, and post-pulmonary 
rehabilitation options. 
 EXACT® 
During initial assessment for pulmonary rehabilitation patients also had the 
opportunity to consent to filling in a daily respiratory symptoms questionnaire 
(EXACT©, EXACT-PRO initiative, Evidera). Patients filled this in via an online 
platform (Qualtrics Software, Utah, United States) or via a paper copy of the 
 67 
 
questionnaire depending on availability of computer or smartphone access. 
EXACT© is a 14-item daily diary (score range 0-51) used to measure patient 
reported symptoms of exacerbations. Incorporated within this is an E-RS™ 11 item 
subscale (score range 0-40) to measure daily respiratory symptoms. The E-RS™ 
subscale is split into the following domains; Breathlessness (5 items, score range 
0-17), Cough/Sputum (3 items, score range 0-11), and Chest (3 items, score range 
0-12). Patients were instructed to fill in the questionnaire every evening for the week 
leading up to pulmonary rehabilitation commencement to provide a baseline 
measure in accordance with user guidelines (EXACT-PRO Initiative, Evidera). 
Patients were also asked to fill in the questionnaire for the first and last week of the 
pulmonary rehabilitation course to provide chronic (Study 1) and acute (Study 3) 
comparisons. A minimum of 4 data points per week were required for inclusion in 
the analysis in line with previous research (Leidy et al., 2014). This recorded data 
was used to provide a weekly average of respiratory symptoms to be used for 
analysis in line with EXACT© and E-RS™ user guidelines (EXACT-PRO Initiative, 
Evidera). Patients reporting to have had an exacerbation at the beginning and/or 
end of pulmonary rehabilitation were excluded from analyses of EXACT® and E-
RS™ scores. 
 Blood collection (Studies 2 - 5) 
Blood samples were collected in accordance with the standard operating 
procedures of the University of Lincoln and previous research (Jones et al., 2015). 
Participants were advised to remain seated performing minimal movement for 5 min 
prior to each blood sample with the exception of any post-exercise samples that 
were drawn within a few minutes of exercise cessation. Blood samples (~ 10 ml) 
were collected into Ethylenediaminetetraacetic acid (K3EDTA) (6 ml) & Sodium 
Citrate (4.5 ml) treated vacutainers (Greiner Bio-One, Kremsmünster, Austria) from 
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the brachiocephalic vein (via standard venepuncture method), using a 21-gauge 
precision needle. A tourniquet was applied to the upper arm to establish the vein, 
before preparing the skin with an antibacterial alcohol swab. The tourniquet was 
maintained during the needle insertion process, and once blood flow was 
established within the second vacutainer, the tourniquet was released. All blood 
samples were maintained at room temperature to reduce the risk of potential 
temperature influences on cellular processing (Vogelaar et al., 2002). 
 Blood analysis  
2.8.1 Total and differential blood leukocytes (Studies 2, 4, and 5) 
An aliquot of whole blood (1 ml) from each EDTA-treated vacutainer was placed 
into a microcentrifuge tube for haematological analysis (total leukocyte, neutrophil, 
lymphocyte and eosinophil counts) using an automated haematology analyser 
(ABX Pentra 60C+ Haematology analyser, HORIBA Medical, Montpellier, France). 
2.8.2 Inflammatory mediators (Studies 2, 4, and 5) 
2.8.2.1 Fibrinogen 
Circulating fibrinogen concentrations were measured via an enzyme-linked 
immunosorbent assay (ELISA) (Human Fibrinogen ELISA Kit, Assaypro LLC, 
Missouri, USA). Fibrinogen concentration was measured in Sodium Citrate treated 
blood. Following collection, blood was placed in a microcentrifuge tube for 
centrifugation at 2500 x g for 15 min at room temperature. Plasma was aliquoted 
into a new microcentrifuge tube before further centrifugation at 2500 x g for 15 min 
at room temperature. Plasma was then aliquoted (leaving the bottom 10% of 
sample) into a new microcentrifuge tube for storage at -80°C.  
Before performing the ELISA, the plasma samples and ELISA reagents were left to 
thaw at room temperature. All steps of the ELISA including incubations were 
performed at room temperature in accordance with manufacturer instructions.  
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2.8.2.2 C-reactive protein  
Circulating CRP concentrations were measured via ELISA (Human C-Reactive 
Protein ELISA Kit, Assaypro LLC, Missouri, USA). CRP concentration was 
measured in K3EDTA treated blood. Following collection, remaining EDTA treated 
blood (see 2.8.1 and 2.8.4.1) was centrifuged at 1500 x g for 11 min at 4°C before 
aliquoting plasma into microcentrifuge tubes for storage at -80°C.  
Before performing the ELISA, the plasma samples and ELISA reagents were left to 
thaw at room temperature. All steps of the ELISA including incubations were 
performed at room temperature in accordance with manufacturer instructions.  
2.8.3 Flow cytometry (Studies 2 & 4) 
An aliquot of whole blood (50 µl) from each EDTA-treated vacutainer was also used 
to measure the expression of established cell surface markers (CD11b, CD62L, 
CD66b) of neutrophils (CD45high, CD16blow) in COPD via flow cytometry 
(FACSVerse, Becton Dickinson (BD) Biosciences, New Jersey, USA) (Blidberg et 
al., 2012; Blidberg et al., 2013; Fortunati et al., 2009; Hoonhorst et al., 2014; 
Noguera et al., 2001). All blood samples were analysed via flow cytometry within 4 
hrs of collection. 
All conjugated monoclonal antibodies were titrated before use in analysis. 
Antibodies were titrated using a 5-step serial dilution with BD Pharmingen™ Stain 
Buffer (1:1) (BD, New Jersey, USA). For each antibody used to measure neutrophil 
expression, an isotype control was used in a separate tube. An additional unstained 
sample was also used to detect background signal alongside the isotype controls. 
Optimal mean fluorescent intensity signals were calculated against back ground 
signal to determine the optimum concentrations (Table 2.1).  
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Table 2.1. Dilution and concentrations of conjugated monoclonal antibodies 
Marker Fluorochrome Volume Dilution Concentration 
CD16b PE 20 µl 1:2 0.125 µg 
CD45 APC-H7 5 µl 1:4 0.250 µg 
CD62L BV421 5 µl 1:2 0.125 µg 
CD66b Alexa-Fluor 647 5 µl 1:4 0.063 µg 
CD11b/Mac-1 BV510 5 µl 1:2 0.125 µg 
Mouse Immunoglobulin 
M, κ Isotype control 
Alexa-Fluor 647 5 µl 1:16 0.0625 µg 
Mouse Immunoglobulin 
G1, κ Isotype control 
BV510 5 µl 1:8 0.125 µg 
Mouse Immunoglobulin 
G1, κ Isotype control 
BV421 5 µl 1:8 0.125 µg 
PE – R-Phycoerythrin, APC – Allophycocyanin, BV – Brilliant Violet 
Once reagents were titrated, two tubes for each blood sample were prepared, one 
for the isotype control panel and one for the CD panel. The compatibility of 
antibodies and their corresponding fluorochromes were advised by BD for the 
optimisation of the panel. Each tube was prepared by first adding 50 µl Brilliant 
Stain Buffer (BD Biosciences, New Jersey, USA) to a falcon tube, before separately 
adding each diluted marker (CD panel: 20 µl CD16b, 5 µl CD45, 5 µl CD62L, 5 µl 
CD66b, 5 µl CD11b; Isotype control panel: 5 µl Alexa-Fluor 647, 5 µl BV510, 5 µl 
BV421). The Brilliant Stain Buffer was added before the conjugated monoclonal 
antibodies to reduce the risk of inappropriate binding of antibodies as per 
manufacturers recommendations. 50 µl of EDTA-treated whole blood was then 
added to each tube before gently mixing via vortex and incubating for 15 min in the 
dark at room temperature. After the incubation period, 450 µl of lysing solution (BD 
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FACS™ Lysing Solution 10X Concentrate diluted 1:10 with deionized water) was 
added and gently mixed again via vortex before incubating for a further 15 min in 
the dark at room temperature. Following incubation the sample was gently mixed 
again via vortex before analysis by flow cytometry (FACSVerse, Becton Dickinson, 
New Jersey, USA).  
To identify neutrophil populations, the antibody panel was optimised using an assay 
with appropriate voltages to detect all cellular populations in forward-scatter and 
side-scatter plots. A performance quality control was performed each day on the 
FACS Verse before calibrating the assay to reduce the risk of errors in data. 
Granulocyte populations were identified using the gating strategy identified in 
Figure 2.2A resembling the light scatter characteristics of granulocytes as described 
previously (Im et al., 2011). The forward scatter component identifies cells based 
on size, but to isolate granulocytes from other white blood cells (e.g. monocytes), 
the side scatter is important as this identifies the granule component of granulocytes 
as seen by an increased intensity of side scatter (Shapiro, 1985). Neutrophils were 
identified from granulocytes by gating on CD16b+ and CD45+ cells as described in 
previous research (Figure 2.2B) (Cortjens et al., 2017), and recommended by the 
manufacturer.  
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       A        B 
 
Figure 2.2. Gating strategies for identification of neutrophils via flow cytometry. a) 
Gating strategy for identifying granulocytes in whole blood using forward and side-
scatter. b) Gating strategy for identifying neutrophils in the granulocyte population 
using CD45+ and CD16b+.  
 
Neutrophil expression of activation markers (CD11b, CD62L and CD66b) was 
measured based on these events captured by the neutrophil gate (Figure 2.2B) 
using interval gates to measure differences between the isotype and CD panel 
(Figure 2.3). Median fluorescent intensity values of positive shifts in the expression 
of each marker (e.g. CD11b positive, CD62L positive, CD66b positive) were used 
for analysis.  
    A         B           C 
 
Figure 2.3. Interval gating strategy to detect shifts in CD11b (A), CD62L (B) and 
CD66b (C) expression between isotype controls and CD antibody panel.  
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Quad gates were also used to phenotype neutrophil populations (% of total cells) 
based on cellular maturity (mature neutrophils (CD16bhigh/CD62Lhigh), immature 
cells (CD16blow/CD62Lhigh), suppressive neutrophils (CD16bhigh/CD62Llow), and 
progenitor neutrophils (CD16blow/CD62Llow)) by plotting CD62L against CD16b 
(Figure 2.4) in accordance with previous research (Cortjens et al., 2017). The 
percentage of total cells in each gate was extracted for analysis.  
 
Figure 2.4. Quad gating strategy for identifying neutrophil phenotypes using CD16b 
and CD62L. 
 
2.8.4 Anti-inflammatory gene expression (Studies 3 & 5) 
2.8.4.1 PBMC isolation  
For peripheral blood mononuclear cell (PBMC) isolation, 5 ml of K3EDTA treated 
whole blood was carefully layered, with an automated pipette, on top of 3 ml of 
Mono-Poly Resolving Medium (MP Biomedicals, USA) in a 15 ml conical tube. The 
samples were then placed in a centrifuge (Centrifuge 5810R, Eppendorf, Hamburg, 
Germany) and spun for 45 min at 800 x g (room temperature) with deceleration 
(braking) set to the lowest possible setting to reduce cell band disturbance. 
Following centrifugation, plasma was carefully aliquoted and placed in a separate 
15 ml conical tube for further centrifugation (see section 2.8.2.2). After removal of 
plasma, a sterile pasteur pipette was used to carefully remove the PBMC band 
before placing in a separate 15 ml conical tube. 
 74 
 
Gibco™ Roswell Park Memorial Institute (RPMI) Medium 1640 (Life Technologies, 
California, USA) treated with streptomycin (100 µg/ml) and penicillin (100 units/ml) 
(5 ml solution) was added to the PBMC cell solution up to a volume of 10 ml before 
centrifugation for 5 min at 1200 x g (room temperature) with full braking applied. 
Following centrifugation, the RPMI 1640 medium was aspirated leaving a cell pellet 
at the bottom of each tube. A further 1 ml of RPMI 1640 medium was added to the 
cell pellet and thoroughly mixed to prepare a cell solution. For each tube, 10 µl of 
this cell solution was added to 10 µl of trypan blue stain and mixed in a 
microcentrifuge tube. This stained solution was then placed in a cell counting slide 
before analysis on an automated cell counter (TC20 Automated Cell Counter, Bio-
Rad, USA). The automated cell counter was used to calculate a final concentration 
of live cells at 1 x 106 cells/ml. Once the dilutions were calculated, the required 
amount of RPMI 1640 medium was added to the original cell solutions and mixed.  
2.8.4.2 PBMC treatment  
Following dilution of the PBMC’s to a working concentration, 200 µl of the cell 
solution was then aliquoted into a standard 96-well plate with 2 wells for each of the 
following treatment points; not-treated (NT), 2 hr treatment, and 6 hr treatment. The 
96-well plates were then placed in an incubator overnight at 37°C and 5% carbon 
monoxide before treatment with 2 µl of dexamethasone (diluted 1:10 with 1640 
RPMI Medium to make a concentration of 1µM) at selected time points (2 hr and 6 
hr) the following day. Following treatment, the cell solutions were pipetted into 
microcentrifuge tubes and centrifuged for 5 min at 2500 x g at a temperature of 4°C. 
Following centrifugation, the supernatant was discarded, leaving a cell pellet which 
was mixed with 200 µl of RLT lysis buffer (Qiagen, Hilden, Germany) containing 
1:100 diluted β-Mercaptoethanol (Sigma-Aldrich, Missouri, USA) before freezing at 
-80°C for later processing of RNA. 
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2.8.4.3 RNA extraction 
RNA was extracted with the use of a Qiagen RNA extraction kit (RNeasy Mini Kit, 
Qiagen, Germany) with all centrifugation procedures taking place at room 
temperature. Samples were taken out of the -80°C freezer and allowed to thaw 
before the whole cell solution was pipetted into a genomic deoxyribonucleic acid 
(gDNA) eliminator column for centrifugation at 8000 x g for 30 s. The gDNA column 
was then discarded before 200 µl of 70% ethanol solution (diluted with RNase free 
water) was mixed gently with the flow through. The 70% ethanol and cell solution 
was then added to an RNA easy spin column and centrifuged at 8000 x g for 15 s. 
The flow through was this time discarded before a 3-step wash procedure was 
performed. The first wash procedure involved adding 700 µl of buffer RW1 (Qiagen, 
Germany) to the spin column before centrifugation at 8000 x g for 15 s. After 
discarding the flow through, this process was repeated but with 500 µl of buffer RPE 
(55ml RPE concentrate mixed with 4 volumes of 100% ethanol) (Qiagen, Germany). 
Finally, 500 µl of buffer RPE was again added to the spin column before 
centrifugation at 8000 x g for 2 min. After the 3-step wash was completed, the spin 
column was placed in a new collection tube and centrifuged for 1 min at maximum 
speed to dry out the RNA membrane. Following this, the spin column was placed 
in a fresh microcentrifuge tube and 30 µl of RNAse-free water was applied directly 
to the spin column membrane before centrifugation at 8000 x g for 1 min. The spin 
column was then discarded and the microcentrifuge tube containing the RNA was 
frozen at -80°C in preparation for reverse transcription processing.  
2.8.4.4 Reverse transcription 
RNA samples were taken out of the -80°C freezer and allowed to thaw before RNA 
was reverse transcribed to complementary deoxyribonucleic acid (cDNA). 5 µl of 
RNA was aliquoted into 0.2 ml polymerase chain reaction (PCR) tubes and mixed 
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with 15 µl of mastermix consisting of the following; 4 µl of 5X variable input linear 
output (VILO) reaction mix, 2 µl of 10X Superscript enzyme mix (Superscript VILO 
mix, Invitrogen, California, USA) and 9 µl of RNAse free water. The PCR tubes were 
then run through a thermal cycler (T100 Thermal Cycler, Bio-Rad, California, USA) 
using the following protocol; lid temperature of 105°C, solution volume of 20 µl, 
stage 1 at 25°C for 10 min, stage 2 at 42°C for 1 hr, stage 3 at 85°C for 5 min, and 
stage 4 where samples were permanently held at 12°C until removal from the 
thermal cycler. Once the thermal cycle was finished, 180 µl of RNAse free water 
was added to each PCR tube and stored in the fridge at 4°C in preparation for PCR.  
2.8.4.5 PCR 
PCR’s were performed using the following genes: Glyceraldehyde 3-phosphate 
dehydrogenase (GAPDH) (housekeeping gene), MKP-1, and GILZ which are both 
corticosteroid inducible genes (Newton & Holden, 2007).  
2.5 µl of cDNA, or control standards, were mixed in a 96 well plate with 7.5 µl of a 
mastermix containing; 2.1 µl of RNAse free water, 5 µl of Syber Green ER reaction 
mix (Invitrogen, California, USA), 0.2 µl of ROX reference dye (Invitrogen, 
California, USA), 0.1 µl forward primer (GAPDH, MKP-1 or GILZ), and 0.1 µl of 
reverse primer (GAPDH, MKP-1 or GILZ) (see Table 2.2 for primer sequences). 
Standard points consisted of diluted cDNA from the 2 hr and 6 hr treated samples 
with 25 µl of each sample placed into the first tube (S1). 180 µl of RNAse free water 
was added to the remaining tubes (S2, S3, S4, S5) before taking 20 µl from S1 and 
mixing with S2, then 20 µl of S2 was taken into S3 and mixed, with this serial dilution 
repeated to tube S5. 180 µl of RNAse free water was added to a tube assigned as 
water only (W) as the final standard point. Once all samples were mixed, the 96 
well plates were sealed and scoured to secure each well individually before analysis 
using a StepOne Plus Real Time PCR System (Thermo-Fisher, USA). A standard 
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ramp speed test protocol was utilised (~2 hr) consisting of 10 min at 95°C before 
40 cycles of 15 secs at 95°C followed by 1 min at 60°C. Following completion of the 
cycles, a melt curve was performed with incremental increases of 0.3°C from 60°C  
to 95°C. The 96 well plates were labelled according to samples and primers on the 
StepOne Software v2.3 (Thermo-Fisher, USA).  
 Statistical Analysis 
Statistical analyses of all data were performed using the statistical computer 
software package Statistical Package for Social Sciences (SPSS) (v22.00; SPSS 
Inc., Chicago, IL, USA). Graphical representations of data were prepared using 
GraphPad Prism (v7; GraphPad Software Inc., California, CA, USA). All data were 
assessed for normal distribution prior to analysis using Shapiro-Wilk. If necessary, 
data were normalised (e.g. using log transformation) before further analysis. If data 
could not be normalised, a nonparametric equivalent was used. Statistical 
significance was accepted at P < 0.05. 
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Table 2.2. Primer sequences for GAPDH, MKP-1 and GILZ. 
Gene Primer Name Accession Number Sequence Annealing temperature 
GAPDH GAPCF NM_002046.3 TTCACCACCATGGAGAAGGC 
 
60 
GAPCR AGGAGGCATTGCTGATGATCT 
 
60 
MKP-1/DUSP1 MKP1RTF NM_004417.3 GCTCAGCCTTCCCCTGAGTA 
 
60 
MKP1RTR GATACGCACTGCCCAGGTACA 
 
60 
GILZ/TSC22D3 GILZ F NM_001015881.1 
NM_004089.3 
NM_198057.2 
GGCCATAGACAACAAGATCG 
 
60 
GILZR1 ACTTACACCGCAGAACCACCA 
 
60 
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3 Chapter THREE 
Study 1 – Clinical outcomes and respiratory symptoms in response to 
pulmonary rehabilitation in the frequent exacerbator phenotype of COPD  
Abstract 
Patients who suffer frequent exacerbations of COPD are recognised as a distinct 
clinical phenotype. Pulmonary rehabilitation is considered one of the most 
beneficial treatments for COPD inducing improvements in exercise capacity and 
quality of life. However, responses to pulmonary rehabilitation between frequent 
and infrequent exacerbators remain unclear. Based on exacerbation history in the 
previous year, 85 mild-very severe COPD patients (FEV1 pred, 52±18%) were 
categorised as frequent (≥2 exacerbations) or infrequent exacerbators (≤1 
exacerbation). The following clinical outcomes for pulmonary rehabilitation were 
analysed: completion rates, incremental shuttle (ISWT) & endurance shuttle walk 
tests (ESWT), chronic respiratory disease questionnaire (CRQ), hospital anxiety 
and depression scale (HADS). The Exacerbations of COPD tool (EXACT®) and 
Evaluating Respiratory Symptoms (E-RS™) measure were also completed daily for 
a week at the beginning and end of rehabilitation. Frequent exacerbators were less 
likely to complete pulmonary rehabilitation (44% vs 69%; p=0.025). Both groups 
experienced significant improvements in ISWT (p<0.001), ESWT (p<0.001) and 
quality of life measures (CRQ (all domains), p<0.001; Depression, p=0.017). 
Pulmonary rehabilitation significantly reduced total EXACT® (p=0.009) and E-RS™ 
scores (p=0.013). Frequent exacerbators were less likely to complete pulmonary 
rehabilitation, but those who complete appear to experience similar benefits to 
infrequent exacerbators. Pulmonary rehabilitation should be encouraged in both 
frequent and infrequent exacerbators of COPD.  
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 Introduction 
Pulmonary rehabilitation is considered to be one of the most cost-effective options 
for treating COPD (Griffiths et al., 2001; Hoogendoorn et al., 2010; Mayers et al., 
2007; Oba, 2007). The benefits of pulmonary rehabilitation are profound in the 
COPD population, especially when assessing outcomes such as exercise capacity 
and quality of life (Nici et al., 2006). However, not all patients who enrol onto, and 
complete pulmonary rehabilitation see the same benefits. Spruit et al. (2015a) have 
previously categorised four subsets of patients following pulmonary rehabilitation: 
‘very good responders’, ‘good responders’, ‘moderate responders’ and ‘poor 
responders’. This has led to proposals that clinical factors such as comorbidities or 
phenotypes might play an influential role in responses to pulmonary rehabilitation 
(Ambrosino et al., 2015; Hassan et al., 2016; Kaul, Farokhi & Megally, 2018).  
One of the most established clinical phenotypes of COPD is the frequent 
exacerbator phenotype which has been shown to be relatively stable (Donaldson 
et al., 2013; Hurst et al., 2010). This phenotype is of significant clinical interest due 
to these patients having increased risk of hospitalisations and mortality (Steer, 
Gibson & Bourke, 2012). Frequent exacerbators also make more visits to their GP, 
receive more medication, and are associated with faster declines in lung function 
and health-related quality of life (Wedzicha, Mackay & Singh, 2013). As future 
exacerbations are best predicted by previous history of exacerbations, there are 
calls for therapies to target this phenotype (Vestbo & Lange, 2015).  
Limited research has assessed responses to pulmonary rehabilitation between 
frequent and infrequent exacerbators of COPD. It has previously been shown that 
exacerbations are a risk factor for non-completion of pulmonary rehabilitation as 
these events have been associated with dropout or poor attendance at outpatient 
pulmonary rehabilitation (Fischer et al., 2009). It has also been shown that acute 
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exacerbations of COPD following pulmonary rehabilitation can have an acute 
detrimental effect on exercise capacity and quality of life (Carr, Goldstein & Brooks, 
2007). However, Bohn et al. (2017) suggested that in patients who manage to 
complete outpatient pulmonary rehabilitation, improvements in exercise capacity 
can be seen to be larger in exacerbators compared to non-exacerbators. This 
improvement was measured by performance in the 6MWT with clinically significant 
improvements in exercise capacity observed in both groups but higher 
improvements were seen in frequent exacerbators. However, improvements in 
quality of life outcomes measured by the SGRQ were not significantly different 
between groups (Bohn et al., 2017). Another study also found that the subgroup of 
‘responders’ to inpatient pulmonary rehabilitation, defined as having achieved the 
MCID for 6MWT, was made up of a higher percentage of frequent exacerbators 
compared to infrequent exacerbators (Zanini et al., 2013). This demonstrates that 
studies are currently limited in this area, especially utilising alternative clinical 
outcomes measures (e.g. ISWT and ESWT) and different settings (e.g. community-
based), and provide conflicting findings creating uncertainty with regards responses 
to pulmonary rehabilitation between the exacerbator phenotypes.   
The benefits of pulmonary rehabilitation stem beyond that of improvements in 
quality of life and exercise capacity. Another key benefit of pulmonary rehabilitation 
is a reduction in breathlessness (McCarthy et al., 2015; Ries et al., 2007). 
Respiratory symptoms are important outcomes to assess in the early detection of 
exacerbations (Beghe et al., 2013). Patients who experience frequent 
exacerbations have been seen to present with significantly higher mMRC dyspnoea 
scores (McGarvey et al., 2015). However, it is important to assess respiratory 
symptoms beyond breathlessness alone including chest tightness, cough and 
sputum production in order to provide a more comprehensive understanding of 
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COPD management, particularly in relation to exacerbation risk (Leidy & Murray, 
2013). In the context of pulmonary rehabilitation, respiratory symptoms are often 
measured as part of a combined assessment of health status (e.g. CAT scores) 
(Bolton et al., 2013). However, this questionnaire relies on patient recall of 
respiratory symptoms over a period of time, not factoring in daily fluctuations in 
symptoms (Dodd et al., 2011). In COPD, respiratory symptoms can fluctuate 
significantly between days, and even within individual days, suggesting that 
patients are susceptible to under- or over-estimating their respiratory symptoms 
when filling in retrospective questionnaires (Kessler et al., 2006; Kessler et al., 
2011; Partridge, Karlsson & Small, 2009). Further research also demonstrates this 
fluctuation in symptoms is accompanied with a steady progression of symptoms 
over time which has been closely related to the frequent exacerbator phenotype 
(Huerta et al., 2015) 
Recently, the EXACT® questionnaire has been developed and validated to 
overcome limitations of previous tools and provide a standardised daily diary to 
assess exacerbations and respiratory symptoms in COPD (Leidy et al., 2010; Leidy 
et al., 2014). This 14-item questionnaire, with subscales monitoring specific 
respiratory symptoms, monitors daily respiratory symptoms in COPD and both the 
EXACT® and E-RS™ have been used in a number of clinical trials of 
pharmacological therapies, proving sensitive for detecting exacerbations and 
changes in respiratory symptoms (Beier et al., 2017; Papi et al., 2017; Tabberer et 
al., 2018). However, these patient reported outcomes have not yet been 
implemented in the context of pulmonary rehabilitation to assess respiratory 
symptoms upon enrolment and response to treatment across relevant clinical 
phenotypes.  
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This study aimed to assess the differences in clinical outcomes and daily reported 
respiratory symptoms pre- and post-pulmonary rehabilitation in frequent and 
infrequent exacerbators of COPD. It was hypothesised that frequent exacerbators 
would be: less likely to complete pulmonary rehabilitation, report greater respiratory 
symptoms but this would be reduced upon completion of pulmonary rehabilitation, 
and achieve comparable clinical benefit to infrequent exacerbators. 
 Methods 
3.2.1 Participants 
Eighty-five COPD patients enrolled on to pulmonary rehabilitation (age 69.5 ± 7.1 
years; FEV1 pred 52 ± 18%; frequent exacerbators = 50; infrequent exacerbators = 
35) between June 2016 and August 2018 and consented to take part in this study.  
3.2.2 Pulmonary rehabilitation baseline and outcome assessment 
Prior to attendance at initial assessment, participants were required to complete the 
HADS (Zigmond & Snaith, 1983) (anxiety and depression domains) and CRQ 
(Williams et al., 2003) (dyspnoea, emotion, fatigue, and mastery domains). 
The participants then performed 3 walk tests (2 x ISWT, 1 x ESWT) to determine 
exercise capacity and tolerance. These walk tests were conducted in accordance 
with European Respiratory Society/American Thoracic Society field test guidelines 
(Holland et al., 2014). Each test was separated by at least 20 min to allow sufficient 
time for recovery. Patients first performed an ISWT on a flat, level surface within a 
community hall. Patients were instructed to walk to and around cones that were 9 
metres apart in time with the bleeps. The walk test was ended when patients were 
unable to make the cone before the bleep sounded or, if patients requested to stop, 
or if the physiotherapist noticed a clear deterioration in health. Following the rest 
period and completion of the repeated ISWT, the furthest distance achieved 
between tests was used to calculate the level to be used on the ESWT in 
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accordance with test guidelines (Revill et al., 1999). The ESWT was performed 
using the procedures outlined for the ISWT.  
The questionnaires and walk tests were repeated at the final assessment following 
completion of the community pulmonary rehabilitation programme. Completion of 
community pulmonary rehabilitation was defined as attendance at 12 or more 
sessions in accordance with previous research (Boutou et al., 2014), and national 
recommendations for pulmonary rehabilitation (Department of Health, 2012b). 
Clinical outcome data were only included if patients met the outlined criteria for 
completion.  
3.2.3 EXACT®  
At initial assessment patients consented to filling in the daily EXACT© questionnaire 
(EXACT-PRO Initiative, Evidera). Questionnaire delivery was determined via 
patient preference (see section 2.6). Patients were instructed to complete the 
questionnaire daily in the week leading up to the beginning of pulmonary 
rehabilitation to provide a baseline measure. Patients then completed the 
questionnaire again for each of the last seven days of pulmonary rehabilitation to 
provide an end of rehabilitation measure. Any patients who reported to have had 
an exacerbation during pulmonary rehabilitation were removed from this specific 
analysis. 
3.2.4 Statistical Analysis 
Data on the proportion of patients within each group (frequent vs infrequent 
exacerbators) who did not complete pulmonary rehabilitation was reported using 
chi-squared analysis. Clinical outcomes (ISWT, ESWT, HADS, CRQ), mean 
EXACT© scores, and mean E-RS™ subscale (including individual domains; 
Breathlessness, Cough/Sputum, and Chest) were analysed using a two-way mixed 
Analysis of Variance (ANOVA) with Bonferroni correction to assess changes 
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between frequent and infrequent exacerbators pre- and post-pulmonary 
rehabilitation. The proportion of participants in each group (frequent and infrequent 
exacerbators) to achieve MCID’s in the following outcomes: ISWT (↑47.5m) (Jones 
et al., 2014a), ESWT (↑154m) (Altenburg et al., 2015), HADS (anxiety, ↓1.3 points; 
depression, ↓1.5 points) (Smid et al., 2017), CRQ (↑0.5 point average) (Jones et 
al., 2014a), and E-RS™ (overall, ↓3 points; breathlessness, ↓2 points; 
cough/sputum, ↓1 point; chest, ↓1 point) (Yang et al., 2018), were also compared 
using chi-squared analysis. Statistical significance was accepted at P < 0.05. 
 Results 
3.3.1 Patient characteristics 
The patient characteristics of frequent and infrequent exacerbators are detailed in 
Table 3.1. All frequent exacerbators were categorised as GOLD grade D (100%) 
with the majority of infrequent exacerbators classified as GOLD grade B (89%). The 
majority of frequent and infrequent exacerbators were categorised as either mMRC 
grade 2, grade 3, or grade 4.  
  
 86 
 
Table 3.1. Patient characteristics 
 
 
Variable 
 
 
Frequent 
 
 
Infrequent 
Age (years)a 69.6 ± 7.0 69.3 ± 7.3 
% Malesb 58% 57% 
Body Mass (kg)a 77.3 ± 17.7 83.0 ± 18.9 
GOLD grade, n (%)c   
A 0 (0) 4 (11) 
B 0 (0) 31 (89) 
C 0 (0) 0 (0) 
D 50 (100) 0 (0) 
FEV1 %predicteda 48 ± 16 57 ± 20 
Charlson Comorbidity Indexa 4.2 ± 1.3 4.2 ± 1.2 
Current smokersb 32% 23% 
mMRC, n (%)c   
0 0 (0) 2 (6) 
1 0 (0) 2 (6) 
2 3 (6) 7 (20) 
3 16 (32) 9 (25) 
4 31 (62) 15 (43) 
aData presented as mean ± SD. bData presented as a % of total population. cData presented as 
total number (% of group). Frequent, n = 50; infrequent, n = 35. 
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3.3.2 Completion rates 
Of those who consented to take part in the study, 54% of COPD patients completed 
pulmonary rehabilitation (frequent exacerbators, n = 22; infrequent exacerbators, n 
= 24). Frequent exacerbators were significantly less likely to complete pulmonary 
rehabilitation when compared to infrequent exacerbators (44% vs 69%; p = 0.025) 
(Figure 3.1). 
 
Figure 3.1. Pulmonary rehabilitation completion rates between frequent and 
infrequent exacerbators. Data presented as % of group to attend 12 or more 
pulmonary rehabilitation classes.*Significant difference between groups (p < 0.05). 
 
3.3.3 Clinical outcomes 
3.3.3.1 Exercise capacity  
A subset of COPD patients did not undertake either the ISWT (frequent, n = 1; 
infrequent, n = 4) or ESWT (frequent, n = 2; infrequent, n = 5) during initial 
assessment for pulmonary rehabilitation meaning exercise capacity data were not 
available for these patients.  
A significant main effect of time was observed showing improvements in exercise 
capacity in both frequent and infrequent exacerbators (ISWT, p < 0.001; ESWT, p 
< 0.001). Both groups met the MCID for ESWT (>↑154m), but only the frequent 
exacerbators group as a whole met the MCID for ISWT (frequent, ↑61m; infrequent, 
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↑41m). Chi-squared analysis demonstrated a larger proportion of infrequent 
exacerbators met the MCID for improvement on the ESWT when compared to 
frequent exacerbators (29% vs 60%; p = 0.038). No significant differences  were 
observed in the proportion of patients in each group who met the MCID for ISWT 
with chi-squared analysis (62% vs 45%; p = 0.278). The ANOVA found no 
independent effects of group (ISWT, p = 0.860; ESWT, p = 0.276), nor were there 
any indications of a time × group interaction (ISWT, p = 0.390; ESWT, p = 0.207) 
(Table 3.2). 
 
Table 3.2. Walk test outcomes pre- and post-rehabilitation  
 
 
 
Walk Test 
 
 
 
Frequent 
 
 
 
Infrequent 
 
Time  
main 
effect 
p-values  
 
Time × group 
interaction 
 
Group  
main 
effect 
ISWT (m)   <0.001* 0.390 0.860 
Pre-Rehab 258 ± 149 262 ± 124    
Post-Rehab 319 ± 147 303 ± 121    
ESWT (m)   <0.001* 0.207 0.276 
Pre-Rehab 347 ± 522 327 ± 325    
Post-Rehab 585 ± 588 794 ± 521    
Data presented as mean ± SD. *Significant main effect of time (p < 0.001). ISWT: frequent, n = 21; 
infrequent, n = 20. ESWT: frequent, n = 20; infrequent, n = 19. 
 
3.3.3.2 Quality of life 
A significant main effect of time showing improvements in all domains of the CRQ 
were observed post-rehabilitation with MCID’s met in both frequent and infrequent 
exacerbators (p < 0.001). Chi-squared analysis demonstrated that there were no 
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significant differences in terms of proportion of frequent and infrequent 
exacerbators to meet the MCID for improvement on the CRQ (50% vs 71%; p = 
0.091). There were no significant group effects on absolute changes in scores of 
CRQ subdomains (Dyspnoea, p = 0.899; Emotion, p = 0.861; Fatigue, p = 0.291; 
Mastery, p = 0.345). No time × group interactions were observed in any of the CRQ 
subdomains between frequent and infrequent exacerbators (Dyspnoea, p = 0.453; 
Emotion, p = 0.452; Fatigue, p = 0.206; Mastery, p = 0.837) (Table 3.3).  
3.3.3.3 Anxiety & Depression 
A significant main effect of time was observed showing a reduction in depression 
scores following pulmonary rehabilitation in both frequent and infrequent 
exacerbators (p = 0.017). However, anxiety (p = 0.197) was not significantly 
reduced as a result of pulmonary rehabilitation. The change in anxiety following 
pulmonary rehabilitation within infrequent exacerbators (↓1.38 points) did meet the 
MCID. MCID’s were not reached for depression in either group as a whole. Chi-
squared analysis showed that no significant differences were observed in the 
proportion of patients in each group who met the MCID for anxiety (36% vs 46%; p 
= 0.685) and depression (45% vs 50%; p = 0.979). The ANOVA found no significant 
group effects between frequent and infrequent exacerbators (Anxiety, p = 0.503; 
Depression, p = 0.348), nor were any time × group interactions observed (Anxiety, 
p = 0.142; Depression, p = 0.538) (Table 3.3).  
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Table 3.3 CRQ and HADS outcomes following pulmonary rehabilitation  
 
 
 
Domains 
 
 
 
Frequent 
 
 
 
Infrequent 
 
Time 
main 
effect 
p-values  
 
Time × group 
interaction 
 
Group 
main 
effect 
Dyspnoea score   <0.001** 0.453 0.899 
Pre-Rehab 2.60 ± 1.28 2.45 ± 1.05    
Post-Rehab 3.58 ± 1.43 3.74 ± 1.14    
Emotion score   <0.001** 0.452 0.861 
Pre-Rehab 4.52 ± 1.37 4.34 ± 1.30    
Post-Rehab 4.98 ± 1.09 5.04 ± 1.17    
Fatigue score   <0.001** 0.206 0.291 
Pre-Rehab 3.70 ± 1.34 3.83 ± 1.42    
Post-Rehab 4.09 ± 1.12 4.66 ± 1.06    
Mastery score   <0.001** 0.837 0.345 
Pre-Rehab 4.34 ± 1.58 4.67 ± 1.43    
Post-Rehab 4.99 ± 1.29 5.38 ± 1.10    
Anxiety score   0.197 0.142 0.503 
Pre-Rehab 6.45 ± 4.79 7.96 ± 4.32    
Post-Rehab 6.55 ± 3.61 6.58 ± 4.04    
Depression score   0.017* 0.538 0.348 
Pre-Rehab 6.09 ± 4.36 7.33 ± 4.56    
Post-Rehab 5.41 ± 3.83 6.00 ± 4.30    
Data presented as mean ± SD. *Significant main effect of time (* p < 0.05, ** p <0.001). Frequent, 
n = 22; infrequent, n = 24. 
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3.3.4 EXACT® and E-RS™  
A subset of patients (frequent, n = 14; infrequent, n = 16) provided sufficient daily 
EXACT® data in the week prior to pulmonary rehabilitation and in the final week of 
the course. There were 3 patients who experienced an exacerbation in the frequent 
group and 2 in the infrequent group leaving 11 frequent and 14 infrequent 
exacerbators in the analysis.  
Pulmonary rehabilitation significantly reduced the average EXACT® weekly score 
in both frequent and infrequent exacerbators (p = 0.009). There was a tendency 
towards a time × group interaction with EXACT® scores but this was not found to 
be statistically significant (p = 0.065). There were no significant differences between 
groups for average weekly EXACT® score (p = 0.120) (Table 3.4). 
The E-RS™ domain was significantly reduced following pulmonary rehabilitation in 
both frequent and infrequent exacerbators (p = 0.013). No significant time × group 
interactions were observed (p = 0.104), nor were there any significant differences 
between groups for the E-RS™ domain (p = 0.189) (Table 3.4). Chi-squared 
analysis showed no significant differences in the proportion of patients in each 
group who met the MCID for the E-RS™ Total (45% vs 36%; p = 0.622).  
Pulmonary rehabilitation significantly reduced scores in the Breathlessness domain 
(p = 0.023), with a tendency towards a similar reduction in the Chest domain (p = 
0.060). There were no significant reductions observed in the Cough/Sputum 
domain following pulmonary rehabilitation (p = 0.136). There was a tendency 
towards a significant time × group interaction in the Cough/Sputum domain but this 
was not found to be statistically significant (p = 0.074). There were no  significant 
time × group interactions in the Breathlessness (p = 0.232) and Chest domains (p 
= 0.270) with pulmonary rehabilitation. There were also no significant differences 
between groups across all of the symptom specific domains (Breathlessness, p = 
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0.263; Cough/Sputum, p = 0.288; Chest, p = 0.357) (Table 3.4). Chi-squared 
analysis demonstrated no significant differences in the proportion of patients in 
each group who met the MCID for the: Breathlessness (36% vs 29%; p = 0.678), 
Cough/Sputum (27% vs 14%; p = 0.420), and Chest domains (45% vs 29%; p = 
0.383). 
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Table 3.4. Patient reported EXACT® questionnaire scores 
Data presented as mean ± SD. Frequent, n = 11; infrequent, n = 14. *Significant main effect of time 
(* p < 0.05, ** p <0.001).  
 
 
 
EXACT® domain 
 
 
 
Frequent 
 
 
 
Infrequent 
 
Time  
main 
effect  
 
p-values  
 
Time × group 
interaction 
 
Group  
main 
effect 
EXACT®-Total  
score 
  0.009* 0.065 0.120 
Pre-Rehab 21.7 ± 8.7 15.6 ± 6.5    
Post-Rehab 17.4 ± 6.5 12.6 ± 5.3    
E-RS™-Total  
score 
  0.013* 0.104 0.189 
Pre-Rehab 17.7 ± 6.5 13.6 ± 5.7    
Post-Rehab 13.8 ± 4.8 12.7 ± 4.2    
Breathlessness  
score 
  0.023* 0.232 0.263 
Pre-Rehab 9.0 ± 4.1 7.1 ± 3.2    
Post-Rehab 7.5 ± 3.0 6.6 ± 2.5    
Cough/Sputum  
score 
  0.136 0.074 0.288 
Pre-Rehab 3.2 ± 0.7 2.5 ± 1.1    
Post-Rehab 2.5 ± 1.0 2.6 ± 0.6    
Chest  
score 
  0.060 0.270 0.357 
Pre-Rehab 3.7 ± 2.0 2.7 ± 1.7    
Post-Rehab 2.6 ± 2.3 2.4 ± 1.7    
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 Discussion 
The main findings from this study suggest that frequent exacerbators are less likely 
to complete pulmonary rehabilitation compared to infrequent exacerbators but in 
those who complete pulmonary rehabilitation, they on average experience similar 
absolute changes in clinical outcomes compared to infrequent exacerbators.  
There is a depth of research assessing how exacerbations may predict completion 
of pulmonary rehabilitation in a mixed cohort but a paucity of studies have 
prospectively investigated the frequent exacerbator phenotype in pulmonary 
rehabilitation. The lower completion rates in frequent exacerbators observed in the 
present study may relate to previous evidence where  exacerbations have been 
reported as a prominent cause of poor uptake and completion of pulmonary 
rehabilitation (Fischer et al., 2009; Hayton et al., 2013; Jones et al., 2014b; Keating, 
Lee & Holland, 2011).  The average completion rate for the current study was 54%, 
which is lower than the national average (62%) reported in the recent UK National 
COPD Pulmonary Rehabilitation Audit (Steiner et al., 2018). This would suggest 
that pulmonary rehabilitation completion rates are poorer in Lincoln compared to 
that observed nationally in the COPD audit (Steiner et al., 2018). Frequent 
exacerbators were observed to have completion rates 18% lower than the national 
average (44% vs 62%) suggesting that the frequent exacerbator phenotype may be 
contributing more than infrequent exacerbators to this poor completion rate (Steiner 
et al., 2018). Although this study suggests frequent exacerbators are less likely to 
complete pulmonary rehabilitation, this study did not provide evidence on the 
specific reasons for drop-out which may directly or indirectly be related to incidence 
of exacerbations (e.g. transportation issues) (Hayton et al., 2013; Keating, Lee & 
Holland, 2011). Future larger scale studies are required assessing the frequent 
exacerbator phenotype and completion rates. Future studies should also gather 
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data on reasons for drop-out to see whether the increased susceptibility to recurrent 
exacerbations in this phenotype is a factor in poor completion of pulmonary 
rehabilitation.  
This study has shown that frequent exacerbators benefit from pulmonary 
rehabilitation in a similar manner to infrequent exacerbators. Improvements in 
traditional outcomes such as: ISWT, ESWT, CRQ and Depression were observed 
in both groups agreeing with previous literature in the COPD population (McCarthy 
et al., 2015). These findings also agree with those of Bohn et al., (2017), Steele et 
al., (2010), and Zanini et al., (2013) showing that frequent exacerbators can 
experience significant benefits as a result of pulmonary rehabilitation, although the 
current study was unable to suggest that frequent exacerbators respond better to 
pulmonary rehabilitation than infrequent exacerbators as seen in the 
aforementioned studies. However, it is important to note that acute exacerbations 
in the post-rehabilitation setting in COPD patients who complete pulmonary 
rehabilitation can have clinically significant reductions in exercise capacity and 
quality of life outcomes (Carr, Goldstein & Brooks, 2007). Furthermore, the 
proportion of patients in each group who met the MCID for the aforementioned 
outcomes was also similar barring the ESWT outcome where infrequent 
exacerbators were more likely to meet the MCID. However, our findings also 
suggest that only the frequent exacerbators group as a whole met the MCID for 
improvement in ISWT. It is important to note that despite no statistically significant 
reductions in anxiety being observed, contrary to previous findings (McCarthy et al., 
2015), only infrequent exacerbators as a whole met the MCID for anxiety and 
neither group met the MCID for depression. It has, however, been shown that 
reductions in anxiety and depression are largely observed in COPD patients 
presenting with severe symptoms (e.g. >11 points) (Harrison et al., 2012), and that 
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the effect of pulmonary rehabilitation can often be underestimated when utilising 
patients with mild symptoms as observed in the current study. Taken together, the 
available evidence suggests COPD patients achieve benefits in the majority of 
traditional clinical outcomes from completion of pulmonary rehabilitation 
irrespective of exacerbation history, but further research is required assessing the 
magnitude of change, particularly in achieving MCID’s for ISWT, ESWT and HADS. 
To date, this is the first study to utilise the recently validated EXACT® tool in the 
context of pulmonary rehabilitation for monitoring exacerbations and respiratory 
symptoms. This study found that pulmonary rehabilitation was effective in reducing 
total EXACT® scores, E-RS™ domain scores and breathlessness scores. These 
findings using the EXACT® tool agree with previous research utilising the CAT 
showing that pulmonary rehabilitation is effective in reducing respiratory symptoms 
(Dodd et al., 2011). The EXACT® questionnaire was designed to standardise the 
assessment of respiratory symptoms including daily fluctuations (Leidy & Murray, 
2013), rather than provide respiratory symptoms based on patient recall at isolated 
timepoints as seen with the CAT (Dodd et al., 2011). However, it is important to 
note that only a subset of patients in this study completed the questionnaire due to 
feasibility issues. For example, willingness to use and access internet platforms 
were a common issue with some patients opting to complete the questionnaire via 
paper. This may again highlight the challenges of utilising technology in an older 
population (Deng, Mo & Liu, 2014). The use of a paper copy of this questionnaire, 
however, introduces elements of bias and is not the preferred mode of delivery in 
the guidance (EXACT-PRO Initiative, Evidera), but issues with internet availability 
and general questionnaire compliance resulted in the introduction of this format. 
Therefore, future research is warranted assessing the feasibility of monitoring 
respiratory symptoms utilising the EXACT® tool throughout the duration of the 
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rehabilitation course and draw comparisons between frequent and infrequent 
exacerbators.  
There are some important factors to consider when interpreting the results of this 
study. Although there were lower completion rates in the frequent exacerbator 
group, there may be contributing factors that were not considered in this study that 
have recently been identified to be linked to poor completion (e.g. frailty, social 
deprivation) (Maddocks et al., 2016; Steiner et al., 2017b). The effects of these 
factors cannot be dismissed, but the aim of the current study was to identify how 
the frequent exacerbator phenotype relates to response to pulmonary rehabilitation. 
Depression and smoking status are other key recognised barriers for non-
completion (Hayton et al., 2013; Keating, Lee & Holland, 2011). However, the 
current study observed comparable characteristics across groups in terms of 
proportion of smokers, depression and other characteristics (e.g. number of 
comorbidities). The EXACT® analyses must also be interpreted with caution as 
these findings only included patients who remained clear of exacerbations during 
pulmonary rehabilitation. This study also excluded COPD patients with co-existing 
lung conditions which must be factored in when interpreting the results of the study. 
This was undertaken to ensure the exacerbation history was related to 
exacerbations of COPD and not that of other lung conditions.  
In conclusion, frequent exacerbators were less likely to complete pulmonary 
rehabilitation compared to infrequent exacerbators. Frequent exacerbators can 
expect to see the same benefits in terms of improvements in exercise capacity and 
quality of life measures. Pulmonary rehabilitation was also effective in reducing 
respiratory symptoms in frequent and infrequent exacerbators as measured by the 
newly validated EXACT® tool. Further research is required assessing responses to 
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pulmonary rehabilitation among the frequent exacerbator phenotype and assessing 
the feasibility of the EXACT® tool in the context of pulmonary rehabilitation.  
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4 Chapter FOUR 
Study 2 – The chronic effects of pulmonary rehabilitation on inflammation 
and immunity in frequent and infrequent exacerbators of COPD 
Abstract 
Frequent exacerbators of COPD have been suggested to have heightened 
systemic inflammation. Exercise in healthy populations has been proposed to 
confer anti-inflammatory properties. The aim of this study was to see whether 
pulmonary rehabilitation modulates markers of systemic inflammation in frequent 
and infrequent exacerbators of COPD. Blood samples were analysed from 30 mild-
very severe COPD patients (FEV1 pred, 52 ± 17%; frequent, n = 16; infrequent, n = 
14) at the start and end of pulmonary rehabilitation. The primary outcome was 
fibrinogen concentration. Secondary outcomes included: CRP concentration, total 
and differential leukocyte counts, neutrophil activation (CD11b, CD62L & CD66b), 
and neutrophil maturity (mature, immature, suppressive, progenitor). Pulmonary 
rehabilitation significantly reduced the resting concentrations of fibrinogen (p = 
0.033). Reductions in total leukocyte (p = 0.018) and blood neutrophil counts (p = 
0.018) were observed at the end of pulmonary rehabilitation in frequent 
exacerbators only. Pulmonary rehabilitation did not significantly reduce the resting 
concentration of plasma CRP (p = 0.937) or blood neutrophil expression of CD11b 
(p = 0.553), CD62L (p = 0.070), or CD66b (p = 0.317). Pulmonary rehabilitation 
significantly reduced the percentage of progenitor neutrophils in both groups (p = 
0.015). None of the other neutrophil subsets were significantly affected by 
pulmonary rehabilitation (mature, p = 0.313; immature, p =0.756; suppressive p = 
0.259).  This study suggests that pulmonary rehabilitation has the potential to 
modify surrogate markers of exacerbation risk in COPD and reduce levels of 
systemic inflammation in frequent exacerbators. Further studies are required to 
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explore the potential anti-inflammatory effects of exercise in COPD and its 
phenotypes utilising both pro- and anti-inflammatory markers.  
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 Introduction 
As established in Study 1, frequent exacerbators are less likely to complete 
pulmonary rehabilitation. Failure to complete pulmonary rehabilitation is an adverse 
indicator for hospital admission (Moore et al., 2016; Steiner et al., 2017a). Those 
who complete pulmonary rehabilitation have been seen to have a lower risk of 
experiencing an exacerbation or hospitalisation admission (Moore et al., 2016). 
However, the mechanisms underpinning a reduced incidence of hospital 
admissions in those who complete pulmonary rehabilitation are unclear.  
Frequent exacerbators display an altered immune profile that is considered to 
provide the potential biological underpinning of recurrent exacerbation events 
(Wedzicha, Mackay & Singh, 2013). Systemic inflammatory parameters such as; 
fibrinogen, CRP, leukocyte, and blood neutrophil counts have been seen to be 
elevated in frequent exacerbators (Donaldson et al., 2005a; Hurst et al., 2010; 
Wedzicha, Mackay & Singh, 2013). A variety of pharmacological therapies have 
been shown to be ineffective or have conflicting results in relation to arresting long-
term persistent systemic inflammation in COPD (King, 2015). The treatment of 
inflammation in COPD does not currently stem beyond that of pharmacological 
treatment, with the effects of non-pharmacological treatments left relatively 
unexplored.  
Recently, Jenkins et al. (2018), (section 1.6.2) synthesised the available evidence 
on maintenance supervised exercise programmes following pulmonary 
rehabilitation and found further reductions in incidence of exacerbations and 
hospitalisations compared to pulmonary rehabilitation alone. Such independent 
effects of exercise interventions on exacerbation risk may suggest that there are 
unexplored mechanisms (Jenkins, Holden & Jones, 2018), compared to previously 
proposed indirect effects (e.g. changes in dyspnoea, physical conditioning and 
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enhanced disease knowledge (Evans & Steiner, 2018)). One potential area is that 
of exercise as an immunomodulator, based on extensive evidence of the anti-
inflammatory effects of exercise in healthy (including aged) individuals (Woods et 
al., 2012). However, questions remain around the potential for such mechanisms in 
COPD with authors claiming that it is not plausible for interventions such as 
pulmonary rehabilitation to affect inflammatory or infectious events directly (Evans 
& Steiner, 2018).  
Previous research has suggested that pulmonary rehabilitation does not affect 
systemic inflammation as characterised by a lack of changes in plasma CRP, 
plasma cytokine concentrations or total blood leukocyte count even in the presence 
of improved exercise capacity (Canavan et al., 2007; Sciriha et al., 2017). Chronic 
exercise training programmes, similar in length to pulmonary rehabilitation have 
been seen to reduce systemic inflammation (e.g. CRP) in other clinical (e.g. type 2 
diabetes) populations (Giannopoulou et al., 2005). Furthermore, walking exercise 
programmes have been seen to have anti-inflammatory effects in a healthy aged 
population with attenuation of CD66b expression on neutrophils and decreased 
shedding of CD62L (Takahashi et al., 2013).  
Contrary to previous findings in COPD, de Alencar Silva et al. (2018) recently found 
that an exercise programme of a similar duration to pulmonary rehabilitation 
induced significant reductions in circulating cytokines including IL-6. However, no 
studies have yet assessed whether pulmonary rehabilitation can play a role in 
reducing other markers of systemic inflammation, which are also widely recognised 
for their reliability as a surrogate marker of exacerbation risk (e.g. fibrinogen) 
(Duvoix et al, 2013). There is a need to further understand and investigate the 
effects of an exercise programme, such as pulmonary rehabilitation, on changes in 
resting systemic inflammation in COPD, placing emphasis on established or novel 
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surrogate markers of the frequent exacerbator phenotype of COPD. Should 
exercise be confirmed to have effects on such outcomes in COPD, it would be 
particularly prudent in the management of the COPD exacerbation phenotype 
where traits like systemic inflammation currently have limited treatment options. 
The aims of this study were to examine the effects of exercise, as part of pulmonary 
rehabilitation, on resting markers of systemic inflammation in patients with frequent 
or infrequent exacerbations of COPD. It was hypothesised that exercise would 
reduce markers of systemic inflammation (fibrinogen & CRP) and attenuate 
markers of neutrophil activation but would not induce a significant decrease in 
resting blood leukocyte cell populations.  
 Methods  
4.2.1 Participants 
4.2.1.1 COPD patients  
Forty COPD patients (age 68.8 ± 7.2 years; FEV1 pred 49 ± 17%; frequent 
exacerbators = 24; infrequent exacerbators = 16) volunteered to take part in this 
study. 
4.2.1.2 Healthy comparators 
Twenty-five healthy comparators (age 67.9 ± 5.5 years; FEV1 pred 101 ± 13%; 
smokers = 10; never smokers = 15) were recruited to provide indications of baseline 
comparative measures between healthy individuals and COPD patients.  
4.2.2 Procedures 
Blood samples were collected in a resting state at the 1st (Pre-Rehab) and 16th 
classes (Post-Rehab) for COPD patients. Any COPD patients reporting an 
inflammatory event (e.g. exacerbation) or receiving antibiotics/corticosteroids at the 
beginning or end of pulmonary rehabilitation were excluded from the study 
analyses. Single blood samples were collected from healthy comparators in a 
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separate clinic from COPD patients with controls put in place for time of day 
(between 10am and 1pm).  The primary outcome was plasma fibrinogen 
concentration (section 2.8.2.1). Secondary outcomes were plasma CRP (section 
2.8.2.2) and total and differential leukocyte count (section 2.8.1).  Markers of 
neutrophil activation (CD11b, CD62L, CD66b) and neutrophil phenotypes (mature 
(CD16bhigh/CD62Lhigh), immature (CD16blow/CD62Lhigh), suppressive 
(CD16bhigh/CD62Llow), and progenitor (CD16blow/CD62Llow)) were also determined 
in a subset of participants (frequent, n = 18; infrequent, n = 11; smokers = 9; never 
smokers = 15) whole blood samples using flow cytometry (section 2.8.3).  
4.2.3 Statistical analysis 
Firstly, indications of differences in baseline fibrinogen concentrations, total and 
differential leukocyte counts, expression of neutrophil activation markers (CD11b, 
CD62L, CD66b), and neutrophil maturity (mature, CD16bhigh/CD62Lhigh, immature, 
CD16blow/CD62Lhigh, suppressive, CD16bhigh/CD62Llow, progenitor, 
CD16blow/CD62Llow) were determined using a one-way ANOVA with Bonferroni 
correction (frequent exacerbators vs infrequent exacerbators vs healthy smokers 
vs healthy never smokers). Differences in CRP concentrations were analysed using 
a Kruskal-Wallis test. For the main analyses, changes in fibrinogen concentrations, 
total and differential leukocyte counts, expression of neutrophil activation markers, 
and neutrophil maturity were analysed pre- and post-rehabilitation in both groups 
(frequent vs infrequent exacerbators; 1st vs 16th) using a two-way mixed ANOVA 
with Bonferroni correction. Any significant main effects observed in the ANOVA 
were further analysed with post-hoc two-tailed paired t-tests. Changes in CRP 
concentrations between pre-rehabilitation and post-rehabilitation were analysed 
using a Wilcoxon signed rank test with differences between groups at each time 
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point analysed using a Mann-Whitney U test. Statistical significance was accepted 
at P < 0.05.  
 Results  
4.3.1 Participants characteristics  
Due to inflammatory events (exacerbations treated with antibiotics or 
corticosteroids: frequent exacerbators (n = 8), infrequent exacerbators (n = 1); 
sciatica: infrequent exacerbators (n = 1)) at the beginning or end of pulmonary 
rehabilitation, 10 COPD patients were removed from the analysis (frequent 
exacerbators, n = 8; infrequent exacerbators, n = 2). Also, plasma samples were 
unable to be obtained from 2 COPD patients resulting in plasma being unavailable 
for the analysis of fibrinogen and CRP (frequent exacerbators, n = 1; infrequent 
exacerbators, n = 1). In the subset of participants who were assessed for neutrophil 
activation markers, 18 participants were excluded from these analyses due to a lack 
of expression of CD16b meaning that neutrophils could not be confidently isolated 
for analysis (frequent exacerbators, n = 6; infrequent exacerbators, n = 4; healthy 
smokers, n = 1; healthy never smokers, n = 7).  
The participant characteristics of frequent and infrequent exacerbators, as well as 
healthy smokers and healthy never smokers are detailed in Table 4.1. Further 
COPD specific characteristics are detailed in Table 4.2. All frequent exacerbators 
were categorised as GOLD grade D (100%) with the majority of infrequent 
exacerbators classified as GOLD grade B (93%). The majority of frequent and 
infrequent exacerbators were categorised as either mMRC grade 2, grade 3, or 
grade 4.  
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Table 4.1. Participant characteristics 
 
 
Variable 
 
 
Frequent 
 
 
Infrequent 
 
 
Healthy smokers 
 
 
Healthy never smokers 
Age (years)a 68.5 ± 6.8 70.6 ± 6.4 67.1 ± 3.1 68.5 ± 6.7 
% Malesb 56% 50% 50% 60% 
Body Mass (kg)a 73.7 ± 12.6 73.3 ± 14.2 78.3 ± 24.7 77.7 ± 14.6 
FEV1 %predicteda 48 ± 17 56 ± 16 93 ± 12 107 ± 11 
aData presented as mean ± SD. bData presented as a % of total population. Frequent, n = 16; infrequent, n = 14; healthy smokers, n = 10; healthy never smokers, n = 15. 
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Table 4.2. COPD specific characteristics 
 
 
Variable 
 
 
Frequent 
 
 
Infrequent 
GOLD grade, n (%)a   
A 0 (0) 1 (7) 
B 0 (0) 13 (93) 
C 0 (0) 0 (0) 
D 16 (100) 0 (0) 
mMRC, n (%)a   
0 0 (0) 1 (7) 
1 0 (0) 0 (0) 
2 2 (12) 4 (29) 
3 7 (44) 3 (14) 
4 7 (44) 7 (50) 
Charlson Comorbidity Indexb 3.8 ± 1.2 4.1 ± 1.2 
Current smokersc 25% 21% 
aData presented as total number (% of group). bData presented as mean ± SD. cData presented as 
a % of total population. Frequent, n = 16; infrequent, n = 14. 
 
4.3.2 Inflammation 
4.3.2.1 Baseline observations  
There was a significant main difference between groups for fibrinogen 
concentration (p = 0.027). Post-hoc analyses demonstrated that only frequent 
exacerbators had a significantly elevated fibrinogen concentration compared to 
healthy never smokers (p = 0.026) (Figure 4.1). 
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Figure 4.1. Baseline fibrinogen concentrations in frequent and infrequent 
exacerbators as well as healthy smokers and never smokers. Lines represent mean 
values. *Significant difference between groups (p < 0.05).  
 
There were no significant main differences observed between groups for: CRP (p 
= 0.089), total blood leukocyte count (p = 0.155), neutrophil count (p = 0.409), 
eosinophil count (p = 0.414), lymphocyte count (p = 0.156), and 
neutrophil/lymphocyte ratio (p = 0.384) (Table 4.3).  
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Table 4.3. Baseline blood counts 
 
 
Variable 
 
 
Frequent  
 
 
Infrequent  
 
 
Healthy 
smokers  
 
 
Healthy never 
smokers  
 
 
p-value 
CRP (mg/L)a 7.1 (3.5-10.8) 10.6 (2.5-11.2) 2.3 (1.4-2.2) 3.3 (2.2-8.7) 0.089 
Total Leukocytes (109·L-1)b 8.1 ± 2.0 6.9 ± 1.2 7.9 ± 2.6 6.7 ± 1.8 0.155 
Neutrophils (109·L-1)b 4.9 ± 1.6 4.1 ± 1.1 4.4 ± 1.9 4.0 ± 1.3 0.409 
Eosinophils (109·L-1)b 0.2 ± 0.1 0.2 ± 0.1 0.2 ± 0.1 0.2 ± 0.1 0.414 
Lymphocytes (109·L-1)b 2.2 ± 0.6  2.0 ± 0.5 2.5 ± 0.9 1.9 ± 0.9 0.156 
Neutrophil/Lymphocytes ratiob 2.4 ± 1.0 2.2 ± 1.0 2.0 ± 0.8 2.4 ± 0.9 0.384 
aData presented as median (25th percentile – 75th percentile). bData presented as mean ± SD. CRP: frequent, n = 15; infrequent, n = 13. All other 
variables: frequent, n = 16; infrequent, n = 14; healthy smokers, n = 10; healthy never smokers, n = 15. 
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There were no significant main differences observed in the expression of CD11b 
between groups (p = 0.539). However, there was a tendency, which did not meet 
statistical significance, towards a main difference between groups for CD62L (p = 
0.078) and CD66b (p = 0.064). There were no significant main differences between 
groups for the neutrophil phenotypes: mature (CD16bhigh/CD62Lhigh, p = 0.119), 
immature (CD16blow/CD62Lhigh, p = 0.305), and progenitor (CD16blow/CD62Llow, p 
= 0.547). There was a tendency towards a main difference between groups for 
suppressive neutrophils (CD16bhigh/CD62Llow, p = 0.081) but this was not 
statistically significant (Table 4.4). 
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Table 4.4. Baseline neutrophil activation markers  
 
 
Neutrophil Marker 
 
 
Frequent 
 
 
Infrequent 
 
 
Healthy smokers 
 
 
Healthy never smokers 
 
 
p-value 
CD11b (MFI) 5083 ± 1157 5647 ± 1072 5644 ± 429 5474 ± 615 0.539 
CD62L (MFI) 24366 ± 4093 25312 ± 7522 28958 ± 6180 31092 ± 5401 0.078 
CD66b (MFI) 10326 ± 2521 9833 ± 2343 14233 ± 4561 10577 ± 2242 0.064 
CD16bhigh/CD62Lhigh (%) 94.2 ± 2.2 95.0 ± 2.2 94.8 ± 2.5 96.1 ± 2.9 0.119 
CD16blow/CD62Lhigh (%)  1.6 ± 0.5 2.0 ± 0.9 2.5 ± 1.9 1.5 ± 0.4 0.305 
CD16bhigh/CD62Llow (%) 4.0 ± 2.2 3.0 ± 1.6 2.6 ± 1.8 2.3 ± 2.9 0.081 
CD16blow/CD62Llow (%) 0.2 ± 0.2 0.1 ± 0.1 0.1 ± 0.1 0.1 ± 0.1 0.547 
Data presented as mean ± SD. MFI, median fluorescent intensity. Frequent, n = 8; infrequent, n = 7; healthy smokers, n = 8; healthy never smokers, n = 8. 
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4.3.2.2 Responses to pulmonary rehabilitation  
There was a significant main effect of time showing a reduction in plasma fibrinogen 
following pulmonary rehabilitation (p = 0.033). No significant differences were 
observed between frequent and infrequent exacerbators for fibrinogen (p = 0.414) 
nor were any time × group interactions observed (p = 0.702) (Figure 4.2). 
 
Figure 4.2. Fibrinogen concentrations in response to pulmonary rehabilitation in 
frequent and infrequent exacerbators. Lines represent mean values. *Significant 
main effect of time (p < 0.05).  
 
Pulmonary rehabilitation did not significantly reduce the concentration of plasma 
CRP (p = 0.733). No significant differences for CRP concentration were observed 
between frequent and infrequent exacerbators at pre-rehabilitation (p = 0.683) and 
post-rehabilitation (p = 0.586) (Figure 4.3).  
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Figure 4.3. CRP concentrations in response to pulmonary rehabilitation in frequent 
and infrequent exacerbators. Lines represent median values. 
 
There was a significant main effect of time on total leukocyte counts (p = 0.032). 
There was also a significant time × group interaction with total leukocyte counts (p 
= 0.041). Post-hoc analyses showed that frequent exacerbators experienced a 
significant reduction in total leukocyte count by the end of pulmonary rehabilitation 
(p = 0.018), whereas infrequent exacerbators did not (p = 0.910). There was no 
significant main effect of group for total leukocyte count (p = 0.222) (Table 4.5). 
There was a tendency towards a main effect of time on neutrophil counts, but this 
did not reach statistical significance (p = 0.057). However, there was a significant 
time × group interaction with neutrophil counts (p = 0.036). Post-hoc analyses 
showed that frequent exacerbators experienced a significant reduction in neutrophil 
count by the end of pulmonary rehabilitation (p = 0.018), whereas infrequent 
exacerbators did not (p = 0.849). There was no significant main effect of group for 
neutrophil count (p = 0.485) (Table 4.5). 
No effects of time (lymphocytes, p = 0.115; eosinophils, p = 0.723; 
neutrophil/lymphocyte, p = 0.524), group (lymphocytes, p = 0.454; eosinophils, p = 
0.479; neutrophil/lymphocyte, p = 0.916), or time × group interactions (lymphocytes, 
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p = 0.570; eosinophils, p = 0.846; neutrophil/lymphocyte, p = 0.123) were observed 
for lymphocytes, eosinophils, and neutrophil/lymphocyte ratio (Table 4.5). 
Table 4.5. Blood cell counts pre- and post-pulmonary rehabilitation 
 
 
 
Variable 
 
 
 
Frequent 
 
 
 
Infrequent 
 
Time 
main 
effect 
p-values  
 
Time × group 
interaction 
 
Group 
main 
effect 
Total leukocytes  
(109·L-1) 
  0.032* 0.041# 0.222 
Pre-Rehab 8.1 ± 2.0 6.9 ± 1.2    
Post-Rehab 6.7 ± 1.1 6.9 ± 1.2    
Neutrophils (109·L-1)   0.057 0.036# 0.485 
Pre-Rehab 4.9 ± 1.0 4.1 ± 1.1    
Post-Rehab 3.8 ± 1.0 4.1 ± 1.1    
Eosinophils (109·L-1)   0.723 0.846 0.479 
Pre-Rehab 0.2 ± 0.1 0.2 ± 0.1    
Post-Rehab 0.2 ± 0.1 0.2 ± 0.1    
Lymphocytes (109·L-1)   0.115 0.570 0.454 
Pre-Rehab 2.2 ± 0.6 2.0 ± 0.4    
Post-Rehab 2.0 ± 0.5 1.9 ± 0.4    
Neutrophil/Lymphocyte  
ratio 
  0.524 0.123 0.916 
Pre-Rehab 2.4 ± 1.0 2.2 ± 1.0    
Post-Rehab 2.1 ± 0.8 2.3 ± 0.8    
Data presented as mean ± SD. *Significant main effect of time (p < 0.05); #Significant time × group 
interaction (p < 0.05). Frequent, n = 16; infrequent, n = 14.  
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Pulmonary rehabilitation did not appear to significantly alter the cell surface 
expression of CD11b (p = 0.553) or CD66b on blood neutrophils (p = 0.317). 
However, there was a tendency towards an increase in the expression of CD62L 
by the end of pulmonary rehabilitation, but this was not found to be statistically 
significant (p = 0.070). There was no significant main effect of group in blood 
neutrophil expression of CD11b (p = 0.161), CD62L (p = 0.503), or CD66b (p = 
0.906). Additionally, there were no significant time × group interactions (CD11b, p 
= 0.936; CD62L, p = 0.491; p = 0.168) (Table 4.6).  
 
Table 4.6. Neutrophil surface expression pre- and post-pulmonary rehabilitation  
 
 
Neutrophil 
Marker 
 
 
 
Frequent 
 
 
 
Infrequent 
 
Time  
main 
effect 
p-values  
 
Time × group 
interaction 
 
Group  
main  
effect 
CD11b (MFI)   0.553 0.936 0.161 
Pre-Rehab 5083 ± 1157 5647 ± 1072    
Post-Rehab 5294 ± 667 5809 ± 647    
CD62L (MFI)   0.070 0.491 0.503 
Pre-Rehab 24366 ± 4093 25312 ± 7522    
Post-Rehab 26036 ± 4797 28209 ± 2087    
CD66b (MFI)   0.317 0.168 0.906 
Pre-Rehab 10326 ± 2521 9833 ± 2343    
Post-Rehab 10064 ± 1979 10735 ± 2043    
Data presented as mean ± SD. MFI, median fluorescent intensity. Frequent, n = 8; infrequent, n = 
7. 
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A significant main effect of time was observed with reductions in the progenitor 
neutrophil subset by the end of pulmonary rehabilitation (p = 0.015). There were no 
main effects of time observed with any of the other neutrophil subsets (mature, p = 
0.313; immature, p = 0.756; suppressive, p = 0.259). There was no main effect of 
group (mature, p = 0.517; immature, p = 0.172; suppressive, p = 0.261; progenitor, 
p = 0.999) or  time × group interactions observed with any of the neutrophil subsets 
(mature, p = 0.805; immature, p = 0.780; suppressive, p = 0.809; progenitor, p = 
0.193) (Table 4.7). 
Table 4.7. Neutrophil phenotypes pre- and post-pulmonary rehabilitation  
 
 
 
Neutrophil Phenotype  
 
 
 
Frequent 
 
 
 
Infrequent 
 
Time  
main 
effect 
p-values  
 
Time × group 
interaction 
 
Group 
main 
effect 
CD16bhigh/CD62Lhigh (%)   0.313 0.805 0.517 
Pre-Rehab 94.2 ± 2.2 95.0 ± 2.1    
Post-Rehab 94.8 ± 2.3 95.3 ± 1.3    
CD16blow/CD62Lhigh (%)   0.756 0.780 0.172 
Pre-Rehab 1.6 ± 0.5 2.0 ± 0.9    
Post-Rehab 1.5 ± 0.6 2.0 ± 0.9    
CD16bhigh/CD62Llow (%)   0.259 0.809 0.261 
Pre-Rehab 4.0 ± 2.2 3.0 ± 1.6    
Post-Rehab 3.7 ± 2.2 2.6 ± 1.3    
CD16blow/CD62Llow (%)   0.015* 0.193 0.999 
Pre-Rehab 0.2 ± 0.2 0.1 ± 0.1    
Post-Rehab 0.1 ± 0.1 0.1 ± 0.0    
Data presented as mean ± SD. *Significant main effect of time (p < 0.05).  Frequent, n = 8; 
infrequent, n = 7. 
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 Discussion 
The main findings from this study suggest that pulmonary rehabilitation can reduce 
circulating fibrinogen concentrations and the percentage of progenitor neutrophils. 
This study also found that pulmonary rehabilitation is capable of reducing total blood 
leukocyte and neutrophil counts in frequent exacerbators of COPD. Pulmonary 
rehabilitation did not significantly reduce the concentration of CRP or modify 
markers of neutrophil activation in the frequent or infrequent exacerbator 
phenotypes of COPD.   
Fibrinogen is an established biomarker for exacerbations of COPD (Chen, Leung & 
Sin, 2016). In the context of pulmonary rehabilitation, this is the first study in the 
COPD population to demonstrate that pulmonary rehabilitation can be effective in 
modulating resting concentrations of fibrinogen irrespective of exacerbation history. 
This evidence agrees with that of previous studies in a healthy population 
demonstrating that an exercise programme can be effective in reducing plasma 
fibrinogen (Ernst, 1993; Dehghan & Faramarzi, 2013; Gomez-Marcos et al., 2014; 
Rashidlamir & Jaafari, 2013). Pulmonary rehabilitation has also been seen to 
reduce fibrinogen levels in patients with lung cancer (Morano et al., 2014). Others, 
however, have not observed any significant reductions in fibrinogen concentrations 
following a period of exercise training in healthy individuals and patients with 
peripheral obstructive arterial disease (Clark et al., 2011; Furukawa et al., 2008; 
Hammett et al., 2006; Mika et al., 2011). Fibrinogen has been demonstrated to have 
pro-inflammatory properties via stimulating the production of MMP-9 and inhibiting 
anti-inflammatory cytokines (Wang et al., 2015). Reductions in this marker can be 
interpreted as an anti-inflammatory response to exercise. It is plausible to suggest 
that this reduction in fibrinogen concentration may provide mechanistic evidence 
towards a reduction in exacerbation risk following pulmonary rehabilitation in COPD 
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(Moore et al., 2016). However, this requires further research with more longitudinal 
based studies assessing fibrinogen, exercise and exacerbation reporting.  
CRP is an acute phase protein indicative of inflammation and a marker that has 
been established as a biomarker for COPD exacerbations (Chen, Leung & Sin, 
2016). This study suggests that pulmonary rehabilitation is not effective at modifying 
resting levels of CRP. This is in agreement with previous work in COPD populations 
(El Gammal et al., 2015; Sciriha et al., 2017; Vogiatzis et al., 2007). The findings 
also agree with previous research in a healthy sedentary population displaying 
elevated CRP levels, whereby 4 months of exercise training did not decrease CRP 
concentrations (Church et al., 2010). However, CRP was highly variable between 
patients in the present study, which is commonly seen in the COPD population 
(Aksu et al., 2013; Silva, Gazzana & Knorst, 2015), perhaps suggesting a larger 
sample size would be required to detect any significant differences. The degree of 
intra-variation with CRP suggests it would be challenging to assess responses of 
CRP to exercise in COPD.  
Total blood leukocyte and neutrophil counts have also been shown to be 
significantly elevated in frequent exacerbators (Hurst et al., 2010). This is the first 
study to show that pulmonary rehabilitation can significantly reduce total blood 
leukocyte and neutrophil counts in frequent exacerbators. This conflicts with 
previous work in a COPD population where pulmonary rehabilitation has not been 
shown to significantly reduce total blood leukocyte or neutrophil counts (El Gammal 
et al., 2015; Sciriha et al., 2017). These studies have assessed responses in the 
COPD population as a whole, whereas the current study stratified patients by 
exacerbation history. The findings suggest that in clinical phenotypes where there 
is scope for anti-inflammatory benefits (e.g. frequent exacerbators of COPD), total 
blood leukocyte or neutrophil counts are amenable to change by pulmonary 
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rehabilitation. However, further research is required assessing the inflammatory cell 
count responses to exercise in both frequent and infrequent exacerbators to further 
support these findings. 
It has previously been proposed  that neutrophil counts alone provide little insight 
into inflammatory responses, whereby assessing markers of neutrophil activation 
markers may be more worthwhile (Oudijk et al., 2005). This is the first study in 
COPD to assess neutrophil activation markers in the context of pulmonary 
rehabilitation. This study did not find any significant changes in neutrophil activation 
markers (CD11b, CD62L and CD66b) following pulmonary rehabilitation. However, 
tendencies towards increases observed with CD62L expression by the end of 
pulmonary rehabilitation suggest that this is a promising activation marker for future 
research assessing changes with chronic exercise. This is suggested to be 
indicative of an anti-inflammatory effect of exercise training as shedding of CD62L 
is observed upon neutrophil activation  (Borregaard & Cowland, 1997; Ley et al., 
2007; Nathan, 2006; Takahashi et al., 2013; Wittmann et al., 2004). Such findings 
are in agreement with the findings of Takahasi et al. (2013) who found that exercise 
training in an aged population increased the resting expression of CD62L indicating 
an anti-inflammatory response to exercise training. Power calculations suggested 
that 75 COPD patients would be required to detect statistical significance at 80% 
power and 5% level of significance in neutrophil CD62L expression with a change 
of 2243 MFI. The current study however, did agree with research by Nawaz et al. 
(2001) who examined CD66b and CD11b neutrophil expression following an 
exercise training programme in patients with intermittent claudication where no 
effects were observed. However, further investigations of these markers are 
warranted given the significance of CD11b and CD66b in neutrophil activation in 
COPD (Fortunati et al., 2009).  
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For the first time in an exercise and COPD setting, phenotyping of blood neutrophils 
(Cortjens et al., 2017), was performed in this study. This study identified that 
pulmonary rehabilitation can reduce the amount of progenitor neutrophils in COPD. 
The progenitor subset is a newly identified small subset of neutrophils, considered 
to have increased degranulation (Cortjens et al., 2017). Progenitor neutrophils have 
also been suggested to have a poorer migration due to reduced CD62L expression 
(Cortjens et al., 2017). Therefore, a reduction in this subset could be deemed as a 
beneficial effect of exercise with a shift towards neutrophil subsets with enhanced 
migration and reduced degranulation (Cortjens et al., 2017). However, no 
significant differences were observed in any of the other neutrophil subsets at the 
end of pulmonary rehabilitation, so whether this decrease results in more mature, 
immature or suppressive neutrophils is unclear. These findings were based on 
observations made in a limited sample size with further research warranted 
assessing shifts in neutrophil subsets in both frequent and infrequent exacerbators 
of COPD in response to exercise to determine pro- and anti-inflammatory effects.  
The findings from the current study imply that pulmonary rehabilitation can have 
anti-inflammatory effects in frequent and infrequent exacerbators. However, not all 
inflammatory parameters were affected which may be indicative of an issue with 
the duration, frequency and/or intensity of the exercise programme (Kruger & 
Mooren, 2007; McCarthy & Dale, 1988; Reihmane et al., 2013). Previously it has  
been indicated that markers such as total leukocyte and neutrophil counts are more 
sensitive to acute inflammatory responses to exercise (van Helvoort et al., 2006). 
Therefore, future research should assess how these markers respond to acute 
exercise and whether modification of the acute inflammatory response changes 
across pulmonary rehabilitation, as seen in exercise training studies in healthy 
populations (Brown et al., 2015). Acute inflammatory responses to exercise may 
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bear more relevance to patients with COPD given the inflammatory nature of the 
disease, whereby acute bursts of inflammation could be deleterious and increase 
the risk of exacerbation (van der Vlist & Janssen, 2010).   
The findings presented require further exploration but begin to assess previously 
unexplored mechanisms of exercise interventions and incidence of exacerbations 
of COPD (Jenkins et al., 2018; Jenkins, Holden & Jones, 2018; Moore et al., 2016). 
Further research establishing the anti-inflammatory benefits of exercise and 
pulmonary rehabilitation, specifically biomarkers relating to exacerbations, in COPD 
may provide a major selling point for the intervention which is currently underfunded 
and underutilised (Hoogendoorn et al., 2010; Jones et al., 2014b; Jones et al., 2017; 
Keating, Lee, & Holland, 2011; Marciniuk et al., 2010; Mayers et al., 2007; Oba, 
2007). 
When interpreting the results of this study it is important to acknowledge limiting 
factors. The comparisons of baseline inflammatory markers were not part of the 
main analyses and utilised small sample sizes between frequent exacerbators, 
infrequent exacerbators, healthy smokers, and healthy never smokers so the 
findings were underpowered. The pulmonary rehabilitation course provided was a 
conventional course delivered in accordance with BTS guidelines (Bolton et al., 
2013). Therefore, no strict restrictions were put in place to standardise the exercise 
training across participants but exercise workload was continually progressed 
throughout the course according to physical capabilities of each patient in line with 
usual care procedures. Whilst healthy comparator groups were recruited to 
demonstrate the altered markers of systemic inflammation at rest in COPD 
exacerbation phenotypes, this study did not recruit a control group of COPD over 
the course of pulmonary rehabilitation. Hence the observed effects over time cannot 
be specifically attributed to the effect of pulmonary rehabilitation alone. The main 
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aim of this study was to compare responses between frequent and infrequent 
exacerbators but it would be prudent for future studies to include such patient 
groups that are not exposed to pulmonary rehabilitation to better understand the 
magnitude of effect on inflammation. It is also important to note that the final 
analysis of neutrophil activation markers was conducted on a small sample size 
and future larger-scale research is required to confirm the current findings. This 
small sample size was attributed to unforeseen issues with using CD16b as a 
marker for identifying neutrophil populations whereby 43% of frequent exacerbators 
and 36% of infrequent exacerbators did not highly express CD16b on neutrophils. 
This is an unusual phenomenon and very little literature is available to explain this. 
One suggestion raised in the literature is a very rare genetic deficiency of CD16 
(Wagner & Hansch, 2004), with another suggestion that ADAM17, which is elevated 
in COPD (Stolarczyk & Scholte, 2018), cleaves neutrophil CD16b (Wang et al., 
2013), but assessment of CD16 genes and ADAM17 were not undertaken in the 
current study. However, this neutrophil CD16b deficiency was not observed to be 
COPD specific as similar observations were made in 11% of healthy smokers and 
47% of healthy never smokers. Due to this deficiency in CD16b, the confidence in 
being able to identify the neutrophil population was reduced, so these participants 
were not included in the analysis meaning the results were underpowered. This 
would suggest that CD16b is not the most suitable marker for identifying neutrophil 
populations. Smokers were also included in the present study, so interpretations 
about findings should be undertaken with caution as smoking has been shown to 
enhance inflammation (Lee, Taneja & Vassallo, 2012). This study also excluded 
COPD patients with other co-morbid respiratory conditions in order to ensure 
exacerbations were related to COPD and not that of other respiratory conditions. 
However, a strength of the study was that the findings reflect ‘real-world’ effects in 
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COPD patients presenting without other co-morbid respiratory conditions, whereby 
pulmonary rehabilitation was not manipulated in any way by the study.  
In conclusion, pulmonary rehabilitation appears to have positive effects in reducing 
plasma fibrinogen concentrations in COPD and may provide more anti-
inflammatory benefits to frequent exacerbators as characterised by reduced total 
blood leukocyte and neutrophil counts. Further research is required to assess 
chronic immune responses to pulmonary rehabilitation utilising a wider range of 
biomarkers for exacerbations.  
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5 Chapter FIVE 
Study 3 – The effects of pulmonary rehabilitation on corticosteroid-inducible 
gene expression in PBMC’s of frequent and infrequent exacerbators of COPD  
Abstract  
Corticosteroids are a commonly used pharmacological treatment of COPD. ICS are 
often prescribed as an anti-inflammatory therapy in frequent exacerbators. 
However, COPD patients have been seen to be resistant to the effects of ICS calling 
into question the effectiveness of corticosteroids. The aim of this study was to 
investigate the effects of pulmonary rehabilitation on the expression of 
corticosteroid-induced anti-inflammatory genes. PBMC’s were isolated from whole 
blood samples of 7 frequent (FEV1 pred, 46 ± 17%) and 7 infrequent exacerbators 
(FEV1 pred, 61 ± 14%) pre- and post-rehabilitation. These were compared to 
PBMC’s isolated from 8 healthy smokers (FEV1 pred, 95 ± 13%) and 8 healthy 
never smokers (FEV1 pred, 107 ± 14%). PBMC’s were treated with corticosteroids 
for 2 & 6 hours before messenger RNA (mRNA) was extracted for the analysis of 
MKP-1 & GILZ gene expression via real-time PCR. Frequent exacerbators had a 
similar response in MKP-1 expression to dexamethasone treatment compared to 
infrequent exacerbators (p = 0.272), healthy smokers (p = 0.098) and healthy never 
smokers (p < 0.999). Pulmonary rehabilitation showed a tendency towards an 
increased MKP-1 expression in both frequent and infrequent exacerbators with 2 
hr treatment (p = 0.060). Frequent exacerbators had a poorer fold increase in MKP-
1 expression following 6 hr treatment with dexamethasone at both pre- and post-
rehabilitation compared to infrequent exacerbators (p = 0.003). GILZ expression 
was not significantly influenced by pulmonary rehabilitation (2 hr, p = 0.774; 6 hr, p 
= 0.734). This study suggests that pulmonary rehabilitation may play a role in 
modulating the effectiveness of corticosteroids in both frequent and infrequent 
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exacerbators of COPD. Whether these potential increases in anti-inflammatory 
gene mRNA results in increased clinical effectiveness of corticosteroids is still to be 
elucidated.  
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 Introduction 
Large sums of money are spent worldwide on pharmacological therapies to help 
reduce the burden of COPD (World Health Statistics, 2011). In COPD, the 
effectiveness of pharmacological therapies, for example, ICS have been called into 
question (Ernst, Saad & Suissa, 2015). The proposed use of ICS in COPD has been 
largely due to their anti-inflammatory properties (Jen, Rennard & Sin, 2012), and 
history of benefit in respiratory diseases such as asthma (Barnes, 2010). It has 
been suggested that ICS reduce exacerbation frequency and lead to improvements 
in health-related quality of life (Spencer et al., 2004; Suissa et al, 2007; Wedzicha, 
Mackay & Singh, 2013). However, some patients with COPD have been seen to 
develop insensitivity to corticosteroids (Lo Tam Loi et al., 2013), with long-term use 
also associated with an increased risk of pneumonia (Suissa et al., 2013). 
There have been attempts to provide a pathological understanding of the reduced 
effectiveness of corticosteroids in COPD (Barnes, 2000; Wilkie, Finch & Schembri, 
2015). It is believed that corticosteroids are more effective in situations where 
inflammation is underpinned by eosinophilia and research suggests that 
corticosteroids are not as effective in situations of neutrophilic inflammation (Kelly 
et al., 2012; Pascoe et al., 2015; Pavord et al., 2016). Neutrophilic inflammation is 
apparent in viral exacerbations and in a large proportion of COPD patients 
(Hoenderdos & Condliffe, 2013; Mallia et al., 2011), which may in part explain the 
reduced effectiveness of corticosteroids. However, there is still a dependency on 
the use of corticosteroids in COPD patients (NICE, 2018), especially in frequent 
exacerbators who have been observed to be more likely to be treated with 
corticosteroids (Capozzolo et al., 2017). Despite this, the same study found that 
patients categorised as having severe COPD will still sustain frequent 
exacerbations regardless of aggressive therapy maintenance (Capozzolo et al., 
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2017). New recommendations suggest that ICS only be used in combination with 
LABA treatment in frequent exacerbators, and if blood eosinophil counts exceed 
100 cells/µl (GOLD, 2019). This suggestion is based on evidence showing that the 
effects of ICS are more pronounced in patients with greater exacerbation frequency 
(Lipson et al., 2018). 
The effectiveness of corticosteroids can be measured by examining changes in 
gene expression. Previously many of the anti-inflammatory effects of 
corticosteroids have been believed to be because of transrepression of pro-
inflammatory transcription factors, but there is considerable growing evidence for 
the importance of corticosteroid-dependent transactivation of anti-inflammatory 
genes for reducing inflammation (Newton & Holden, 2007). Genes, directly induced 
by corticosteroids, have been established previously (Kelly et al., 2012; King et al., 
2009; Newton & Holden, 2007). MKP-1 is believed to play a role in inhibiting the 
pro-inflammatory response (Barnes, 2008). These anti-inflammatory actions are 
due to the ability of MKP-1 to inactivate pro-inflammatory MAPK’s, in particular p38 
and extracellular signal-regulated kinases (ERK), which results in decreased 
cytokine production (Barnes, 2008). GILZ is also an established corticosteroid-
inducible gene and targets key inflammatory transcription factors suppressing 
inflammatory gene expression (Berrebi et al., 2003; Eddleston et al., 2007; Godot 
et al., 2006; Mittelstadt & Ashwell, 2001). Therefore, cells with a reduced expression 
of these corticosteroid-inducible genes have been seen to have an impaired 
response to corticosteroids (Kang et al., 2008; Lasa et al., 2002).  
There have been calls for a better understanding of corticosteroids in COPD to 
improve treatment response (Leung & Sin, 2018). It has been previously suggested 
that non-pharmacological therapies such as exercise can provide similar benefits 
to that of pharmacological therapies in terms of disease prevention and control 
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(Vina et al., 2012). However, whether exercise can play a role in enhancing the 
effectiveness of pharmacological therapies in COPD is unclear. In Study 2 , we 
established the capacity of pulmonary rehabilitation to reduce systemic 
inflammation (i.e. pro-inflammatory factors) but whether programmes can also 
impact on the action of anti-inflammatory treatments in the form of corticosteroids 
remains unclear. In COPD, it has been suggested that patients may need 
pulmonary rehabilitation to fully achieve the benefits of current and new therapies 
(Katajisto et al., 2015). Current suggestions are that the benefits of pulmonary 
rehabilitation on pharmacological treatment are indirect, such as a result of 
increased knowledge and/or better inhaler technique as opposed to any direct 
biological effects (Evans & Steiner, 2018). However, these suggestions are largely 
hypothetical and hence there remains a lack of research that have explored the 
underlying mechanisms. 
Therefore, the aim of this study was to assess whether pulmonary rehabilitation 
could increase the expression of corticosteroid inducible genes (MKP-1 & GILZ) in 
frequent and/or infrequent exacerbators of COPD. It was hypothesised that 
corticosteroid inducible gene expression would be lower in frequent exacerbators, 
but that pulmonary rehabilitation would increase the effectiveness of corticosteroids 
in both frequent and infrequent exacerbators.    
 Methods  
5.2.1 Participants 
5.2.1.1 COPD patients 
Seven frequent (age 67 ± 7 years; FEV1 pred 46 ± 17%) and 7 infrequent 
exacerbators (age 68 ± 7 years; FEV1 pred 61 ± 14%) took part in this study based 
on sample sizes previously utilised in intervention studies assessing changes in 
MKP-1 & GILZ gene expression (Kelly et al., 2012; King et al., 2009).  
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5.2.1.2 Healthy comparators  
Eight smokers (age 68 ± 3 years; FEV1 pred 95 ± 13%) and 8 healthy never smokers 
(age 69 ± 8 years; FEV1 pred 107 ± 14%) were also recruited to provide reference 
control groups (baseline comparisons) in this study.  
5.2.2 Procedures 
Blood samples were collected in a resting state at the 1st (Pre-Rehab) and 16th 
classes (Post-Rehab) of pulmonary rehabilitation for the COPD patients. Single 
resting blood samples were collected at a similar time of day (between 10am and 
1pm) for the healthy comparators in separate clinics from the COPD patients. 
PBMC’s were isolated using a density medium and treated with dexamethasone 
(1μM) (not-treated (NT), 2 hr, 6 hr) as outlined in section 2.8.4. The expression of 
corticosteroid inducible genes MKP-1 and GILZ were measured by real-time PCR 
(section 2.8.4). 
The primary aim of this study was to assess changes in corticosteroid-inducible 
gene expression (MKP-1 & GILZ) with pulmonary rehabilitation. The secondary 
aims of this study were to assess changes in gene expression following differing 
treatments (2 hr & 6 hr) and compare gene expression between groups (frequent 
exacerbators, infrequent exacerbators, healthy smokers, healthy never smokers).    
5.2.3 Statistical analyses 
Comparisons of NT raw data were analysed across all groups using a Kruskal-
Wallis test. Changes in NT samples pre- to post-pulmonary rehabilitation were 
compared within groups (frequent and infrequent exacerbators) using paired 
samples t-tests. An independent t-test was utilised to compare NT raw data post-
rehab between frequent and infrequent exacerbators. Comparisons of 
dexamethasone treated samples (2 hr & 6 hr) for each gene (MKP-1 & GILZ) were 
analysed as fold increases against NT samples (normalised to 1) between all 
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groups (frequent exacerbators, infrequent exacerbators, healthy smokers, healthy 
never smokers) using a two-way mixed ANOVA with Bonferroni correction. 
Changes in gene expression, expressed as a fold against NT, at 2 hr and 6 hr 
treatments (MKP-1 & GILZ) were analysed pre- and post-rehabilitation in frequent 
and infrequent exacerbators using a two-way mixed ANOVA with Bonferroni 
correction. Any significant main effects were further analysed with post-hoc paired 
t-tests. Statistical significance was accepted at P < 0.05. 
 Results  
5.3.1 Participant characteristics  
The participant characteristics of frequent and infrequent exacerbators, as well as 
healthy smokers and healthy never smokers are detailed in Table 5.1. Further 
COPD specific characteristics are detailed in Table 5.2. All frequent exacerbators 
were categorised as GOLD grade D (100%) with the majority of infrequent 
exacerbators classified as GOLD grade B (86%). The majority of frequent and 
infrequent exacerbators were categorised as either mMRC grade 2, grade 3, or 
grade 4.  
 
Table 5.1. Participant characteristics 
 
 
Variable 
COPD HEALTHY 
 
Frequent Infrequent Smokers Never smokers 
Age (years)a 67.4 ± 7.3 68.0 ± 7.0 67.5 ± 3.3 69.1 ± 7.8 
% Malesb 71% 57% 50% 75% 
Body Mass (kg)a 75.0 ± 14.5 76.9 ± 5.9 80.3 ± 22.3 74.8 ± 11.2 
FEV1 %predicteda 46 ± 17 61 ± 14 95 ± 13 107 ± 14 
aData presented as mean ± SD. bData presented as a % of total population. Frequent, n = 7; 
infrequent, n = 7; smokers, n = 8; never smokers = 8. 
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Table 5.2. COPD specific characteristics 
 
 
Variable 
 
Frequent Infrequent 
GOLD grade, n (%)c   
A 0 (0) 1 (14) 
B 0 (0) 6 (86) 
C 0 (0) 0 (0) 
D 7 (100) 0 (0) 
Charlson Comorbidity Indexa 4.0 ± 1.7 3.4 ± 1.0 
Current smokersb 17% 40% 
mMRC, n (%)c   
0 0 (0) 1 (14) 
1 0 (0) 0 (0) 
2 2 (29) 1 (14) 
3 2 (29) 2 (29) 
4 3 (42) 3 (43) 
ICS users, n (%)c 5 (71) 4 (57) 
Daily beclomethasone 
equivalent (µg)a 
1120 ± 502 1100 ± 600 
aData presented as mean ± SD. bData presented as a % of total population. cData presented as 
total number (% of group). Frequent, n = 7; infrequent, n = 7. 
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5.3.2 Gene expression 
5.3.2.1 COPD patients & healthy comparators 
5.3.2.1.1 Gene expression in not-treated samples  
A significant main difference between groups for MKP-1 mRNA expression in 
PBMC’s was observed for NT samples (p = 0.006). Post-hoc tests showed that 
infrequent exacerbators had a lower basal MKP-1 expression in NT PBMC’s when 
compared to frequent exacerbators (p = 0.019) and healthy never smokers (p = 
0.010), but similar expression when compared to healthy smokers (p = 0.341). 
Frequent exacerbators were observed to have ~3x and healthy never smokers 
~3.5x higher MKP-1 mRNA expression in NT PBMC’s compared to infrequent 
exacerbators. Post-hoc analyses demonstrated no significant differences between 
frequent exacerbators, healthy smokers, and healthy never smokers (all 
comparisons, p < 0.999).  
A significant main difference between groups for GILZ mRNA expression in PBMC’s 
was observed for NT samples (p = 0.005). Post-hoc tests showed that infrequent 
exacerbators had a lower GILZ expression in NT PBMC’s when compared to 
healthy never smokers (p = 0.008), and healthy smokers (p = 0.020). Infrequent 
exacerbators had a tendency towards a lower basal GILZ expression compared to 
frequent exacerbators but this was not statistically significant (p = 0.055). Frequent 
exacerbators and healthy smokers were observed to have ~3.5x higher, and 
healthy never smokers ~2.5x higher GILZ mRNA expression in NT PBMC’s 
compared to infrequent exacerbators. No significant differences were observed 
between frequent exacerbators, healthy smokers, and healthy never smokers (all 
comparisons, p < 0.999). 
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5.3.2.1.2 Fold changes following dexamethasone treatment 
There was a significant main effect of time showing an increased expression of 
MKP-1 following treatment with dexamethasone (p < 0.001). A significant time × 
group interaction was observed for MKP-1 expression (p < 0.001). Post-hoc t-tests 
demonstrated increases in MKP-1 expression with corticosteroid treatment in 
frequent (NT vs 2 hr, p = 0.001; NT vs 6 hr, p < 0.001) and infrequent exacerbators 
(NT vs 2 hr, p = 0.001; NT vs 6 hr, p < 0.001; 2 hr vs 6 hr, p = 0.005). No significant 
differences for MKP-1 expression were observed in frequent exacerbators between 
2 hr and 6 hr treatments (p = 0.258). Increases in MKP-1 expression between NT 
vs 2 hr (healthy smokers, p < 0.001; healthy never smokers, p = 0.001) and NT vs 
6 hr (healthy smokers, p < 0.001; healthy never smokers, p = 0.001) were observed 
in the healthy groups, but no significant increases were observed between 2 hr vs 
6 hr (healthy smokers, p = 0.573; healthy never smokers, p = 0.064). For frequent 
exacerbators, fold increases from NT of ~3.5x (2 hr time point) and ~3.5x (6 hr time 
point) were observed. For infrequent exacerbators, fold increases from NT of ~5x 
(2 hr time point) and ~8x (6 hr time point) were observed. For healthy smokers, fold 
increases of ~7.5x (2 hr time point) and ~6x (6 hr time point) were observed. Finally, 
healthy never smokers had fold increases from NT of ~4.5x (2 hr time point) and 
~3x (6 hr timepoint). A significant main difference between groups was observed 
for MKP-1 expression (p = 0.009). Post-hoc tests showed that healthy smokers 
were observed to have an enhanced MKP-1 response to dexamethasone treatment 
compared to healthy never smokers (p = 0.027). No differences were observed 
between frequent exacerbators vs infrequent exacerbators (p = 0.272), frequent 
exacerbators vs healthy smokers (p = 0.098), frequent exacerbators vs healthy 
never smokers (p < 0.999), infrequent exacerbators vs healthy smokers (p < 0.999), 
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and infrequent exacerbators vs healthy never smokers (p = 0.088) for MKP-1 
expression following treatment with dexamethasone (Figure 5.1).  
 
Figure 5.1. Fold changes in MKP-1 gene expression from NT in isolated PBMC’s 
following 2 hr or 6 hr of 1μM dexamethasone treatment in frequent and infrequent 
exacerbators of COPD compared to healthy smokers and never smokers. 
*Significant increase between time points (p < 0.05). †Significant difference 
between groups (p < 0.05).  
 
There was a significant main effect of time showing an increased expression of 
GILZ following treatment with dexamethasone (main effect, p < 0.001; NT vs 2 hr, 
p = 0.001; NT vs 6 hr, p = 0.001). No significant main effect was observed between 
2 hr vs 6 hr (p < 0.999). For frequent exacerbators, fold increases from NT of ~6.5x 
(2 hr time point) and ~7x (6 hr time point) were observed. For infrequent 
exacerbators, fold increases from NT of ~12.5x (2 hr time point) and ~14x (6 hr time 
point) were observed. For healthy smokers, fold increases of ~11x (2 hr time point) 
and ~8.5x (6 hr time point) were observed. Finally, healthy never smokers had fold 
increases from NT of ~10.5x (2 hr time point) and ~9x (6 hr timepoint). No significant 
time × group interaction was observed for GILZ expression (p = 0.176). There were 
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no significant main differences between groups for GILZ expression (p = 0.227) 
(Figure 5.2).  
 
Figure 5.2. Fold changes in GILZ gene expression from NT in isolated PBMC’s 
following 2 hr or 6 hr of 1μM dexamethasone treatment in frequent and infrequent 
exacerbators of COPD compared to healthy smokers and never smokers.  
 
5.3.2.2 Responses to pulmonary rehabilitation  
5.3.2.2.1 Gene expression in not-treated samples 
Following completion of pulmonary rehabilitation, no significant differences in MKP-
1 mRNA expression were observed in NT samples of frequent exacerbators when 
compared to pre-rehabilitation (p = 0.134). Similarly, no significant differences in 
NT MKP-1 expression were observed between pre- and post-pulmonary 
rehabilitation in infrequent exacerbators (p = 0.279). No significant differences were 
observed between frequent and infrequent exacerbators for MKP-1 expression in 
NT samples at post-rehabilitation (p = 0.265).  
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No significant differences in GILZ mRNA expression were observed in NT samples 
of frequent exacerbators when compared to pre-rehabilitation (p = 0.873). There 
was a significant increase in basal GILZ expression post-rehabilitation in infrequent 
exacerbators (p = 0.019). This change in basal GILZ expression in infrequent 
exacerbators was equivalent to a ~3.5x fold increase. No significant differences in 
GILZ expression of NT samples were observed between groups post-rehabilitation 
(p = 0.624).  
5.3.2.2.2 Fold changes following dexamethasone treatment 
Pulmonary rehabilitation showed a tendency towards an increased MKP-1 gene 
expression with 2 hr of dexamethasone treatment in both groups, but this was not 
found to be statistically significant (p = 0.060). No significant time × group 
interactions (p = 0.719) or differences between groups (p = 0.250) were observed 
with MKP-1 gene expression following 2 hr treatment with dexamethasone (Figure 
5.3A).  
No main effect of time with pulmonary rehabilitation was observed for GILZ 
expression following 2 hr treatment with dexamethasone (p = 0.774). No significant 
main time × group interactions (p = 0.192) or differences between groups (p = 
0.167) were observed for GILZ gene expression following 2 hr treatment with 
dexamethasone at pre-rehabilitation and post-rehabilitation (Figure 5.3B). 
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Figure 5.3. Fold changes in MKP-1 (A) and GILZ (B) gene expression from NT in 
isolated PBMC’s following 2 hr of 1μM dexamethasone treatment in frequent and 
infrequent exacerbators of COPD pre- and post-rehabilitation.  
 
No significant main effects of time were observed with pulmonary rehabilitation and 
MKP-1 expression following 6 hr of dexamethasone treatment (p = 0.118). No 
significant time × group interactions (p = 0.279) were observed with MKP-1 gene 
expression following 6 hr treatment with dexamethasone. There was a significant 
difference between groups whereby frequent exacerbators were observed to have 
a poorer MKP-1 response to 6 hr dexamethasone treatment compared to infrequent 
exacerbators across both pre-rehabilitation and post-rehabilitation (p = 0.003) 
(Figure 5.4A). 
No main effect of time with pulmonary rehabilitation was observed for GILZ 
expression following 6 hr treatment with dexamethasone (p = 0.734). No significant 
main time × group interactions (p = 0.168) or differences between groups (p = 
0.151) were observed for GILZ gene expression following 6 hr treatment with 
dexamethasone at pre-rehabilitation and post-rehabilitation (Figure 5.4B). 
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Figure 5.4. Fold changes in MKP-1 (A) and GILZ (B) gene expression from NT in 
isolated PBMC’s following 6 hr of 1μM dexamethasone treatment in frequent and 
infrequent exacerbators of COPD pre- and post-rehabilitation. †Significant 
difference between groups (p < 0.05).   
 
 Discussion  
The main findings from this study suggest that frequent exacerbators may have a 
poorer response to corticosteroid treatment compared to infrequent exacerbators 
but that pulmonary rehabilitation may have the potential to modulate MKP-1 
expression in response to corticosteroid treatment in both frequent and infrequent 
exacerbators.  
MKP-1 and GILZ are established corticosteroid inducible genes (Kelly et al., 2012; 
King et al., 2009; Newton & Holden, 2007), and this is the first study to assess how 
these genes are influenced by a non-pharmacological intervention such as 
pulmonary rehabilitation. This evidence suggests that pulmonary rehabilitation may 
play a role in modulating corticosteroid effectiveness in both frequent and infrequent 
exacerbators of COPD. The tendency towards an upregulation of MKP-1 in 
response to exercise training draws similarities with previous research in rodents 
whereby MKP-1 was significantly up-regulated following stimulation at the end of 
an exercise training programme (Chen, Chen & Jen, 2010). However, the 
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mechanisms underpinning the upregulation of MKP-1 are currently unclear. One 
proposed mechanism is that acute exercise temporarily upregulates MKP-1 
expression and that regular exercise training may result in a translation of this acute 
effect into increased basal levels of MKP-1 (Chen, Chen & Jen, 2010). For COPD 
patients overall, sample size calculations suggest that sample sizes of 55 and 45 
would be required to detect statistical significance in MKP-1 expression with 2 hr 
and 6 hr treatments with fold changes of 1.41 and 1.74 respectively using 80% 
power and 5% level of significance. For GILZ, sample sizes of 1282 and 661 would 
be required to detect statistical significance with fold changes of 0.66 and 1.05 for 
2 hr and 6 hr treatments respectively. For frequent exacerbators only, sample sizes 
of 26 and 7 would be required to detect statistical significance in MKP-1 expression 
with 2 hr and 6 hr treatments with fold changes of 1.81 and 2.91 respectively. 
Sample sizes of 26 and 32 would be required to detect statistical significance in 
GILZ expression with 2 hr and 6 hr treatments with fold changes of 3.78 and 4.23 
respectively for frequent exacerbators. 
The current study provides further evidence of the benefits of pulmonary 
rehabilitation in the management of COPD by showing potential improvements in 
pharmacological treatment response. Study 2 highlighted the ability of pulmonary 
rehabilitation to reduce pro-inflammatory mediators with the current study showing 
that pulmonary rehabilitation may also play an important role in upregulating anti-
inflammatory genes. The implications of this may involve the repurposing of 
corticosteroids in treatment pathways if levels of reversal of corticosteroid 
resistance can be achieved, particularly when there has been limited success in 
establishing anti-inflammatory treatments in COPD (Cazzola et al., 2012). 
Furthermore, increasing the effectiveness of corticosteroids may also reduce the 
dosage requirement for treatment responses resultantly reducing the side effects 
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of corticosteroids (Wood-Baker et al., 2005). Further research needs to confirm the 
effects of different treatment timepoints and other corticosteroid inducible genes in 
response to pulmonary rehabilitation. It would also be insightful to assess these 
responses in the context of early pulmonary rehabilitation where corticosteroids are 
routinely used during acute exacerbations to see whether pulmonary rehabilitation 
could have any biological effects that may play a role in improved recovery at a 
patient level.  
For some time, many treatment pathways have recommended the use of ICS in 
COPD patients who remain breathless or continue to suffer recurrent exacerbations 
despite LABA therapy (GOLD, 2019). As such ICS use is often observed to be more 
prevalent in frequent exacerbators (Capozzolo et al., 2017). There are increasing 
calls, including the updated NICE guidance (NICE, 2018), for prescription of ICS to 
be limited to COPD patients who present with asthmatic features/corticosteroid 
responsiveness (e.g. blood eosinophilia) due to the questions over the 
effectiveness of ICS for reducing exacerbations (Ernst, Saad & Suissa, 2015), and 
increased risk of pneumonia with long-term ICS use (Suissa et al., 2013). This is 
the first study to compare corticosteroid effectiveness amongst frequent, infrequent 
exacerbators and healthy comparators. This study found that corticosteroid 
treatment induced MKP-1 and GILZ mRNA expression in both COPD patients and 
healthy controls. This study also suggested that frequent exacerbators had a poorer 
response to prolonged corticosteroid treatment. Although data presented in this 
study would suggest that this difference was only apparent with MKP-1 expression 
and not GILZ. Given the downstream effects of MKP-1 in inhibiting the expression 
of numerous pro-inflammatory mediators (King et al., 2009), these findings would 
suggest that corticosteroid treatment has a reduced effectiveness in frequent 
exacerbators and may in part explain the inability to suppress inflammation 
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commonly observed in this subset of COPD patients (Hurst et al., 2010). On the 
other hand, it could also be argued that frequent exacerbators may be less 
responsive to corticosteroids due to having greater neutrophilic inflammation 
(Hoenderdos & Condliffe, 2013). Further research is required to explore the 
differences in anti-inflammatory gene expression between exacerbation 
phenotypes of COPD, utilising measures of proteins as well as mRNA.  
Questions have also been raised around how long it takes for corticosteroids to take 
effect and whether COPD patients require a treatment that takes more of an 
immediate effect (GOLD, 2019). This study is the first study to identify that isolated 
PBMC’s from COPD patients have a differential temporal response to that of 
healthy individuals. The current study observed that serum starved PBMC’s 
stimulated with corticosteroids from COPD patients experienced an increase in 
MKP-1 expression between 2 hr and 6 hr treatment points, which was not observed 
in healthy comparators. This response may indicate that in patients with COPD, 
corticosteroids take longer to have an effect. The delayed response may go some 
way to explaining the ‘overuse’ and developed resistance of ICS in COPD patients 
with a perceived dependency on effect of the drugs (Koehorst-ter Huurne et al., 
2018). This relationship warrants further investigation drawing comparisons 
between phenotypes.  
When interpreting the findings of this study, it is important to consider that these 
results are based on gene expression within PBMC’s only and future research 
should attempt to assess responses in structural cells where corticosteroids have 
also been observed to inhibit pro-inflammatory responses (e.g. epithelial and 
smooth muscle cells) (Ito et al., 2000). However, previous studies have highlighted 
the usefulness of utilising PBMC’s for assessing corticosteroid sensitivity in patients 
with respiratory disease (Goleva et al., 2012; Hew et al., 2006). It is also important 
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to consider that no concurrent control group was utilised in this study to confirm the 
observations seen with pulmonary rehabilitation. These data were provided from 
mRNA on two corticosteroid inducible genes which provide a limited insight into 
other corticosteroid inducible pathways in COPD. MKP-1 and GILZ were chosen as 
they are well-established corticosteroid-inducible genes (Kelly et al., 2012; King et 
al., 2009; Newton & Holden, 2007), but future research should utilise a wider range 
of corticosteroid-inducible genes (e.g. regulator of G-protein signalling 2 (RGS2) 
(Holden et al., 2014)), and assess beta2-agonist treatments that are also thought to 
have synergistic effects with ICS on anti-inflammatory pathways (Johnson, 2004).  
In conclusion, this study highlighted the potential role that pulmonary rehabilitation 
can have in increasing the effectiveness of corticosteroids in patients with COPD. 
This study underlined the poorer expression of MKP-1 in response to 
corticosteroids in frequent exacerbators of COPD compared to infrequent 
exacerbators. Further research is required to assess the ability of corticosteroids to 
activate anti-inflammatory gene pathways in frequent and infrequent exacerbators 
in response to pulmonary rehabilitation.  
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6 Chapter SIX 
Study 4 – Inflammatory responses to acute exercise during pulmonary 
rehabilitation in patients with COPD 
Abstract  
Healthy individuals unaccustomed to exercise can experience acute increases in 
inflammatory mediators in the circulation before an induction of an anti-
inflammatory environment with regular bouts of exercise. Short bursts of 
inflammation in COPD can lead to exacerbations. The aim of this study was to 
assess the effects of acute exercise on inflammatory parameters in frequent and 
infrequent exacerbators of COPD at the start (Phase 1) and end (Phase 2) of 
pulmonary rehabilitation.  Blood samples were collected pre- and post-exercise at 
the 2nd class (Phase 1, n = 40; mild-severe COPD; FEV1 pred, 51 ± 17%; frequent, 
n = 26; infrequent, n = 14) and last class (Phase 2, n = 27; frequent, n = 16; 
infrequent, n = 11) of pulmonary rehabilitation. Circulating fibrinogen & CRP 
concentrations and total/differential leukocyte counts were measured. Established 
markers of neutrophil activation (CD11b, CD62L & CD66b) were assessed in blood 
neutrophils (CD45+/CD16b+). Respiratory symptoms were assessed pre-
rehabilitation and upon commencement of pulmonary rehabilitation via the EXACT® 
questionnaire (Phase 1). Acute exercise (Phase 1) did not result in significant 
changes in fibrinogen (p = 0.579) or CRP (p = 0.641). Total leukocyte counts were 
significantly increased following acute exercise in both groups (p = 0.002). 
Infrequent exacerbators had a significant increase in neutrophil counts following 
acute exercise (p = 0.001). CD62L expression was significantly reduced following 
acute exercise in frequent exacerbators (p = 0.009). The proportion of immature 
neutrophils significantly increased following acute exercise (p = 0.002). There was 
significant decrease in Cough/Sputum symptoms (p = 0.012) and a tendency 
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towards a significant decrease in EXACT® scores (p = 0.051) upon commencement 
of pulmonary rehabilitation. Pulmonary rehabilitation (Phase 2) did not significantly 
alter the fibrinogen (p = 0.089), CRP (p = 0.718), total leukocyte counts (p = 0.459), 
neutrophil counts (p = 0.769), CD62L expression (p = 0.220), and immature 
neutrophil (p 0.888) responses to acute exercise. Frequent exacerbators had a 
significantly decreased CD62L expression in response to acute exercise compared 
to infrequent exacerbators across both the start, and end of, pulmonary 
rehabilitation bouts (p = 0.004). In conclusion, acute bouts of moderate exercise 
appear to induce an inflammatory response commonly observed in healthy 
individuals. Both frequent and infrequent exacerbators appear to adopt largely 
similar immune responses to acute bouts of exercise, but some inflammatory 
responses do differ. Preliminary evidence suggests that these immune responses 
do not appear to correspond to an increase in respiratory symptoms during the early 
stages of pulmonary rehabilitation. A period of pulmonary rehabilitation does not 
appear to alter inflammatory responses to acute exercise in frequent or infrequent 
exacerbators.  
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 Introduction 
Study 1 identified that frequent exacerbators of COPD are less likely to complete 
pulmonary rehabilitation but achieve clinically significant benefits when doing so. 
Some qualitative evidence suggests that patients do not attend pulmonary 
rehabilitation because of a perception of increased respiratory symptoms with 
exercise (Guo & Bruce, 2014). However, clinical trial and real-life evidence is 
gathering showing that completion of pulmonary rehabilitation leads to a reduced 
incidence of exacerbations & hospitalisations (Moore et al., 2016; Steiner et al., 
2017a). Study 2 has shed some light on the potential underlying mechanisms, 
characterised by a reduction in fibrinogen concentration, an established biomarker 
of exacerbations (Chen, Leung & Sin, 2016). However, the effects of acute bouts 
of exercise in COPD are unclear whereby short bursts of inflammation resulting 
from exercise have been proposed to increase the risk of exacerbation (van der 
Vlist & Janssen, 2010). This may bare significant relevance for frequent 
exacerbators given that they are more susceptible to elevated levels of 
inflammation at rest (Donaldson et al., 2005a; Perera et al., 2007). 
It has previously been suggested that COPD patients avoid exercise due to a 
dyspnoea-related fear leading to worsening outcomes (Boot, van Exel & van der 
Gulden, 2009). One potential mechanism for this worsening in outcomes and 
symptoms may result from the acute inflammatory response to exercise commonly 
seen in healthy individuals (Walsh et al., 2011), which is becoming increasingly 
apparent in COPD patients (Jenkins et al., 2015; van der Vlist & Janssen, 2010; 
van Helvoort et al., 2005). Inflammatory mediators such as fibrinogen and 
neutrophil count can be seen to be increased post-exercise in healthy and diseased 
populations (Ahmadizad & El-Sayed, 2005; Jenkins et al., 2015; Li-Saw-Hee et al., 
2001; Montgomery et al., 1996; Quindry et al., 2003). In frequent exacerbators, 
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fibrinogen and neutrophil counts can be seen to be elevated at rest with 
inflammatory and clinical responses to acute exercise yet to be determined in this 
phenotype of COPD (Donaldson et al., 2005a; Hurst et al., 2010; Wedzicha, 
Mackay & Singh, 2013). It has been suggested that responses to acute exercise 
depend on underlying factors (e.g. training state (Brown et al., 2015)). Some have 
suggested that acute exercise may be pro-inflammatory in the early stages of an 
exercise training programme but continuing exercise on a regular basis may favour 
an anti-inflammatory response (Kasapis & Thompson, 2005).  
Previous research has suggested that acute exercise triggers an inflammatory 
response in healthy individuals as characterised by the mobilisation of neutrophils 
and increased concentrations of fibrinogen and CRP (Bizheh & Jaafari, 2011; 
Montgomery et al., 1996; Nieman et al., 2005). In COPD, an acute bout of exercise 
has been seen to increase neutrophil counts (van Helvoort et al., 2006; Jenkins et 
al., 2015). However, research assessing the inflammatory responses to acute 
exercise prior to, during and following pulmonary rehabilitation found that 
pulmonary rehabilitation did not affect the acute inflammatory responses of CRP 
(Canavan et al., 2007). This is further supported by Spruit et al. (2007) who found 
that an acute exercise bout to symptom limitation did not induce significant 
elevations in CRP or IL-6 in hospitalised and stable COPD patients. Acute bouts of 
exercise have also been seen to induce changes in the expression of cell surface 
receptors of neutrophils in healthy populations (Gray et al., 1993; Smith et al., 1996; 
van Eeden et al., 1999). For example, CD62L expression, which is shed by 
neutrophils upon activation has been seen to be decreased following exercise 
indicating an increase in neutrophil activation following exercise (Borregaard & 
Cowland, 1997; Ley et al., 2007; Nathan, 2006; Wittmann et al., 2004). However, 
the degree of the inflammatory response to exercise is dependent upon the type, 
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duration and intensity of exercise (Syu, Chen & Jen, 2012). Such increases in 
neutrophil activation may have deleterious effects in a population such as COPD 
that are characterised by neutrophilic inflammation (Hoenderdos & Condliffe, 2013; 
Quint & Wedzicha, 2007).  
It has been suggested that immunological responses to exercise in COPD may hold 
the key to explaining exacerbation prevention and management (Jenkins, Holden 
& Jones, 2018). In healthy populations, assessing acute responses to exercise 
have been suggested to have more clinical significance than training-induced 
alterations in resting immune/inflammatory parameters (Brandt & Pedersen, 2010). 
However, the acute effects of exercise on inflammation in COPD patients entering 
a rehabilitation programme, in particular those patients characterised as having 
heightened inflammation at rest (i.e. frequent exacerbators) warrant further 
investigation.  
There is a clear lack of evidence assessing the effects of acute exercise, pre- and 
post-pulmonary rehabilitation, on markers of systemic inflammation in frequent and 
infrequent exacerbators of COPD. Therefore, this study aimed to assess whether 
acute exercise in frequent and infrequent exacerbators increases markers of 
systemic inflammation. This study also aimed to assess whether acute responses 
to exercise differed following exercise training (e.g. end of a pulmonary 
rehabilitation programme). It was hypothesised that markers of systemic 
inflammation would increase following acute exercise during the early stages of 
pulmonary rehabilitation regardless of exacerbation history. It was also 
hypothesised that these effects would diminish following an exercise training 
programme (e.g. pulmonary rehabilitation). In order to achieve these objectives, the 
study was split into two phases: 
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• Phase 1 – Immune responses to an initial acute bout of exercise during 
pulmonary rehabilitation in frequent and infrequent exacerbators of COPD  
• Phase 2 – Immune responses to an acute bout of exercise following 
completion of pulmonary rehabilitation in frequent and infrequent 
exacerbators of COPD 
 
 Methods  
6.2.1 COPD patients 
40 COPD patients (age 69 ± 7 years; FEV1 pred 51 ± 17%; frequent exacerbators 
= 26; infrequent exacerbators = 14) were recruited.  
6.2.2 Procedures  
COPD patients performed exercises as part of a pulmonary rehabilitation 
programme as outlined in section 2.5. Exercise targets were adjusted for each 
session by the physiotherapist depending on performance, progression and health 
status of each patient.  No dietary interventions or restrictions were put in place for 
this study.  
Blood samples were taken pre- and post-exercise at the beginning (Phase 1, 2nd 
class) and end (Phase 2, 16th class) of the pulmonary rehabilitation programme, 
providing patients did not drop-out of the course. The time of blood sample 
collection was controlled at the 2nd and 16th classes for each patient. The 2nd class 
of the programme was chosen for assessment of acute responses to exercise as 
the 1st class of pulmonary rehabilitation is an induction/familiarisation session where 
the performing of exercises is limited.  
The primary outcome (for both phases) of fibrinogen concentration (sodium citrate) 
and secondary outcome of CRP concentration (K3EDTA) were quantified in plasma 
through the use of ELISA’s (see section 2.8.2). Secondary outcomes of 
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total/differential leukocyte counts were quantified via haematological analysis (see 
section 2.8.1). Further secondary measures were undertaken on a subset of 
patients whole blood (frequent, n = 21; infrequent, n = 12) to assess markers of 
neutrophil activation (CD11b, CD62L, CD66b) and neutrophil phenotypes (mature, 
CD16high/CD62Lhigh; suppressive, CD16high/CD62Llow; immature, 
CD16low/CD62Lhigh; progenitor, CD16low/CD62Llow) with the use of flow cytometry 
(section 2.8.3). For Phase 1, a further subset also consented to completing the 
EXACT® questionnaire daily (section 2.6) in the week leading up to pulmonary 
rehabilitation (pre-rehabilitation) and the first week of pulmonary rehabilitation 
(Week 1) (frequent, n = 20; infrequent, n = 11) to quantify changes in respiratory 
symptoms. 
6.2.3 Statistical Analysis 
For Phase 1, data were analysed as absolute values (pre- vs post-exercise) 
whereas Phase 2 data were analysed as mean differences between pre- and post-
exercise (beginning vs end of pulmonary rehabilitation). Changes in fibrinogen 
concentrations, total/differential cell counts, expression of neutrophil activation 
markers (CD11b, CD62L, CD66b), neutrophil maturity (mature, CD16high/CD62Lhigh; 
suppressive, CD16high/CD62Llow; immature, CD16low/CD62Llow; progenitor, 
CD16low/CD62Llow), and EXACT® scores (Phase 1 only) including E-RS™ subset 
scores (pre-rehabilitation vs. week 1) were analysed using a two-way mixed 
ANOVA with Bonferroni correction (Phase 1, pre- vs. post-exercise, frequent vs. 
infrequent; Phase 2, pre- vs. post-rehabilitation, frequent vs. infrequent 
exacerbators). Any significant main effects observed in the ANOVA were further 
analysed with post-hoc two-tailed paired t-tests. For Phase 1, changes in CRP 
concentrations between pre- and post-exercise were analysed using a Wilcoxon 
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signed rank test with differences between groups at each time point analysed using 
a Mann-Whitney U test.  Statistical significance was accepted at P < 0.05.  
 Results 
6.3.1 Phase 1  
6.3.1.1 Patient characteristics 
Sodium citrate plasma samples were unable to be obtained from 3 COPD patients 
for the analysis of fibrinogen (frequent exacerbators, n = 2; infrequent exacerbators, 
n = 1) with 1 K3EDTA plasma sample unable to be obtained for the analysis of CRP 
(frequent exacerbators, n = 1). In the subset of participants who were assessed for 
neutrophil activation markers, 13 participants were excluded from these analyses 
due to a lack of expression of CD16b meaning that neutrophils could not be 
confidently isolated for analysis (frequent exacerbators, n = 8; infrequent 
exacerbators, n = 5). Insufficient data point entries (≥4 days) were completed for 5 
COPD patients with the EXACT® questionnaire so these data were not included in 
the analyses (frequent exacerbators, n = 4; infrequent exacerbators, n = 1).  
The patient characteristics of frequent and infrequent exacerbators are detailed in 
Table 6.1. All frequent exacerbators were categorised as GOLD grade D (100%) 
with the majority of infrequent exacerbators classified as GOLD grade B (93%). The 
majority of frequent and infrequent exacerbators were categorised as either mMRC 
grade 2, grade 3, or grade 4.  
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Table 6.1. Patient characteristics 
 
 
Variable 
 
 
Frequent 
 
 
Infrequent 
Age (years)a 68 ± 6 71 ± 7 
% Malesb 62% 50% 
Body Mass (kg)a 78 ± 18 76 ± 17 
GOLD grade, n (%)c   
A 0 (0) 1 (7) 
B 0 (0) 13 (93) 
C 0 (0) 0 (0) 
D 26 (100) 0 (0) 
FEV1 %predicteda 48 ± 16 57 ± 18 
Charlson Comorbidity Indexa 3.7 ± 1.2 4.1 ± 1.1 
Current smokersb 27% 17% 
mMRC, n (%)c   
0 0 (0) 1 (7) 
1 0 (0) 0 (0) 
2 2 (7) 4 (29) 
3 9 (35) 3 (21) 
4 15 (58) 6 (43) 
aData presented as mean ± SD (t-test). bData presented as a % of total population (chi-squared). 
cData presented as total number (% of group). Frequent, n = 26; infrequent, n = 14. 
 
 
6.3.1.2 Inflammatory responses 
There was no significant change in fibrinogen concentrations following an acute 
bout of exercise at the beginning of pulmonary rehabilitation (p = 0.579). No 
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differences in fibrinogen concentrations were observed between groups (p = 0.724) 
nor were any time × group interactions seen (p = 0.204) (Table 6.2).  
Table 6.2. Fibrinogen concentration in response to an acute bout of exercise at 
the beginning of pulmonary rehabilitation 
 
 
 
Variable 
 
 
 
Frequent 
 
 
 
Infrequent 
 
Time 
main 
effect 
p-values  
 
Time × group 
interaction 
 
Group 
main 
effect 
Fibrinogen  
(mg/dL) 
  0.579 0.724 0.204 
Pre-exercise 736 ± 148 661 ± 202    
Post-exercise 713 ± 144 656 ± 194    
Data presented as mean ± SD. Fibrinogen: frequent, n = 24; infrequent, n = 13.  
 
There were no significant differences in CRP concentrations following an acute bout 
of exercise (p = 0.264). CRP concentrations were also not seen to be different 
between groups at pre-exercise (p = 0.784) or post-exercise (p = 0.965) (Figure 
6.1).  
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Figure 6.1. CRP concentrations in response to an acute bout of exercise at the 
beginning of pulmonary rehabilitation in frequent and infrequent exacerbators. 
Lines represent median values. 
 
There was a significant main effect of time showing an increase in total leukocyte 
count following an acute bout of exercise (p = 0.002). No time × group interactions 
were observed with total leukocyte counts (p = 0.107). Although not statistically 
significant, there was a tendency towards a higher total leukocyte count in frequent 
exacerbators when compared to infrequent exacerbators (p = 0.069).  
There was a significant main effect of time showing an increase in neutrophil counts 
post-exercise (p < 0.001). A significant time × group interaction was also seen with 
neutrophil counts (p = 0.012). Post-hoc analyses showed that infrequent 
exacerbators experienced a significant increase in neutrophil counts (p = 0.001) 
which was not observed in frequent exacerbators (p = 0.162). There was a tendency 
towards a higher neutrophil count in the frequent exacerbators group, but this did 
not reach statistical significance (p = 0.088).  
No significant main effects of time were observed for lymphocyte (p = 0.473) or 
eosinophil counts (p = 0.811). There were also no significant time × group 
interactions for lymphocyte (p = 0.487) or eosinophil counts (p = 0.137), nor were 
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any significant differences observed between groups for lymphocyte (p = 0.611) or 
eosinophil counts (p = 0.286).  
There was a significant main effect of time showing an increase in the 
neutrophil/lymphocyte ratio following exercise (p = 0.003). A significant time × group 
interaction was also observed with neutrophil/lymphocyte ratio following acute 
exercise (p = 0.007). Post-hoc analyses showed that infrequent exacerbators 
experienced a significant increase in neutrophil/lymphocyte ratio following acute 
exercise (p = 0.018) which was not apparent in frequent exacerbators (p = 0.711). 
No significant differences in neutrophil/lymphocyte ratio were seen between 
frequent and infrequent exacerbators (p = 0.242) (Table 6.3). 
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Table 6.3. Changes in cell counts in response to an acute bout of exercise at the 
beginning of pulmonary rehabilitation 
 
 
 
Variable 
 
 
 
Frequent 
 
 
 
Infrequent 
 
Time  
main 
effect 
p-values 
Time × 
group 
interaction 
 
Group 
main 
effect 
Total Leukocytes  
(109·L-1) 
  0.002* 0.107 0.069 
Pre-exercise 7.9 ± 2.2 6.4 ± 0.9    
Post-exercise 8.1 ± 2.2 7.3 ± 1.3    
Neutrophils (109·L-1)   <0.001** 0.012# 0.088 
Pre-exercise 4.8 ± 1.7 3.7 ± 0.8    
Post-exercise 5.0 ± 1.8 4.5 ± 1.0    
Eosinophils (109·L-1)   0.811 0.137 0.286 
Pre-exercise 0.3 ± 0.2 0.2 ± 0.1    
Post-exercise 0.2 ± 0.2 0.2 ± 0.1    
Lymphocytes (109·L-1)   0.473 0.487 0.611 
Pre-exercise 2.0 ± 0.7 1.9 ± 0.4    
Post-exercise 2.1 ± 0.7 1.9 ± 0.4    
Neutrophil/Lymphocyte  
ratio 
  0.003* 0.007# 0.242 
Pre-exercise 2.6 ± 1.1 2.0 ± 0.7    
Post-exercise 2.8 ± 1.6 2.4 ± 0.7    
Data presented as mean ± SD. *Significant effect of time (*p < 0.05; ** p < 0.001). #Significant time 
× group interaction (p < 0.05). Frequent, n = 26; infrequent, n = 14. 
 
 
 156 
 
6.3.1.3 Neutrophil surface expression 
There was no main effect of time on neutrophil CD11b (p = 0.856) or CD66b (p = 
0.902) expression with an acute bout of exercise at the beginning of pulmonary 
rehabilitation. No time × group interactions were observed for CD11b (p = 0.710) 
and CD66b (p = 0.344). Nor were there any significant differences between frequent 
and infrequent exacerbators in terms of neutrophil CD11b (p = 0.465) and CD66b 
(p = 0.699) expression (Table 6.4).  
 
Table 6.4. Responses of neutrophil activation markers to acute exercise at the 
beginning of pulmonary rehabilitation  
 
 
Neutrophil 
Marker  
 
 
 
Frequent 
 
 
 
Infrequent 
 
Time 
main 
effect 
p-values  
 
Time × group 
interaction 
 
Group 
main 
effect 
CD11b (MFI)   0.856 0.710 0.465 
Pre-exercise 5401 ± 707  5707 ± 955    
Post-exercise 5435 ± 858 5609 ± 524    
CD66b (MFI)   0.902 0.344 0.699 
Pre-exercise 9506 ± 2852 9337 ± 3376    
Post-exercise 9919 ± 2585 9018 ± 3634    
Data presented as mean ± SD. MFI, median fluorescent intensity. Frequent, n = 13; infrequent, n = 
7. 
 
An acute bout of exercise at the beginning of pulmonary rehabilitation did not induce 
a statistically significant main effect of time on neutrophil CD62L expression (p = 
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0.809). However, significant time × group interactions were observed with an acute 
exercise bout (p = 0.044). Post-hoc analyses showed that frequent exacerbators 
experienced a significant decrease in CD62L expression post-exercise (p = 0.009), 
which was not observed in infrequent exacerbators (p = 0.377). No significant 
differences between groups were observed for neutrophil CD62L expression (p = 
0.118) (Figure 6.2). 
 
Figure 6.2. Changes in neutrophil CD62L expression following an acute bout of 
exercise at the beginning of pulmonary rehabilitation in frequent and infrequent 
exacerbators. Lines represent mean values. *Significant difference between pre- 
and post-exercise (p < 0.05).  
 
There were no significant main effects of time on mature (CD16bhigh/CD62Lhigh) (p 
= 0.799), suppressive (CD16bhigh/CD62Llow) (p = 0.272), or progenitor 
(CD16blow/CD62Llow) (p = 0.544) neutrophil subsets following an acute bout of 
exercise. There were also no significant time × group interactions (mature, p = 
0.856; suppressive, p = 0.533; progenitor, p = 0.765) or differences between groups 
(mature, p = 0.928; suppressive, p = 0.823; progenitor, p = 0.898) (Table 6.5). 
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Table 6.5. Neutrophil phenotypes in response to acute exercise at the beginning 
of pulmonary rehabilitation 
 
 
 
Neutrophil Marker  
 
 
 
Frequent 
 
 
 
Infrequent 
 
Time 
main 
effect 
p-values  
 
Time × group 
interaction 
 
Group 
main 
effect 
CD16bhigh/CD62Lhigh (%)   0.799 0.856 0.928 
Pre-exercise 92.7 ± 3.6 92.6 ± 1.9    
Post-exercise 92.6 ± 2.7 92.4 ± 0.8    
CD16bhigh/CD62Llow (%)   0.272 0.533 0.823 
Pre-exercise 5.7 ± 3.7 5.3 ± 2.4    
Post-exercise 5.2 ± 2.8 4.6 ± 2.0    
CD16blow/CD62Llow (%)   0.554 0.765 0.898 
Pre-exercise 0.2 ± 0.1 0.1 ± 0.0    
Post-exercise 0.2 ± 0.1 0.2 ± 0.3    
Data presented as mean ± SD. Frequent, n = 13; infrequent, n = 7. 
 
A significant main effect of time showing an increase in the percentage of immature 
(CD16blow/CD62Lhigh) neutrophils was observed post-exercise (p = 0.002). No time 
and group interactions (p = 0.691) or differences between groups (p = 0.176) were 
observed with an acute exercise bout for the immature neutrophil subset (Figure 
6.3). 
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Figure 6.3. Changes in percentage of immature neutrophils following an acute bout 
of exercise at the beginning of pulmonary rehabilitation in frequent and infrequent 
exacerbators. Lines represent mean values. *Significant main effect of time (p < 
0.05).  
 
6.3.1.4 EXACT® and E-RS™  
A tendency towards a decrease in total EXACT® score was observed in both groups 
following the commencement of pulmonary rehabilitation (p = 0.051). There was no 
significant time × group interactions observed (p = 0.670), nor any significant 
differences between groups (p = 0.217). An example of daily reported EXACT® 
scores between pre-rehab and week 1 for one patient is provided (Figure 6.4). 
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Figure 6.4. An example of daily EXACT® scores for one patient in the week prior to 
(Pre-Rehab), and week of (Week 1), commencing pulmonary rehabilitation.  
 
There was a tendency towards a decrease in E-RS™ score in both groups upon 
commencement of pulmonary rehabilitation, but this was not found to be statistically 
significant (p = 0.083). No time × group interactions (p = 0.667) or differences 
between groups (p = 0.296) were observed with E-RS™ score.  
There were no significant effects of time on breathlessness (p = 0.515) or chest 
symptoms (p = 0.560) between pre-rehabilitation and week 1. No significant time × 
group interactions (breathlessness, p = 0.686; chest, p = 0.649) or differences 
between groups (breathlessness, p = 0.391; chest, p = 0.488) were observed.  
There was a significant main effect of time showing a reduction in cough/sputum 
symptoms upon commencing pulmonary rehabilitation (p = 0.012). No significant 
time × group interactions (p = 0.567) or differences between groups (p = 0.090) 
were observed (Table 6.6).  
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Table 6.6. Patient reported EXACT® scores between pre-rehabilitation and week 
1 
 
 
 
EXACT® domain 
 
 
 
Frequent 
 
 
 
Infrequent 
 
Time 
main 
effect 
p-values  
Time × 
group 
interaction 
 
Group 
main 
effect 
EXACT®-Total score   0.051 0.670 0.217 
Pre-Rehab 19.3 ± 10.6 14.6 ± 5.7    
Week 1 18.1 ± 10.8 13.7 ± 6.7    
E-RS™-Total score   0.083 0.667 0.296 
Pre-Rehab  15.5 ± 8.2 12.4 ± 4.9    
Week 1 14.7 ± 8.4 11.8 ± 5.5    
Breathlessness score   0.515 0.686 0.391 
Pre-Rehab  7.8 ± 4.8 6.5 ± 3.2    
Week 1 7.7 ± 4.9 6.4 ± 3.1    
Cough/Sputum score   0.012* 0.567 0.090 
Pre-Rehab  3.0 ± 0.8 2.6 ± 0.4    
Week 1 2.8 ± 1.0 2.2 ± 0.6    
Chest score   0.560 0.649 0.488 
Pre-Rehab  3.3 ± 2.2 2.6 ± 1.7    
Week 1 3.1 ± 2.2 2.6 ± 2.0    
Data presented as mean ± SD. *Significant main effect of time (p < 0.05). Frequent, n = 16; 
infrequent, n = 10.   
 
6.3.2 Phase 2 
6.3.2.1 Patient characteristics 
There were 13 COPD patients lost due to follow-up (frequent exacerbators, n = 10; 
infrequent exacerbators, n = 3) at the end of pulmonary rehabilitation. Sodium 
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citrate plasma samples were unable to be obtained from 2 COPD patients for the 
measurement of fibrinogen (frequent exacerbators, n = 1; infrequent exacerbators, 
n = 1). Four COPD patients were lost in the follow-up for the measurement of 
neutrophil activation markers (frequent exacerbators, n = 2; infrequent 
exacerbators, n = 2).  
The patient characteristics of frequent and infrequent exacerbators are detailed in 
Table 6.7. All frequent exacerbators were categorised as GOLD grade D (100%) 
with the majority of infrequent exacerbators classified as GOLD grade B (91%). The 
majority of frequent and infrequent exacerbators were categorised as either mMRC 
grade 2, grade 3, or grade 4.  
  
 163 
 
Table 6.7. Patient characteristics 
 
 
Variable 
 
 
Frequent 
 
 
Infrequent 
Age (years)a 69 ± 7 69 ± 6 
% Malesb 63% 45% 
Body Mass (kg)a 76 ± 15 72 ± 16 
GOLD grade, n (%)c   
A 0 (0) 1 (9) 
B 0 (0) 10 (91) 
C 0 (0) 0 (0) 
D 16 (100) 0 (0) 
FEV1 %predicteda 48 ± 18 53 ± 15 
Charlson Comorbidity Indexa 4.0 ± 1.3 4.0 ± 1.2 
Current smokersb 19% 18% 
MRC, n (%)c   
0 0 (0) 1 (9) 
1 0 (0) 0 (0) 
2 1 (6) 3 (27) 
3 7 (44) 2 (18) 
4 8 (50) 5 (46) 
aData presented as mean ± SD (t-test). bData presented as a % of total population (chi-squared). 
cData presented as total number (% of group). Frequent, n = 16; infrequent, n = 11. 
 
 
6.3.2.2 Inflammatory responses 
There was a tendency towards an effect of condition (p = 0.089) on fibrinogen 
concentration but this was not found to be statistically significant. There were no 
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significant condition × group interactions (p = 0.705) or differences between groups 
(p = 0.098) when comparing fibrinogen responses to acute exercise between bouts 
taking place at the start and end of pulmonary rehabilitation.     
No significant effects of condition (p = 0.718) or condition × group interaction (p = 
0.616) were observed when comparing CRP responses to acute exercise between 
bouts taking place at the start and end of pulmonary rehabilitation. There was a 
tendency towards a difference between groups but this was not statistically 
significant (p = 0.064) (Table 6.8). 
Table 6.8. Comparisons of systemic inflammatory responses to acute bouts of 
exercise at the beginning and end of pulmonary rehabilitation 
 
 
 
Variable 
 
 
 
Frequent 
 
 
 
Infrequent 
 
Condition 
main 
effect 
p-values  
Condition × 
group 
interaction 
 
Group 
main 
effect 
Fibrinogen (mg/dL)   0.089 0.705 0.098 
2nd class  
(pre vs post) 
-57 ± 146 -14 ± 189    
16th class  
(pre vs post) 
12 ± 112 92 ± 160    
CRP (mg/L)   0.718 0.616 0.064 
2nd class  
(pre vs post) 
0.5 ± 5.3 1.5 ± 2.2    
16th class  
(pre vs post) 
-0.8 ± 5.7 3.1 ± 7.2    
Data expressed as mean differences ± SD between pre- and post-exercise at the 2nd and 16th 
classes. Fibrinogen: frequent, n = 15; infrequent, n = 10. CRP: frequent, n = 16; infrequent, n = 11. 
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No significant effects of condition were observed for total leukocyte count (p = 
0.459), neutrophil count (p = 0.769), lymphocyte count (p = 0.280), and 
neutrophil/lymphocyte ratio (p = 0.510) when comparing responses to acute 
exercise between bouts taking place at the start and end of pulmonary 
rehabilitation. There were also no significant condition × group interactions (total 
leukocyte, p = 0.156; neutrophil, p = 0.197; lymphocyte, p = 0.736; 
neutrophil/lymphocyte, p = 0.278) or differences between groups (total leukocyte, p 
= 0.552; neutrophil, p = 0.150; lymphocyte, p = 0.105; neutrophil/lymphocyte, p = 
0.283).  
No significant effect of condition was observed for eosinophil count (p = 0.532) 
when comparing responses to acute exercise bouts at the start and end of 
pulmonary rehabilitation. However, a significant condition × group interaction (p = 
0.012) was observed. Post-hoc analyses showed that frequent exacerbators had a 
significantly different response to acute exercise between bouts taking place at the 
start and end of pulmonary rehabilitation as characterised by an increase in 
eosinophil count in response to acute exercise at the end of pulmonary 
rehabilitation, as opposed to a decrease observed at the start (p = 0.025). No 
significant differences between conditions for eosinophil count were observed for 
infrequent exacerbators (p = 0.180). No significant group differences were observed 
for eosinophil count (p = 0.733) (Table 6.9). 
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Table 6.9. Comparisons of mean differences in blood count responses to acute 
bouts of exercise at the beginning and end of pulmonary rehabilitation  
 
 
 
Variable 
 
 
 
Frequent 
 
 
 
Infrequent 
 
Condition 
main 
effect 
p-values  
Condition 
× group  
interaction 
 
Group 
main 
effect 
Total Leukocytes  
(109·L-1) 
  0.459 0.156 0.552 
2nd class (pre vs post) 0.10 ± 1.32 0.75 ± 0.94    
16th class (pre vs post) 0.81 ± 1.08 0.52 ± 0.96    
Neutrophils (109·L-1)   0.769 0.197 0.150 
2nd class (pre vs post) 0.11 ± 0.91 0.80 ± 0.82    
16th class (pre vs post) 0.51 ± 0.80 0.54 ± 0.80    
Eosinophils (109·L-1)   0.532 0.012# 0.733 
2nd class (pre vs post) -0.02 ± 0.05 0.01 ± 0.03    
16th class (pre vs post) 0.01 ± 0.03 -0.01 ± 0.02    
Lymphocytes (109·L-1)   0.280 0.736 0.105 
2nd class (pre vs post) 0.04 ± 0.28 -0.09 ± 0.37    
16th class (pre vs post) 0.15 ± 0.28 -0.03 ± 0.31    
Neutrophil/Lymphocyte 
ratio 
  0.510 0.278 0.283 
2nd class (pre vs post) 0.14 ± 0.63 0.45 ± 0.58    
16th class (pre vs post) 0.18 ± 0.53 0.26 ± 0.60    
Data expressed as mean differences ± SD between pre- and post-exercise at the 2nd and 16th 
classes. #Significant condition × group interaction (p < 0.05). Frequent, n = 16; infrequent, n = 11. 
 
 
 167 
 
6.3.2.3 Neutrophil surface expression 
No significant effects of condition were observed for CD11b (p = 0.390), CD62L (p 
= 0.220) and CD66b expression (p = 0.810) when comparing responses between 
acute bouts of exercise at the start and end of pulmonary rehabilitation. No 
significant condition × group interactions (CD11b, p = 0.568; CD62L, p = 0.251; 
CD66b, p = 0.455) were observed. There was a significant difference between 
groups for CD62L expression whereby frequent exacerbators had significantly 
decreased CD62L expression in response to acute exercise (p = 0.004). No 
significant differences between groups were observed for CD11b (p = 0.831) and 
CD66b (p = 0.636) expression (Table 6.10). 
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Table 6.10. Comparison of mean differences for neutrophil activation markers in 
response to acute exercise at the beginning and end of pulmonary rehabilitation 
 
 
Neutrophil 
Marker  
 
 
 
Frequent 
 
 
 
Infrequent 
 
Condition 
main 
effect 
p-values 
Condition 
× group 
interaction 
 
Group 
main 
effect 
CD11b (MFI)   0.390 0.568 0.831 
2nd class  
(pre vs post) 
17 ± 780 215 ± 460    
16th class  
(pre vs post) 
-51 ± 696 -115 ± 744    
CD62L (MFI)   0.220 0.251 0.004† 
2nd class  
(pre vs post) 
-1734 ± 1771 4083 ± 4431    
16th class  
(pre vs post) 
-1841 ± 3873 1002 ± 3082    
CD66b (MFI)   0.810 0.455 0.636 
2nd class  
(pre vs post) 
364 ± 2029 -304 ± 475    
16th class  
(pre vs post) 
149 ± 1311 111 ± 1432    
Data expressed as mean differences ± SD between pre- and post-exercise at the 2nd and 16th 
classes. †Significant main difference between groups (p < 0.05). MFI, median fluorescent intensity. 
Frequent, n = 11; infrequent, n = 5. 
 
No significant effects of condition were observed for mature (CD16bhigh/CD62Lhigh) 
(p = 0.162), immature (CD16blow/CD62Lhigh) (p = 0.888), suppressive 
(CD16bhigh/CD62Llow) (p = 0.114), or progenitor (CD16blow/CD62Llow) (p = 0.964) 
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neutrophil subsets when comparing between acute bouts of exercise at the start 
and end of pulmonary rehabilitation. No significant condition × group interactions 
were observed for mature (p = 0.633), immature (p = 0.639), suppressive (p = 
0.722), or progenitor (p = 0.876) neutrophil subsets. No significant differences 
between groups were observed for mature (p = 0.669), immature (p = 0.586), 
suppressive (p = 0.892), or progenitor (p = 0.939) neutrophil subsets when 
comparing responses to acute exercise at the start and end of pulmonary 
rehabilitation (Table 6.11). 
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Table 6.11. Comparison of neutrophil phenotypes in response to acute bouts of 
exercise at the beginning and end of pulmonary rehabilitation  
 
 
 
Neutrophil Marker 
 
 
 
Frequent 
 
 
 
Infrequent 
 
Condition 
main 
effect 
p-values  
Condition 
× group  
interaction 
 
Group 
main 
effect 
CD16bhigh/CD62Lhigh (%)   0.162 0.633 0.669 
2nd class (pre vs post) -0.14 ± 2.12 -0.16 ± 2.01    
16th class (pre vs post) -0.75 ± 1.58 -1.37 ± 0.94    
CD16blow/CD62Lhigh (%)   0.888 0.639 0.586 
2nd class (pre vs post) 0.54 ± 0.46 0.69 ± 1.39    
16th class (pre vs post) 0.45 ± 0.46 0.74 ± 1.17    
CD16bhigh/CD62Llow (%)   0.114 0.722 0.892 
2nd class (pre vs post) -0.42 ± 2.06 -0.52 ± 1.76    
16th class (pre vs post) 0.31 ± 1.52 0.62 ± 1.21    
CD16blow/CD62Llow (%)   0.964 0.876 0.939 
2nd class (pre vs post) 0.00 ± 0.15 0.00 ± 0.07    
16th class (pre vs post) -0.01 ± 0.33 0.01 ± 0.03    
Data expressed as mean differences ± SD between pre- and post-exercise at the 2nd and 16th 
classes. Frequent, n = 11; infrequent, n = 5. 
 
 Discussion 
The main findings from this study suggest that acute exercise in frequent and 
infrequent exacerbators at the start of pulmonary rehabilitation does not result in 
significant increases in the concentrations of fibrinogen and CRP. However, 
increases in total leukocyte counts and circulating immature neutrophils are 
observed following this initial acute bout of exercise. These acute inflammatory 
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responses to exercise did not correspond to increases in respiratory symptoms in 
either group. Following a period of pulmonary rehabilitation, no significant changes 
in fibrinogen, CRP, total leukocyte, and neutrophil count responses to acute 
exercise were observed. Comparisons between acute bouts at the start and end of 
pulmonary rehabilitation also showed that frequent exacerbators had significantly 
decreased CD62L responses compared to infrequent exacerbators.  
This is the first study in the COPD population to assess fibrinogen concentrations 
in response to acute exercise bouts at the beginning and end of pulmonary 
rehabilitation. The present findings suggest that acute bouts of exercise in the 
context of a traditional pulmonary rehabilitation programme are not sufficient to 
significantly alter the concentrations of fibrinogen. Of the limited evidence available 
assessing fibrinogen responses to acute exercise, the present findings disagree 
with previous research in other clinical populations (e.g. atrial fibrillation) (Li-Saw-
Hee et al., 2001), whereby fibrinogen levels were observed to increase following an 
acute bout of exercise. It is important to note that others have utilised strenuous 
exercise to assess fibrinogen responses (Li-Saw-Hee et al., 2001). It has previously 
been suggested that acute exercise, especially if prolonged or highly intense, can 
induce inflammation (Woods et al., 2012). The current study did not control for 
exercise intensity but conceivably, at least at the start of pulmonary rehabilitation, 
absolute exercise intensity was low. Therefore, it may be deemed that exercise 
needs to be strenuous, or prolonged in duration, to induce increases in fibrinogen 
concentration. Nevertheless, the findings indicate that acute exercise as part of 
pulmonary rehabilitation, even at end of the programme, does not exacerbate key 
markers of systemic inflammation in either frequent or infrequent exacerbators of 
COPD. Further research is warranted to confirm whether fibrinogen responses to 
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acute exercise in COPD, may differ if exercise or pulmonary rehabilitation 
programmes prescribe higher exercise intensities.  
This study also found that CRP was not significantly elevated following acute bouts 
of exercise at the start and end of pulmonary rehabilitation. This agrees with 
previous research in the context of pulmonary rehabilitation whereby CRP was not 
seen to be elevated following acute bouts of exercise at the beginning and end of 
pulmonary rehabilitation (Canavan et al., 2007). The conclusions from the Canavan 
et al. (2007) study suggested that pulmonary rehabilitation was unlikely to enhance 
systemic inflammation. The findings also agree with previous research utilising an 
acute exercise bout to symptom limitation outside of the context of pulmonary 
rehabilitation in hospitalised and stable COPD patients whereby no significant 
increases in CRP were observed post-exercise (Spruit et al., 2007). In the healthy 
population, a systematic review has demonstrated inconsistent effects of bouts of 
acute exercise on CRP concentrations (Brown et al., 2015). In COPD, the available 
evidence to date, suggests a lack of effect of acute exercise on CRP 
concentrations. However, it is important to note that CRP was highly variable 
between patients in the current study demonstrating the differing degrees of 
systemic inflammation present in patients with COPD (Study 2; Aksu et al., 2013; 
Silva, Gazzana & Knorst, 2015), and this may in part explain any lack of effect 
observed with acute exercise. Research should assess the effects of different 
modalities of acute exercise on CRP concentrations before any firm conclusions 
can be drawn. 
Although inflammation as characterised by fibrinogen and CRP concentrations was 
not increased with acute exercise, current study findings demonstrated changes in 
immune cell trafficking, regardless of whether the bout was at the beginning or end 
of pulmonary rehabilitation, as defined by increases in total leukocyte counts in both 
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groups and neutrophil counts in infrequent exacerbators only. This agrees with well-
established literature assessing acute inflammatory responses to exercise in the 
healthy population (Brown et al., 2015; Nieman et al., 1991; Quindry et al., 2003), 
and the limited existing evidence in COPD populations (Jenkins et al., 2015; Menon 
et al., 2012; van Helvoort et al., 2005). While it is not surprising to see these effects, 
it could be hypothesised that the acute inflammatory response to exercise could 
diminish by the end of pulmonary rehabilitation as a result of exercise training 
(Beavers, Brinkley & Nicklas, 2010). This was not observed in the current study 
which may suggest that despite the absolute exercise intensity being lower at the 
start of pulmonary rehabilitation, the programme in the current study was structured  
in such a way (progressive programme (Singh & Steiner, 2013)), that the relative 
exercise intensity remains the same. Resultantly, the stress applied on the immune 
system is similar on an individual basis with each exercise class of pulmonary 
rehabilitation. However, it would be insightful to assess inflammatory responses to 
two controlled bouts of exercise, in terms of intensity and duration, before and after 
an exercise training programme as recently undertaken (de Alencar Silva et al., 
2018). The findings of de Alencar Silva et al. (2018) refute the findings proposed 
here as it was observed that 12 weeks of exercise training reduced the acute 
inflammatory responses to exercise. It is important to note that the aforementioned 
study utilised a longer exercise programme, in terms of duration, and controlled the 
acute exercise bouts when comparing findings to that of the current study. 
Despite no significant changes in neutrophil counts with acute exercise in frequent 
exacerbators, there was a significant reduction in CD62L expression post-exercise. 
These responses were not observed in infrequent exacerbators, who experienced 
an increase in neutrophil count with acute exercise. The findings observed with 
frequent exacerbators in the current study agree with that of previous literature 
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suggesting a reduction in CD62L expression is commonly seen post-exercise 
(Kurokawa et al., 1995; van Eeden et al., 1999). This observed response in frequent 
exacerbators is typically indicative of an increased activation of neutrophils (Figure 
1.1; Ley et al., 2007). An increased activation of neutrophils may in part be 
explained by the acute inflammatory response to exercise whereby neutrophils 
activate to release free radicals which aid in the clearance of damaged host tissue 
(Peake & Suzuki, 2004; Peake, 2002). CD62L is a marker for adhesion of 
neutrophils to endothelial cells (Monteseirin et al., 2005) which may suggest that 
frequent exacerbators are experiencing more firm adhesion following exercise and 
possible migration through tissue to sites of inflammation (Figure 1.1; Ley et al., 
2007). The interpretation of this is open to discussion, as the inflammatory response 
could be deemed as ‘good’ due to the need to activate the immune system to 
resolve host tissue damage commonly experienced with exercise (Peake & Suzuki, 
2004; Peake, 2002). However, it could also be deemed as ‘bad’ due to the 
inflammatory nature of COPD and the frequent exacerbator phenotype, whereby 
acute increases in inflammation may contribute towards more chronic inflammatory 
processes (Oudijk, Lammers & Koenderman, 2003). However, when taking into 
account the EXACT® & E-RS™ data, this would suggest that in the initial phases 
these changes do not appear to increase respiratory symptoms. With regards to 
CD11b and CD66b, the current research disagrees with previous research in a 
healthy population which demonstrated an increase in CD11b expression post-
exercise (Pizza et al., 1996; Smith et al., 1996; van Eeden et al., 1999), with similar 
observations seen in a clinical population of claudicant patients (Nawaz et al., 2001; 
Turton et al., 1998). Previous research has also demonstrated that an acute bout 
of exercise induces increases in CD66b expression (Nawaz et al., 2001), conflicting 
with the findings observed in the current study. However, in the Nawaz et al. (2001) 
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study, such observations were only seen in the lower limb exercise group and not 
in the upper limb exercise group demonstrating an important potential effect of 
modality of exercise. The lack of effects seen with CD11b in the upper limb exercise 
group (Nawaz et al., 2001), agrees with the findings of the current study. There is 
a need to further understand neutrophil activation responses to acute exercise in 
frequent and infrequent exacerbators of COPD and determine clinical effects of 
such changes.  
This study was also the first study to utilise the newly proposed phenotyping 
approach of neutrophils in an exercise setting with a COPD population (Cortjens et 
al., 2017). An acute bout of exercise was seen to increase the percentage of 
immature neutrophils in both groups following exercise at the beginning of 
pulmonary rehabilitation with similar responses observed following completion of 
the programme. No concomitant changes were observed amongst the remaining 
neutrophil phenotypes as a result of this change. This approach has not yet been 
adopted in the field of exercise immunology so comparative literature is not yet 
available. However, these results support the notion long proposed in healthy 
populations whereby the physical stress of exercise induces an inflammatory 
response and a temporary neutrophilia, with increased release of immature 
neutrophils from the bone marrow (Suzuki et al., 1999; Yamada et al., 2002), which 
is more exaggerated in untrained individuals (Risoy et al., 2003). This increased 
release of immature neutrophils from the bone marrow has been proposed to be 
down to the need to compensate for the exhaustion of mature neutrophils from the 
marginated pools during, and following exercise which is typically observed and 
robust irrespective of the population of interest (Suzuki et al., 1999; Yamada et al., 
2002). This study has demonstrated this is apparent in both frequent and infrequent 
exacerbators of COPD with infrequent exacerbators experiencing this in the 
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presence of an increase in neutrophil count post-exercise. It would be insightful to 
utilise this phenotypic approach in future to further explore the effects of acute 
exercise on neutrophil phenotypes.  
Although measuring the responses of inflammatory markers to acute exercise 
provides mechanistic explanations, it could be argued that this provides limited 
information on the effects of exercise on patient reported symptoms. This was the 
first study to utilise the EXACT® questionnaire in the context of pulmonary 
rehabilitation for monitoring of daily respiratory symptoms. This study found that 
commencing a pulmonary rehabilitation programme did not increase EXACT® 
scores and respiratory symptoms despite acute inflammatory responses to 
exercise. In fact, this study demonstrated a tendency towards a decrease in 
respiratory symptoms upon commencing pulmonary rehabilitation. This is positive 
given that acute inflammatory responses to exercise have been linked with 
increased susceptibility to symptoms of infection (Walsh et al., 2011). However, 
increased susceptibility to respiratory symptoms may also arise from factors such 
as the environment (e.g. dry/cold air) and/or exercise-induced asthma rather than 
an actual infectious event (Walsh et al., 2011). Interestingly, the most pronounced 
effects of exercise on respiratory symptoms were seen in the Cough/Sputum 
domain suggesting that commencing pulmonary rehabilitation may play a role in 
airway clearance, agreeing with previous recommendations for utilising exercise as 
a form of airway clearance (Bott et al., 2009). Although these findings were only 
observed in a subset of patients, it may suggest that exercise, in the context of a 
pulmonary rehabilitation programme, may lead to early decreases in respiratory 
symptoms. Further exploration of respiratory symptom monitoring in the context of 
pulmonary rehabilitation is required assessing potential mechanisms for decreases 
in symptoms.  
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This study implies that acute exercise does not appear to worsen inflammation in 
frequent and infrequent exacerbators as characterised by a lack of increase in 
established biomarkers of exacerbations (fibrinogen & CRP). Acute exercise does 
appear to induce a classical inflammatory response to exercise, as observed 
previously in healthy (Brown et al., 2015; Nieman et al., 1991; Quindry et al., 2003), 
and COPD populations (Jenkins et al., 2015; Menon et al., 2012; van Helvoort et 
al., 2005), as characterised by increases in total leukocyte counts. This 
inflammatory response did not correspond to an increase in respiratory symptoms, 
in fact, there was tendency towards an immediate reduction in respiratory 
symptoms upon commencing the pulmonary rehabilitation programme. Importantly, 
this study suggested that a period of pulmonary rehabilitation was insufficient to 
arrest observed inflammatory responses to acute bouts of exercise. These findings 
warrant further follow-up assessing acute inflammatory responses to exercise and 
how they correspond to reported respiratory symptoms in frequent and infrequent 
exacerbators of COPD.  
When interpreting the findings of the current study, it is important to consider 
several limiting factors. Some potentially important cofounders were not accounted 
for such as exercise duration and intensity of both groups, and current physical 
activity status of the individuals taking part, whereby physically active lifestyles have 
been seen to alleviate some of the inflammatory responses seen with an acute bout 
of exercise (Gokhale, Chandrashekara & Vasanthakumar, 2007; Woods et al., 
2012). Research should take these into account when assessing responses 
amongst differing phenotypes of COPD before conclusions can be made. Another 
important factor to consider is that the acute exercise bouts were not controlled at 
the beginning and end of pulmonary rehabilitation. The duration and absolute 
intensity were not the same between the two timepoints, but the modality of 
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exercise and relative intensity were kept consistent. Finally, the sample size used 
to make inferences about the neutrophil activation markers was impacted by an 
unforeseen deficiency of CD16b expression in subsets of patients meaning the 
results were underpowered. This reduced the confidence to be able to separate 
neutrophils from eosinophils, and research has previously suggested two possible 
causes; a rare hereditary deficiency of CD16 (Wagner & Hansch, 2004), or a 
shedding of CD16b via the action of ADAM17 (Wang et al., 2013). These proposals 
could not be assessed in the current study and future studies should be wary of the 
use of CD16b as a marker for identifying neutrophils.   
In conclusion, acute bouts of exercise at the beginning and end of pulmonary 
rehabilitation do not appear to alter fibrinogen or CRP concentrations but do induce 
increases in total leukocyte counts. Increases in total leukocytes counts with 
exercise is accompanied by an increase in the percentage of immature neutrophils 
in circulation. Frequent exacerbators appear to respond differently, in terms of 
reductions in neutrophil CD62L expression, following acute exercise. Future 
research should attempt to further determine the clinical implications of such 
changes in inflammatory parameters with acute exercise in frequent and infrequent 
exacerbators of COPD.    
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7 Chapter SEVEN 
Study 5 – A pilot study assessing physical activity levels between frequent 
and infrequent exacerbators of COPD following pulmonary rehabilitation  
Abstract  
Pulmonary rehabilitation is considered to be ineffective at inducing long-term 
increases in physical activity levels of COPD patients. Exacerbations of COPD have 
been associated with reduced physical activity levels. It is unclear whether frequent 
exacerbators of COPD are less physically active than infrequent exacerbators. The 
primary aim of this pilot study was to explore physical activity in frequent 
exacerbators of COPD. The secondary aim of this pilot study was to explore 
inflammatory profiles of frequent and infrequent exacerbators following pulmonary 
rehabilitation. COPD patients (frequent, n = 9; infrequent, n = 9; moderate-very 
severe COPD; FEV1 pred, 52 ± 15) who had previously enrolled onto pulmonary 
rehabilitation (>3 months) were recruited for 7 days of physical activity monitoring 
(Actigraph wGT3X-BT). Daily step counts were recorded and physical activity levels 
were categorised as sedentary (0 to 1.5 metabolic equivalent of task (METS)), light 
(1.5 to 3 METS), and moderate-to-vigorous (>3 METS). % of time spent in standing, 
seated, and lying positions were also recorded. Blood samples were collected and 
analysed for circulating fibrinogen & CRP concentrations, total/differential cell 
counts, and anti-inflammatory gene expression (MKP-1 & GILZ). Effects sizes were 
calculated for outcomes and classified as small (d = 0.2), medium (d = 0.5), or large 
(d = 0.8). Frequent exacerbators recorded fewer daily steps (d = 0.3) and spent less 
time in light (d = 0.8) and moderate-to-vigorous activities (d = 0.3). Trivial 
differences between groups were observed for time spent in sedentary activities (d 
= 0.1). Frequent exacerbators spent less time in the standing position (d = 0.4) and 
more time in seated positions (d = 0.6). Fibrinogen (d = 0.3) and CRP (d = 0.2) were 
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observed to be elevated in frequent exacerbators. Total leukocyte (d = 0.6), 
neutrophil (d = 0.5), and lymphocyte counts (d = 0.7) were observed to be lower in 
frequent exacerbators. Lower GILZ expression in response to dexamethasone 
treatment was observed in frequent exacerbators (2 hr, d = 0.8; 6 hr, d = 0.5). This 
pilot study suggests that frequent exacerbators are less physically active and spend 
more time in sedentary positions following pulmonary rehabilitation. Frequent 
exacerbators appeared to have heightened levels of known biomarkers for 
exacerbations and poorer response to corticosteroid treatment. Larger-scale trials 
are required assessing physical activity in the frequent exacerbator phenotype.   
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 Introduction 
In healthy individuals, physical activity levels have been shown to contribute to the 
primary and secondary prevention of several chronic diseases such as COPD 
(Warburton, Nicol & Bredin, 2006). In comparison to healthy counterparts, COPD 
patients present with decreased daily physical activity levels and increased time 
spent in a sedentary state (Pitta et al., 2005). This is believed to be due to the nature 
of disease whereby patients limit their physical activity to avoid symptoms such as 
dyspnoea (Giacomini et al., 2012). Pulmonary rehabilitation is designed to provide 
COPD patients with the tools to be able to translate increases in exercise capacity 
into increased physical activity levels (Troosters et al., 2005; Spruit et al., 2015b). 
Despite the benefits of pulmonary rehabilitation, there is a poor transition into higher 
physical activity levels following completion of the programme (Mantoani et al., 
2016). COPD patients with lower physical activity levels have been suggested to 
have an increased risk of hospitalisation and mortality, whereas physically active 
COPD patients experience a reduced frequency of exacerbations (Donaire-
Gonzalez et al., 2015; Garcia-Aymerich et al., 2006; Garcia-Aymerich et al., 2007; 
Garcia-Aymerich et al., 2009; Mercken et al., 2005; Nguyen et al., 2015). These 
findings, accompanied with the benefits of pulmonary rehabilitation (Studies 1-4), 
reiterate the importance for COPD patients to be physically active.  
Understanding physical activity is complex, with suggestions that utilising step 
counts as a classical measure alone is insufficient as it does not account for upper 
body movements (Sylvia et al., 2014). Studies have utilised step counts pre-, during 
and post-pulmonary rehabilitation as determinants of changes in physical activity 
(Dallas et al., 2009; Demeyer et al., 2014; Nolan et al., 2017). Although step counts 
are still an important indicator of physical activity (O’Connell, OLaighin & Quinlan, 
2017), research has also progressed illustrating the importance of quantifying 
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physical activity as time spent in various intensities of activities (Mesquita et al., 
2017; van Remoortel et al., 2013). This is important given the recent shift in focus 
in the field of physical activity whereby more focus is being placed on time spent in 
a sedentary state (Physical Activity Guidelines Advisory Committee, 2018), as 
opposed to only monitoring whether individuals meet the physical activity guidelines 
of 150 min of moderate physical activity per week (Department of Health, 2011). It 
has recently been shown that transitions from sedentary states to light physical 
activity can be associated with health benefits in COPD (Mesquita et al., 2017; 
Physical Activity Guidelines Advisory Committee, 2018).  
During onset of moderate to severe exacerbations, acute decreases in physical 
activity levels are common (Alahmari et al., 2014; Alahmari et al., 2016; Pitta et al., 
2006), with frequent exacerbations accelerating physical activity level decline 
(Alahmari et al., 2014). Physical activity levels have been observed to recover within 
14 days of exacerbation onset (Alahmari et al., 2014), but this hasn’t always been 
observed as Pitta et al. (2006) still observed lower physical activity levels at 1-month 
post-discharge for acute exacerbation of COPD. Alahmari et al. (2016) also 
demonstrated that acute exacerbations can lead to larger decreases in time spent 
in light activity per day in frequent exacerbators. However, there are a lack of 
studies monitoring differences in physical activity between frequent and infrequent 
exacerbators when in a stable state. Further information on this would be useful in 
order to develop specific interventions that target physical activity in frequent 
exacerbators.   
Studies 2, 3, and 4 have demonstrated the anti-inflammatory benefits of pulmonary 
rehabilitation in frequent exacerbators of COPD, as characterised by reduced 
fibrinogen concentrations, total leukocyte counts, and tendencies towards an 
increased gene expression in response to corticosteroid treatment. Being physically 
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active has been associated with having lower levels of systemic inflammation, as 
characterised by reduced fibrinogen, CRP, and total leukocytes in healthy 
individuals (Colbert et al., 2004; Hamer & Stamatakis, 2009; King et al., 2003). 
However, the benefits of being physically active have been seen to diminish 
following a period of physical inactivity (Fuente et al., 2005; Syu et al., 2012). In 
COPD, physical inactivity has been related to elevated fibrinogen and CRP 
concentrations (Garcia-Aymerich et al., 2009; Waschki et al., 2012; Watz et al., 
2008). This is further supported by Moy et al. (2014) who found that COPD patients 
who have lower physical activity levels and higher levels of CRP are markedly more 
likely to suffer an acute exacerbation of COPD compared to those who are more 
physically active and have lower levels of CRP. It is important to grasp an 
understanding of which markers may be useful as surrogate markers of 
inflammation to measure in the post-pulmonary rehabilitation setting when 
designing future interventions to target physical activity in frequent exacerbators.  
In order to inform a larger scale intervention study in the future, a pilot study was 
undertaken to explore physical activity and sedentary behaviour between frequent 
and infrequent exacerbators of COPD following pulmonary rehabilitation. Secondly, 
on the basis that a successful physical activity intervention would reduce levels of 
systemic inflammation in frequent exacerbators, potential surrogate markers that 
could be used as mechanistic endpoints in a future study were explored. It was 
hypothesised that frequent exacerbators would have lower physical activity levels 
and higher levels of systemic inflammation. 
 Methods 
7.2.1 COPD patients 
Forty COPD patients were approached for participation with 18 COPD patients (age 
71 ± 7 years; FEV1 pred 52 ± 15%; frequent exacerbators = 9; infrequent 
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exacerbators = 9) successfully re-recruited >3 months following pulmonary 
rehabilitation.  
7.2.2 Selection criteria 
7.2.2.1 Inclusion criteria 
Patients with a clinical diagnosis of any severity of COPD and had previously 
enrolled on pulmonary rehabilitation and consented to take part in Study 2.  
7.2.2.2 Exclusion criteria 
Patients were excluded if they displayed with any of the following: unstable ongoing 
cardiovascular events, other active inflammatory conditions (e.g. rheumatoid 
arthritis, cancer), known asthma, allergic rhinitis or other respiratory diseases (e.g. 
bronchiectasis, pulmonary fibrosis). Patients were also excluded if they had an 
inability or unwillingness to sign informed consent.  
7.2.3 Recruitment 
COPD patients who enrolled on to pulmonary rehabilitation and consented to take 
part in Study 2 were re-recruited via the Respiratory Team as a convenience 
sample for this pilot study. COPD patients were sent study information packs 
including a study information sheet and declaration of interest (DOI) form. Patients 
who were interested in taking part returned the DOI form in a pre-paid envelope. 
Interested patients were then contacted to discuss further study procedures and 
screen eligibility in line with the inclusion and exclusion criteria. If patients were 
deemed eligible to take part in the study, the first clinic visit of two was arranged at 
one of the following GP medical practices: Birchwood Medical Practice, Lindum 
Medical Practice, Nettleham Medical Practice.    
7.2.4 Procedures 
At the first clinic visit, COPD patients provided verbal and written consent before 
providing information on medical history, mainly confirming exacerbation history 
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and current comorbidities (presented using the Charlson Comorbidity Index 
(Charlson et al., 1987)), since enrolling on pulmonary rehabilitation. Patients were 
categorised as either a frequent (≥2 exacerbations in the previous 12 months) or 
infrequent exacerbator (<2 exacerbations in the previous 12 months). Height and 
body mass measurements were then obtained before the performing of an exhaled 
carbon monoxide test (MicroCo Meter, CareFusion). Patients were provided with 
an accelerometer (wGT3X-BT, ActiGraph, Pensacola, FL, USA) and instructed to 
wear this around their waist for 7 days in line with previous procedures (Demeyer 
et al., 2014).  
Following the first clinic visit, patients returned to the GP medical practice at a 
mutually agreed time (between 9.30am-1pm) and date (8-10 days following the first 
clinic visit). Accelerometers were returned to determine physical activity patterns 
before obtaining a blood sample in a rested state. The characteristics of physical 
activity included: daily step count, time spent in activity modes (sedentary, light, 
moderate-to-vigorous), % of time spent in positions (standing, sitting, lying), and 
wear time. Activity levels were determined using thresholds previously utilised in 
COPD patients whereby sedentary behaviour (<1.5 METS), light physical activity 
(1.5 to 3 METS), and moderate-to-vigorous physical activity (>3 METS) were used 
to classify each 1 minute epoch of data: sedentary behaviour (<220); light physical 
activity (220-480) and moderate-to-vigorous physical activity (>480 activity counts) 
(Mesquita et al., 2017). A minimum wear time of 10 hours per day (Byrom & Rowe, 
2016), was required for a minimum of 5 days of measurement (Mesquita et al., 
2017). Non-wear bouts were determined after 60 minutes of consecutive zero 
epochs across all 3 axes which is commonly utilised in physical activity studies 
(Byrom & Rowe, 2016).  
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The proposed primary clinical outcome for a future trial is daily step count. The 
secondary clinical outcomes were time spent in modes of activity (sedentary, light, 
moderate-to-vigorous), and % of time spent in positions (standing, sitting, lying). 
The proposed primary mechanistic endpoint for a future study is plasma fibrinogen 
(section 2.8.2.1). Other mechanistic outcomes included plasma CRP concentration, 
(section 2.8.2.2), total and differential blood leukocyte counts (section 2.8.1), and 
gene expression from isolated PBMC’s treated with dexamethasone (MKP-1, GILZ) 
(section 2.8.4). 
7.2.5 Statistical analysis 
Due to the nature of this pilot study, analyses were treated as exploratory and 
mainly reported descriptively. The data will provide information on the parameters 
needed for a realistic sample size calculation for a future, definitive randomised 
controlled trial of a physical activity intervention for frequent exacerbators of COPD. 
Cohen’s d effect sizes were utilised to measure differences between frequent and 
infrequent exacerbators for the following outcomes; daily step count, time spent in 
mode of activity (sedentary, light, moderate-to-vigorous), % of time spent in 
positions (standing, sitting, lying), fibrinogen and CRP concentrations, whole blood 
counts, and corticosteroid-induced gene expression (MKP-1 & GILZ, 2 hr & 6 hr). 
Gene expression was analysed using fold changes at 2 hr & 6 hr treatments 
compared to NT samples as per Study 3. Differences in measures between 
frequent exacerbators and infrequent exacerbators were classified as: small (d = 
0.2), medium (d = 0.5), and large (d = 0.8) (Cohen, 1988). 
 Results  
7.3.1 Patient characteristics 
The patient characteristics are detailed in Table 7.1. Frequent exacerbators were 
all categorised as GOLD D (100%), with the majority of infrequent exacerbators 
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categorised as GOLD B (89%). The majority of frequent and infrequent 
exacerbators were categorised as either MRC grade 2, grade 3, or grade 4.  
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Table 7.1. Patient characteristics 
 
 
Variable 
 
 
Frequent 
 
 
Infrequent 
Age (years)a 74 ± 6 68 ± 7 
% Malesb 78% 44% 
Body Mass (kg)a 80 ± 6 73 ± 10 
GOLD grade, n (%)c   
A 0 (0) 1 (11) 
B 0 (0) 8 (89) 
C 0 (0) 0 (0) 
D 9 (100) 0 (0) 
FEV1 %predicteda 53 ± 16 51 ± 15 
Charlson Comorbidity Indexa 4.7 ± 1.1 3.9 ± 1.1 
% Current smokersb 0% 33% 
MRC, n (%)c   
0 0 (0) 1 (11) 
1 0 (0) 0 (0) 
2 1 (11) 3 (33) 
3 3 (33)  3 (33) 
4 5 (56) 2 (22) 
aData presented as mean ± SD (t-test). bData presented as a % of total population (chi-squared). 
cData presented as total number (% of group). Frequent, n = 9; infrequent, n = 9. 
 
7.3.2 Physical activity levels 
A decreased daily step count was observed in frequent exacerbators (mean 
difference -687 steps, 95% confidence interval (CI) [-856,-518], d = 0.3). 
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Differences between groups were trivial for time spent in sedentary activities per 
day (frequent exacerbators +7 min, 95% CI [-5,19], d = 0.1). Frequent exacerbators 
spent less time in light (-12 min, 95% CI [-15,-9], d = 0.8) and moderate-to-vigorous 
physical activity on a daily basis (-5 min, 95% CI [-6,-4], d = 0.3) (Figure 7.1). 
       A             B 
              
C                                                                 D
  
Figure 7.1. Daily step counts (A), time spent in sedentary (B), light (C) and 
moderate-to-vigorous intensity activity (MVPA) (D) in frequent and infrequent 
exacerbators. 
 
Frequent exacerbators were observed to spend less time in standing positions (-
2%, 95% CI [-3,-1], d = 0.4) and more time in seated positions (+4%, 95% CI [3,5], 
d = 0.6). Time spent in lying positions were observed to be lower in frequent 
exacerbators compared to infrequent exacerbators (-5%, 95% CI [-6,-4], d = 0.7) 
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(Figure 7.2). Frequent exacerbators recorded a lower wear time of the Actigraph (-
1.5 hrs per day, 95% CI [-3,0], d = 0.4). 
A                                                                    B 
 
C 
 
Figure 7.2. Amount of time spent in standing (A), sitting (B) and lying (C) position 
in frequent and infrequent exacerbators. 
 
7.3.3 Inflammation 
Fibrinogen (+19 mg/dL, 95% CI [2,36], d = 0.3), CRP (+3.6 mg/L, 95% CI [1.9,5.2], 
d = 0.2), and eosinophil counts (+0.02 cells per 109·L-1, 95% CI [0.01,0.02], d = 0.2) 
were observed to be elevated in frequent exacerbators. Total leukocyte (-1.0 cells 
per 109·L-1, 95%CI [-1.1,-0.9], d = 0.6), neutrophil (-0.8 cells per 109·L-1, 95% CI [-
0.9,-0.6], d = 0.5), and lymphocyte counts (-0.3 cells per 109·L-1, 95% CI [-0.4,-0.2], 
d = 0.7) were seen to be lower in frequent exacerbators. The differences between 
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frequent (-0.1, 95% CI [-0.2,-0.1], d = 0.1) and infrequent exacerbators for 
neutrophil/lymphocyte ratio were trivial (Table 7.2). 
Table 7.2. Inflammatory parameters between frequent and infrequent exacerbators 
 
 
Variable 
 
 
Frequent 
 
 
Infrequent 
 
 
Cohen’s d 
Fibrinogen (mg/dL)a 783 ± 58 764 ± 96 0.3 
C-Reactive Protein (mg/L)b 7.3 (3.3-8.0) 3.4 (2.3-4.1) 0.2 
Total Leukocytes (109·L-1)a 6.6 ± 1.8 7.6 ± 1.5 0.6 
Eosinophils (109·L-1)a 0.2 ± 0.1 0.2 ± 0.1 0.2 
Neutrophils (109·L-1)a 4.1 ± 1.6 4.8 ± 1.3 0.5 
Lymphocytes (109·L-1)a 1.5 ± 0.3 1.8 ± 0.5 0.7 
Neutrophil/Lymphocytes ratioa 2.8 ± 1.0 2.9 ± 1.1 0.1 
aData presented as mean ± SD. bData presented as a median (25th percentile – 75th percentile). 
Frequent, n = 9; infrequent, n = 9.  
 
7.3.4 Gene expression 
Differences in MKP-1 expression following dexamethasone treatment for 2 hr 
between frequent (+0.1 fold, 95% CI [0.12,0.14], d = 0.1) and infrequent 
exacerbators were observed to be trivial, but 2 hr treatment on GILZ expression 
suggested a lower response in frequent exacerbators (-1.5 fold, 95% CI [-1.9,-1.1], 
d = 0.8) (Figure 7.3). 
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     A                                                              B  
 
Figure 7.3. Fold changes in MKP-1 (A) and GILZ (B) gene expression from NT in 
isolated PBMC’s following 2 hr of 1μM dexamethasone treatment in frequent and 
infrequent exacerbators of COPD.   
 
Trivial effects were observed with MKP-1 expression following 6 hr of 
dexamethasone treatment (frequent exacerbators -0.3 fold, 95% CI [-0.4,-0.1], d = 
0.1) between frequent and infrequent exacerbators, whereas GILZ expression was 
lower in response to 6 hr dexamethasone treatment in frequent exacerbators (-1.5 
fold, 95% CI [-1.7,-1.3], d = 0.5) (Figure 7.4). 
A                                                               B 
 
Figure 7.4. Fold changes in MKP-1 (A) and GILZ (B) gene expression from NT in 
isolated PBMC’s following 6 hr of 1μM dexamethasone treatment in frequent and 
infrequent exacerbators of COPD. 
 
 Discussion 
The main findings from this pilot study suggest that frequent exacerbators record 
fewer daily steps and spend less time in light and moderate-to-vigorous intensity 
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activities. The current findings also suggested that frequent exacerbators spend 
less time in standing positions and more time in sitting positions. Frequent 
exacerbators also provided indications of having heightened levels of fibrinogen 
and CRP, and lower anti-inflammatory gene in response to corticosteroid treatment.  
It is well established that COPD patients are less physically active (Arne et al., 2011; 
Pitta et al., 2005; Vorrink et al., 2011), and that exacerbations can lead to acute 
decreases in physical activity levels (Alahmari et al., 2014; Alahmari et al., 2016; 
Pitta et al., 2006), with recovery of activity levels not always observed following 
acute exacerbations (Pitta et al., 2006). However, it is unclear whether certain 
phenotypes, for example frequent exacerbators, are more susceptible to physical 
inactivity. This study provides preliminary evidence towards suggesting that 
frequent exacerbators, when stable, may spend more time in sedentary states as 
characterised by reduced steps, less time in light and moderate-to-vigorous 
physical activities, and spending more time sitting. Frequent exacerbators were 
observed on average to make 687 less steps per day compared to infrequent 
exacerbators which falls within the threshold for the proposed MCID for step counts 
in COPD (Demeyer et al., 2016). The step counts observed in the current study are 
comparable to that cited in previous literature assessing physical activity in COPD 
patients (Demeyer et al., 2014; Demeyer et al., 2016). This evidence provides 
support to previous research which suggested, despite a lack of statistical 
significance, that frequent exacerbators spend more time in sedentary states and 
less time in higher physical activities (Valido et al., 2014). There is also evidence 
suggesting that frequent exacerbators experience a faster decline in physical 
activity over time (Alahmari et al., 2014; Donaldson et al., 2005b). Possible 
explanations for the physical inactivity in frequent exacerbators may be the 
perception of exacerbating symptoms with exertion (Troosters et al., 2013), or an 
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accumulation of the acute effects of each exacerbation on physical activity level 
(Alahmari et al., 2014). It is important to address physical activity levels in frequent 
exacerbators, given that being physically active has been associated with a 
reduction in hospitalisations and mortality (Donaire-Gonzalez et al., 2015; Garcia-
Aymerich et al., 2006; 2007; 2009; Mercken et al., 2005; Nguyen et al., 2015), and 
future interventions should target ways of addressing this issue. A starting point, as 
previously suggested by Mesquita et al. (2017), would be to target sedentary 
behaviour in favour of light activities, which may be more easily achievable than 
inducing increases in moderate activities (Spruit et al., 2015b). This is supported by 
a study suggesting that a greater quantity of low-intensity physical activity is 
effective at reducing the risk of COPD hospitalisation (Donaire-Gonzalez et al., 
2015). However, it is unclear whether it is structured physical activity (i.e. exercise) 
programmes or general physical activity behaviours that have greatest influence on 
exacerbation frequency as exercise maintenance programmes post-pulmonary 
rehabilitation have also been shown to reduce exacerbation risk (Jenkins et al., 
2018).  
Another important factor associated with physical activity is the relationship with 
reduced levels of inflammation in both healthy (Colbert et al., 2004; Hamer & 
Stamatakis, 2009; King et al., 2003), and COPD populations (Gimeno-Santos et al., 
2014). This study suggests that fibrinogen and CRP which are known biomarkers 
of exacerbations (Donaldson et al., 2005a; Hurst et al., 2010; Wedzicha, Mackay & 
Singh, 2013), are worthwhile markers to assess in the context of physical activity in 
frequent exacerbators due to the scope for improvement in inflammation with 
physical activity interventions in this population. The use of these markers has also 
been supported in previous research suggesting physically active COPD patients 
have lower levels of CRP (Kantorowski et al., 2018; Moy et al., 2014). The visually 
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elevated levels of fibrinogen and CRP in the frequent exacerbators are in line with 
pre-pulmonary rehabilitation observations in Study 2. However, total leukocyte, 
neutrophil, and lymphocyte counts were observed to be lower in frequent 
exacerbators which disagrees with observations in Study 2 where these cell 
subsets were visually elevated in frequent exacerbators pre-pulmonary 
rehabilitation. Given the post-pulmonary rehabilitation population utilised in this 
study, it is important to note the reductions observed in total leukocyte and 
neutrophil counts in frequent exacerbators following pulmonary rehabilitation (Study 
2) may have an influence on the findings of the current study. In other words, 
markers that are sensitive to changes with pulmonary rehabilitation may not relate 
to all measures of physical activity. Also, pulmonary rehabilitation may act to restore 
perturbations in inflammatory measures between frequent and infrequent 
exacerbators and that greater physical activity levels are required to see further 
changes in inflammatory measures.  This reiterates the importance of the 
requirement for larger scale trials utilising proposed inflammatory markers of 
frequent exacerbators.  
Study 3 was the first study to assess changes in gene expression in response to 
corticosteroid treatment in frequent and infrequent exacerbators of COPD 
undertaking pulmonary rehabilitation. The current study aimed to further assess the 
differences between frequent and infrequent exacerbators at rest to see how the 
groups compare following pulmonary rehabilitation. The current study suggested 
that frequent exacerbators had a poorer response to corticosteroid treatment as 
well as poorer physical activity levels. Interestingly, this was observed with GILZ 
expression whereas Study 3 only observed changes or differences between groups 
with MKP-1 expression. These results suggest that physical activity levels and 
exacerbation history may play a role in the ability of corticosteroids to amplify anti-
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inflammatory GILZ gene expression. Further research is warranted building on the 
current findings, and that of Study 3, to see whether physical activity levels may be 
an independent determinant in the effectiveness of corticosteroid treatment in 
COPD and determine whether MKP-1 and/or GILZ are key pathways to explore 
moving forwards. 
The findings of this study may be used to inform a sample size calculation and 
decision over the primary outcome of a future intervention study targeting physical 
activity behaviours in frequent exacerbators. Based on the available data, to detect 
a change of 687 steps in frequent exacerbators a sample size of 247 participants  
would be required to have 80% power at the 5% level of significance. Based on 
reversing the differences seen in frequent exacerbators in other measures of this 
study, the following samples sizes would be required: 26 participants for time spent 
in light activity, 239 participants for time spent in moderate-to-vigorous activity, 128 
participants for time spent standing, 123 participants for time spent sitting. 
When interpreting the findings of this study, it is important to note the limitations. 
This study was a pilot study assessing a small population of COPD patients. 
Inflammatory parameters in COPD patients have been seen to vary significantly 
between patients (Sapey et al., 2008), making it difficult to draw comparisons with 
small sample sizes. It is also important to note that the cohort of patients recruited 
had recently completed pulmonary rehabilitation (<18 months) and it cannot be 
excluded whether the anti-inflammatory benefits observed in Study 2 were still 
maintained whereby pulmonary rehabilitation appeared to alleviate differences in 
inflammation between frequent and infrequent exacerbators. Also, the location of 
the device may have influenced the data presented in this study as the wearing of 
the accelerometer on the thigh has been proposed to be the optimal location for 
analysing sedentary behaviours (Byrom & Rowe, 2016). Finally, this study did not 
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exclude smokers and the impact of this on physical activity levels and inflammation 
must be considered when interpreting the findings. 
In conclusion, this pilot study suggests that frequent exacerbators are less 
physically active than infrequent exacerbators. Frequent exacerbators were 
suggested to have a poorer response to corticosteroid treatment potentially relating 
physical activity levels to the effectiveness of corticosteroid treatment. It is unclear 
whether physical inactivity is a cause of the frequent exacerbator phenotype or 
whether it is an effect of recurrent exacerbations.  Future trials should attempt to 
establish causal relationships between the frequent exacerbator phenotype and 
physical activity. It would be worthwhile for future studies to clarify the role of 
inflammation in meditating this relationship, the current study provides some 
surrogate markers that could be used for that purpose.  
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8 Chapter EIGHT 
General Discussion 
The series of studies presented in this thesis (Studies 1-5) were designed to assess 
the frequent exacerbator phenotype of COPD in the context of pulmonary 
rehabilitation. The main focus of this thesis was to see whether the frequent 
exacerbator phenotype responds differently to pulmonary rehabilitation when 
compared to infrequent exacerbators, in terms of clinical outcomes at a patient level 
and one of the key underlying biological mechanisms of this frequent exacerbator 
phenotype, systemic inflammation (Bhowmik et al., 2000; Donaldson et al., 2005a; 
Perera et al., 2007).  
Firstly, this thesis examined whether the frequent exacerbator of COPD phenotype 
had any impact on the completion rates and benefits of pulmonary rehabilitation 
(Study 1). As inflammation is a key therapeutic target of the frequent exacerbator 
phenotype, the following studies assessed the inflammatory responses to chronic 
exercise in the form of pulmonary rehabilitation (Studies 2 and 3). The studies were 
designed to see whether pulmonary rehabilitation could be effective in reducing 
resting inflammation in frequent and infrequent exacerbators and to see whether 
changes in immune profiles were similar in both groups. Previously identified 
elevated inflammatory mediators in frequent exacerbators were selected for 
analysis in the form of fibrinogen, CRP, total leukocytes and neutrophils (Study 2; 
Donaldson et al., 2005a; Hurst et al., 2010; Wedzicha et al., 2013). Novel measures 
of inflammation were also investigated in these studies, specifically whether chronic 
exercise modified measures of blood neutrophil activation or subsets (Study 2) and 
expression of corticosteroid inducible genes (Study 3). Inflammatory responses to 
exercise were assessed in two different contexts in this thesis. The studies of 
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chronic exercise were followed up with assessment of acute inflammatory 
responses to exercise in frequent and infrequent exacerbators (Study 4), given that 
acute exercise has previously been proposed to trigger an inflammatory response 
in COPD patients (van Helvoort et al., 2006). The assessment of acute responses 
were split into two sub-studies with the aim of assessing inflammatory responses 
to exercise in both an ‘untrained’ (beginning of rehabilitation) and ‘trained’ (end of 
rehabilitation) state. Finally, a pilot study of follow-up assessments of physical 
activity levels and inflammation were undertaken in a subset of frequent and 
infrequent exacerbators post-pulmonary rehabilitation to see whether future 
physical activity interventions in the frequent exacerbator phenotype would be 
worthwhile (Study 5).  
 Clinical outcomes of pulmonary rehabilitation 
8.1.1 Completion rates 
Despite the benefits of pulmonary rehabilitation in increasing exercise capacity and 
improving quality of life (McCarthy et al., 2015), there is still a major issue with 
completion rates of pulmonary rehabilitation (Steiner et al., 2018). Factors such 
depression, smoking status, frailty, and social deprivation have been linked to poor 
completion of pulmonary rehabilitation (Hayton et al., 2013; Keating, Lee & Holland, 
2011; Maddocks et al., 2016; Steiner et al., 2017b). However, it was unclear 
whether a recognised phenotype such as frequent exacerbators were at a higher 
risk for poor completion given that exacerbations are a risk factor for non-
completion (Fischer et al., 2009). The first experimental study detailed in Study 1 
highlighted the poorer completion rates in frequent exacerbators when compared 
to infrequent exacerbators. This provides evidence towards the proposed notion 
that exacerbations are a prominent cause of poor completion of pulmonary 
rehabilitation (Fischer et al., 2009; Hayton et al., 2013; Keating, Lee & Holland, 
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2011). Although it is plausible to think that this is the case in a clinical setting, there 
is a lack of evidence demonstrating that this is conclusively the case. Completion 
rates have been a long-serving issue for clinicians when delivering pulmonary 
rehabilitation and have been highlighted by the UK National COPD Pulmonary 
Rehabilitation Audit (Steiner et al., 2018). For the first time, Study 1 highlights the 
potential use for phenotyping COPD patients to identify potentially ‘at risk’ 
populations for poor completion of pulmonary rehabilitation.  
In theory, it could be expected that COPD patients who have 2 or more 
exacerbations within 12 months (frequent exacerbators) are more at risk of non-
completion. Especially given that a pulmonary rehabilitation course takes place 
over a sizeable period of the year, particularly if this spanned the winter period or if 
one considers the time lapses between initial and final assessments (usually 1 week 
to 1 month before or after pulmonary rehabilitation) meaning that the window of 
pulmonary rehabilitation treatment could last up to 4 months. Clearly, this is a 
significant issue for patients who experience at least 2 exacerbations in a 12 month 
period. 
Previously, it has been suggested that frequent exacerbators are a rare phenotype 
of COPD (Han et al., 2017), but Study 1 shows for the first time that this may not 
necessarily be the case when assessing COPD patients presenting to pulmonary 
rehabilitation programmes. In the cohort recruited to this study, 59% of patients 
were classified as frequent exacerbators. With poor completion rates being a 
worldwide issue with pulmonary rehabilitation, and a specific target of the ongoing 
UK National COPD Pulmonary Rehabilitation Audit (Steiner et al., 2018), it is 
possible that the message arising from this study is that the ‘elevated’ presence of 
frequent exacerbators may be playing a significant role. It is important to consider 
that the elevated presence of frequent exacerbators in pulmonary rehabilitation 
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maybe due to underlying reasons for referral (e.g. recent exacerbation) (Bolton et 
al., 2013). Nevertheless, regardless of whether frequent exacerbators are ‘rare’ or 
not, this phenotype represents a large social and economic burden in COPD 
(Wedzicha et al., 2013), including poorer completion rates of pulmonary 
rehabilitation presented in Study 1.   
COPD patients who present to pulmonary rehabilitation with poorer baseline 
measurements have been observed to have larger improvements in outcomes 
upon completion (Spruit et al., 2015a). It was plausible to hypothesise that frequent 
exacerbators may stand to experience larger improvements in clinical outcomes 
when compared to infrequent exacerbators as it has been suggested previously 
that frequent exacerbators demonstrated poorer baseline measures (Valido et al., 
2014). The assessment of frequent and infrequent exacerbators who completed 
pulmonary rehabilitation demonstrated statistically and clinically significant 
improvements in clinical outcomes. However, no clinical or significant differences 
in baseline measures were seen between frequent and infrequent exacerbators 
suggesting responses to pulmonary rehabilitation were similar in magnitude. These 
conflicting findings require further assessment in future research. The beneficial 
responses observed reiterates the importance of making sure that pulmonary 
rehabilitation is inclusive to all COPD patients, especially as both phenotypes stand 
to benefit from the intervention.  
Although both frequent and infrequent exacerbators benefit from pulmonary 
rehabilitation upon completion, this still leaves a significantly unanswered question, 
what about the COPD patients who do not complete? Are these patients more 
impaired in terms of exercise capacity and psychological status making the 
prospect of pulmonary rehabilitation more daunting? Is pulmonary rehabilitation 
perceived to be of a lack of benefit to them, hence poor completion? The 
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assessment of this demographic of patients requires further research to enable the 
tailoring of interventions to help support these COPD patients towards pulmonary 
rehabilitation completion as completion rates may stem from factors beyond that of 
exacerbation history. With further evidence, steps can be made to specifically 
assess what interventions can be undertaken to help support frequent exacerbators 
through pulmonary rehabilitation. Firstly, efforts need to be made to establish the 
underlying causes of poor completion in frequent exacerbators.  
Assessment of the data collected in Study 1 in terms of baseline measures, found 
that the exercise capacity for those that completed (mean difference; ISWT: 
frequent +99m, infrequent +82m; ESWT: frequent +120m, infrequent +126m) 
pulmonary rehabilitation was higher at baseline compared to those that failed to 
complete by clinically significant margins (Figure 8.1A & Figure 8.1B). Baseline total 
CRQ scores were seen to be poorer in frequent exacerbators who did not complete 
(-3.1 points) whereas baseline scores appeared to be higher in infrequent 
exacerbators who did not complete pulmonary rehabilitation compared to those that 
did (+0.6 points) (Figure 8.1C). Further breakdown unveiled that non-completers 
reported poorer scores on the fatigue domain of the CRQ (frequent -0.8 points, 
infrequent -0.6 points). Similar observations were made with anxiety scores as non-
completing frequent exacerbators had higher baseline anxiety compared to 
frequent exacerbator completers (+2.5 points) whereas non-completing infrequent 
exacerbators had lower anxiety compared to infrequent exacerbator completers (-
2.7 points) (Figure 8.1 D). Both non-completing frequent (+1.2 points) and 
infrequent exacerbators (+0.9 points) had higher baseline levels of depression 
compared to completing frequent and infrequent exacerbators (Figure 8.1E). These 
data warrant further investigations of the characteristics of non-completers as these 
patients may have poorer baseline exercise capacity and poorer control over their 
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condition which maybe increasing the risk of non-completion. Placing focus on this 
may identify a population who stand to potentially have more scope to benefit from 
pulmonary rehabilitation further reiterating the need to intervene with these patients.  
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Figure 8.1. Baseline clinical measures for ISWT (A), ESWT (B), total CRQ score 
(C), Anxiety score (D), and Depression score (E) in frequent and infrequent 
exacerbators who completed compared to frequent and infrequent exacerbators 
who did not complete. Statistics analysed using a Mann-Whitney U test to compare 
differences between completers and non-completers. *Significant difference 
between groups (p < 0.05). Bars represent mean values ± SD.  
 
 204 
 
A notable limitation arising from Study 1 is the lack of information surrounding 
reasons for drop out of pulmonary rehabilitation. This provides a lack of clarity in 
the underlying reasons for poor completion in the frequent exacerbator phenotype 
whereby factors not independently related to this phenotype, such as transport and 
lack of social support, have been previously associated (Hayton et al., 2013; 
Keating, Lee & Holland, 2011). This thesis has adopted a different approach of 
looking at a specific phenotype of COPD which may incorporate some factors that 
have previously been shown to relate to poor completion (e.g. smoking status and 
depression) (Hayton et al., 2013; Keating, Lee & Holland, 2011). Study 1 showed 
patients were matched for smoking status and HADS at baseline but the effects of 
other known factors such as frailty and social deprivation cannot be dismissed 
(Maddocks et al., 2016; Steiner et al., 2017b). Future research, which could be 
undertaken as part of a clinical audit, should establish the factors relating to poor 
completion in frequent exacerbators before considering adopting the phenotyping 
approach in the context of pulmonary rehabilitation.  
The big question that would be left unanswered, and is certainly beyond the scope 
of this thesis, would be how to get more frequent exacerbators of COPD to complete 
pulmonary rehabilitation. Completion of pulmonary rehabilitation is currently a hot 
topic in the COPD community with a magnitude of work left to undertake tackling 
this issue. It would be speculative to make specific recommendations in this area, 
but the available evidence from this thesis does at least suggest that the frequent 
exacerbator phenotype are a prevalent, specific group of patients where a 
consideration of interventions to support completion of pulmonary rehabilitation is 
needed. 
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8.1.2 Maintenance of pulmonary rehabilitation  
Having established the benefits of pulmonary rehabilitation in terms of clinical 
outcomes for both frequent and infrequent exacerbators, Study 5 concluded the 
experimental aspect of this thesis by following up a subset of frequent and 
infrequent exacerbators post-pulmonary rehabilitation. One of the main concerns 
surrounding pulmonary rehabilitation is the lack of effective lifestyle change (e.g. 
increased physical activity levels) in subsets of COPD patients upon completion 
(Mesquita et al., 2017). Maintenance exercise programmes have been shown to be 
beneficial for patients with COPD in maintaining and sometimes even enhancing 
the benefits obtained from the initial course (Jenkins et al., 2018). However, these 
programmes are scarce and there is a distinct general lack of feasible options for 
COPD patients following pulmonary rehabilitation. Furthermore, evidence has also 
suggested that the intensity of physical activity is important to consider when 
looking at the susceptibility to exacerbation (Donaire-Gonzalez et al., 2015). Given 
the newly established findings in the context of this thesis, it was interesting to 
assess physical activity levels in subsets of patients following pulmonary 
rehabilitation. 
There is limited evidence on physical activity in frequent exacerbators, but previous 
evidence has suggested that frequent exacerbators may be less active compared 
to infrequent exacerbators (Valido et al., 2014). Furthermore, frequent exacerbators 
have been seen to have faster declines in physical activity levels (Alahmari et al., 
2014). However, there is still a lack of clarity around physical activity levels in 
frequent exacerbators. Study 5 aimed to assess physical activity characteristics in 
frequent and infrequent exacerbators of COPD following pulmonary rehabilitation.  
Although Study 5 was only a pilot study to inform further larger scale trials, there 
were early indications that physical activity levels were lower in frequent 
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exacerbators following pulmonary rehabilitation. The most notable observations 
were the lower recorded daily step counts and the lesser amount of time spent in 
lower intensity physical activity in frequent exacerbators. This has been raised as a 
potentially important target for reducing incidence of exacerbations in COPD by 
transitioning sedentary activity into light activity, rather than placing too much 
emphasis on trying to transition straight into higher intensity activities (Donaire-
Gonzalez et al., 2015; Mesquita et al., 2017). Placing focus on transitioning into 
higher intensities could be detrimental from the psychological aspect of the patient 
whereby heightened levels of activity may be perceived to exacerbate symptoms 
which could trigger a cascade of events back to physical inactivity (Fischer et al., 
2007; Harris, Hayter & Allender, 2008; Taylor et al., 2007; Young et al., 1999). 
Therefore, placing focus on lighter physical activities in the initial phase, may be 
more beneficial given its ability to reduce exacerbations of COPD (Donaire-
Gonzalez et al., 2015), especially in a population such as frequent exacerbators 
who are more susceptible to exacerbations.  
COPD patients with lower physical activity levels have been suggested to have 
heightened levels of systemic inflammation (Garcia-Aymerich et al., 2009; Waschki 
et al., 2012; Watz et al., 2008). However, despite the differences in physical activity 
levels between frequent and infrequent exacerbators there were no definitive 
differences in inflammation. Given the pilot nature of this study combined with the 
variable inter-patient inflammation (Sapey et al., 2008), further larger scale trials 
are warranted. However, this pilot study provided indications on suitable markers 
for use, placing emphasis on the utility of fibrinogen as a useful biomarker in 
frequent exacerbators. CRP was highly variable, in agreement with previous 
research (Aksu et al., 2013), and this should be considered when designing future 
trials.  
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This pilot study provided useful information on physical activity in the frequent 
exacerbator phenotype following pulmonary rehabilitation which can be used to 
design future research trials monitoring physical activity in this phenotype with the 
aim of developing targeted physical activity interventions to maintain the benefits of 
pulmonary rehabilitation. If this research study was to be undertaken again, a larger 
sample size would be recruited utilising different inclusion/exclusion criteria. For 
example, enlarge the potential recruitment pool by opening recruitment to all COPD 
patients and not just those who took part in Study 2. It would also be insightful to 
have an inflammatory profile timeline with assessment of physical activity and 
inflammation at pre-rehabilitation, post-rehabilitation and then at a designated 
follow-up time point. This would allow for stronger correlations between the effects 
of pulmonary rehabilitation and physical activity on inflammation to see whether 
maintenance or enhancement of physical activity levels following completion of 
pulmonary rehabilitation translates to modulated inflammation compared to those 
who have decline in physical activity levels.  
 Inflammation 
8.2.1 Inflammatory biomarkers of exacerbations and frequent exacerbators 
It has been established that several markers of systemic inflammation increase in 
response to exacerbations (Hurst et al., 2010). Research has also suggested that 
the frequent exacerbator phenotype presents with higher levels of fibrinogen in a 
stable state compared to infrequent exacerbators (Donaldson et al., 2005a). It is 
believed that plasma fibrinogen levels are elevated in COPD due to the systemic 
inflammatory nature of the disease triggered by persistent elevated IL-6 levels 
(Wedzicha et al., 2000). In frequent exacerbators, elevated IL-6 and CRP levels are 
observed in recovery periods following exacerbation contributing to persistent post-
exacerbation inflammation, which may in part explain the higher baseline 
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inflammation (Perrera et al., 2007; Wedzicha et al., 2013). An inability to resolve 
inflammation following exacerbation has been linked to clustering of events which 
may explain why frequent exacerbators are more susceptible to exacerbations 
(Wedzicha et al., 2013).  In Studies 2 & 3, baseline comparisons were made 
between frequent and infrequent exacerbators for markers of inflammation. 
8.2.2 Baseline differences   
8.2.2.1 Fibrinogen 
Fibrinogen has been heavily implicated in the frequent exacerbator phenotype and 
is regarded as an important biomarker for exacerbations (Hurst et al., 2010). In 
Study 2, frequent exacerbators had non-significant, elevations in fibrinogen levels 
compared to infrequent exacerbators. This agrees with previous research which 
demonstrated that fibrinogen is elevated in frequent exacerbators (Donaldson et 
al., 2005a; Hurst et al., 2010). The findings in Study 2 provided further evidence of 
the usefulness of fibrinogen as a marker in frequent exacerbators.  
8.2.2.2 C-reactive protein 
CRP has also been identified as a biomarker for exacerbations (Thomsen et al., 
2013), and is elevated in frequent exacerbators (Perera et al., 2007). The data 
presented in Study 2 provided further suggestions that CRP might be elevated in 
the frequent exacerbator phenotype, however variability was large with the use of 
this marker agreeing with previous findings (Aksu et al., 2013). The variability 
demonstrated when assessing CRP may suggest that this marker is not the most 
suitable for detecting patients more likely to exacerbate, or patients who are 
frequent exacerbators. Whilst CRP may still prove useful as a marker for 
assessment in frequent exacerbators, caution should be urged with the sensitivity 
of CRP to change.  
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8.2.2.3 Total leukocyte and neutrophil counts 
Total leukocyte and neutrophil counts have been commonly observed to be 
elevated during exacerbations as well as in a stable state in frequent exacerbators 
(Hurst et al., 2010). Study 2 provided further evidence that elevated total leukocyte 
and neutrophil counts maybe implicated in the frequent exacerbator phenotype. 
Therefore, total leukocyte and neutrophil counts are worthy markers to assess in 
frequent exacerbators. However, this was not repeated in Study 5 which may 
suggest they are not useful in all settings (e.g. physical activity) as fibrinogen.   
8.2.2.4 Neutrophil activation markers 
It has been acknowledged that neutrophil counts provide little information on 
neutrophil function, whereby the latter may be of more importance when assessing 
inflammation (Oudijk et al., 2005). In COPD, neutrophil activation markers such as 
CD11b & CD66b have been seen to be upregulated whilst CD62L has been shown 
to be downregulated in comparison to healthy subjects (Fortunati et al., 2009). 
However, no comparisons of neutrophil activation, or neutrophil phenotypes have 
been made in frequent and infrequent exacerbators. The data presented in Study 
2 suggested that CD11b and CD66b expression were similar between frequent and 
infrequent exacerbators. Frequent exacerbators did show a tendency towards 
decreased neutrophil CD62L expression at rest, which is indicative of an enhanced 
neutrophil activation (Takahashi et al., 2013). These markers were assessed on 
small subsets of patients and it would be insightful to undertake further 
assessments of these markers, in particular neutrophil CD62L.  
For the first time in COPD, Study 2 undertook phenotyping of neutrophils following 
the recent identification of four neutrophil subsets (mature, immature, suppressive, 
progenitor) (Cortjens et al., 2017). Frequent exacerbators showed a tendency 
towards having a lower percentage of mature neutrophils and a higher percentage 
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of suppressive neutrophils compared to infrequent exacerbators. This would 
suggest that frequent exacerbators have impaired neutrophil phenotype as 
characterised by having larger percentages of neutrophils which suppress 
functional capabilities. Given the promising findings presented, it would be 
worthwhile adopting this neutrophil phenotyping approach further in the context of 
future research in COPD.  
8.2.2.5 Corticosteroid responses 
ICS are a commonly used anti-inflammatory pharmacological therapy in COPD 
(Jen, Rennard & Sin, 2012). However, the effectiveness of ICS has been called into 
question (Ernst, Saad & Suissa, 2015), due to a developed insensitivity in COPD 
patients (Lo Tam Loi et al., 2013). Study 3 was the first study to compare the 
responses of corticosteroid inducible genes following treatment with 
dexamethasone in frequent and infrequent exacerbators. The results suggested 
that frequent exacerbators may have a poorer response to corticosteroid treatment 
compared to infrequent exacerbators, which was further observed in Study 5. This 
would imply that corticosteroids are less effective in frequent exacerbators and may 
in part explain the inability to suppress inflammation and exacerbations in this 
phenotype. These promising findings should be explored further to confirm the 
findings reported in Studies 3 & 5 and develop an understanding of the mechanisms 
for a reduced response to corticosteroid treatment.  
8.2.3 Inflammatory responses to exercise  
Having highlighted the benefits of pulmonary rehabilitation in both frequent and 
infrequent exacerbators, in terms of commonly used clinical outcomes, this thesis 
began to address an underexplored and important area, exercise immunology in 
COPD. It is well established that chronic inflammation is a central component 
underpinning the pathophysiology of COPD (Rovina, Koutsoukou & Koulouris, 
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2013; Stockley, Mannino & Barnes, 2009). However, there are currently a lack of 
treatments aimed at controlling systemic inflammation in COPD (Santos et al., 
2016).  
The concept of exercise immunology in clinical populations is very much in its 
infancy. The anti- and pro-inflammatory effects of exercise in healthy populations 
have led to suggestions that exercise can be used as a treatment to ameliorate the 
symptoms of chronic conditions (Gleeson et al., 2011). These findings, combined 
with the observations of reduced exacerbations with pulmonary rehabilitation 
(Moore et al., 2016), and enhanced effects with continued maintenance exercise 
(Jenkins et al., 2018), provided the rationale for exploring the effects of exercise on 
inflammatory parameters. However, it is important to reiterate that pulmonary 
rehabilitation is not specifically aimed at reducing inflammation in COPD (Evans & 
Steiner, 2018).  Following the poorer completion rates in frequent exacerbators 
(Study 1), and the identification of heightened inflammation in this phenotype 
(Bhowmik et al., 2000; Donaldson et al., 2005a; Perera et al., 2007), it was 
important to assess inflammatory processes in frequent exacerbators and whether 
pulmonary rehabilitation can have similar, or more beneficial, effects in this 
phenotype. This follows a call for a better understanding of the potential unknown 
mechanistic benefits of pulmonary rehabilitation given the limited available 
evidence (Jenkins, Holden & Jones, 2018).  
8.2.3.1 Fibrinogen 
Studies 2 & 4 were the first studies to utilise fibrinogen in the context of exercise 
immunology in COPD. Study 2 showed that pulmonary rehabilitation reduced the 
concentration of fibrinogen. For the first time, this provides the foundations for 
demonstrating anti-inflammatory effects of pulmonary rehabilitation in COPD as 
characterised by a reduction in the resting concentration of fibrinogen. Based on  
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evidence presented in Study 1, it would appear that in frequent exacerbators who 
complete pulmonary rehabilitation, reductions in fibrinogen concentrations occur 
alongside improvements in traditional clinical outcomes (e.g. exercise capacity). 
Study 4 progressed the utilisation of fibrinogen by examining the responses to 
acute exercise. Fibrinogen has been previously observed to be elevated post-
exercise in a healthy population (Montgomery et al., 1996). Study 4 suggested 
that acute exercise does not exacerbate fibrinogen concentrations in patients with 
COPD regardless of exercise training. However, the acute exercise undertaken in 
previous studies of healthy populations was strenuous and prolonged 
(Montgomery et al., 1996), suggesting that higher exercise intensities and 
durations are required to trigger elevations in fibrinogen. The findings presented in 
Study 2 warrant further investigation to provide the mechanistic effects of exercise 
training on reduced fibrinogen concentration and whether these reductions 
correspond to a reduced incidence of exacerbations. Currently, the mechanisms 
underpinning a reduced fibrinogen concentration following exercise training are 
poorly understood. Nevertheless, the previously suggested ability of IL-6 to 
mediate fibrinogen concentrations (Gabay & Kushner, 1999; Mackiewicz et al., 
1991), may in part explain the current findings as IL-6 levels have been shown to 
be decreased following regular exercise training (Fischer, 2006). However, IL-6 
was not measured in this thesis and comparisons could not be drawn between IL-
6 and fibrinogen. Another proposed mechanism is a change in adiposity with 
exercise training (Bodary et al., 2003). Adiposity itself is associated with 
inflammation, and a reduction in adiposity with exercise may lead to a reduction in 
fibrinogen levels with further acute phase reactants also reduced (Panagiotakos et 
al., 2005). The findings in Study 4 also require further research to assess changes 
in fibrinogen concentration in response to acute bouts of exercise varying in 
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duration and intensity, particularly with the interest in the use of interval exercise 
programmes in COPD.  
8.2.3.2 C-reactive protein 
In the context of exercise immunology, CRP has been recognised as a contentious 
marker with a previous review reporting vast conflicting findings (Michigan, Johnson 
& Master, 2011). A more recent meta-analysis has suggested that exercise is 
effective at reducing CRP concentration regardless of age (Fedewa, Hathaway & 
Ward-Ritacco, 2017). Previous studies have assessed CRP responses to 
pulmonary rehabilitation (Canavan et al., 2007; Sciriha et al., 2017) and an isolated 
acute bout of exercise (Spruit et al., 2007). Findings from these studies showed no 
effect which were supported by data presented in this thesis (Studies 2 & 4). It is 
also important to note that exercise responses of CRP in healthy populations has 
been conflicting with research suggesting that reductions in CRP following exercise 
training are only present when accompanied by a significant reduction of body 
weight or body fat (Choi, Joseph, Pilote, 2013).  
This thesis poses the question of the suitability for assessment of CRP in the 
context of exercise in COPD. Studies 2 & 4 demonstrated the degree of variability 
between COPD patients in CRP concentrations further echoing issues found in 
previous research (Aksu et al., 2013). This was further confirmed in Study 5 where 
a pilot study in a post-pulmonary rehabilitation setting demonstrated the variability 
of CRP both between and within patients over time. Hence, based on the available 
evidence to date, systemic CRP may be of limited use in understanding the 
relationship between exercise, inflammation and exacerbations.  
8.2.3.3 Total leukocytes and neutrophil counts 
Total leukocyte and neutrophil count responses to exercise have been more widely 
explored in a healthy population (Pyne, 1994; Walsh et al., 2011), with limited 
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experimental evidence available in COPD (Jenkins et al., 2015; van Helvoort et al., 
2005). A position statement suggested that exercise training programmes may 
need to be prolonged (Walsh et al., 2011), to have any effect on resting leukocyte 
and neutrophil counts and that an 8-week programme, similar in duration to that of 
previous research (Canavan et al., 2007; Sciriha et al., 2017), would not be 
sufficient enough to induce changes in these parameters. However, it was 
acknowledged that the COPD population suffer from chronic inflammation, in 
particular frequent exacerbators, whereby such parameters are significantly 
elevated compared to healthy individuals therefore creating a larger scope for 
reductions in these markers with exercise training. Interestingly, Study 2 for the first 
time showed that frequent exacerbators can experience significant reductions in 
total leukocyte and neutrophil counts. This is a novel finding suggesting that 
pulmonary rehabilitation has the potential to reduce differences in parameters of 
inflammation between frequent and infrequent exacerbators which may partly 
explain the reduction in risk of exacerbations with pulmonary rehabilitation (Moore 
et al., 2016). Study 4 highlighted the transient increases in circulating total leukocyte 
count and neutrophil count in response to acute exercise in COPD irrespective of 
training status (i.e. accustomed to exercise). This is in line with a large body of 
evidence in healthy individuals and hence simply reflects a typical physiological 
response to an acute stressor such as exercise. These transient changes are 
predominantly thought to be due to the demargination of cells from endothelial 
tissue or an inflammatory response to exercise-induced muscle damage (Brown et 
al., 2015; Pyne, 1994). Further research is required to determine the clinical 
implications of this modulation of inflammation. 
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8.2.3.4 Neutrophil activation markers  
Study 2 & 4 adopted the novel approach of assessing responses of these neutrophil 
activation markers in response to exercise in frequent and infrequent exacerbators. 
Study 2 did not find any significant effects of pulmonary rehabilitation on neutrophil 
markers, but there was a tendency towards a significant increase in CD62L at the 
end of pulmonary rehabilitation. Based on previous evidence of the role of CD62L, 
it is conceivable to suggest that reduced neutrophil activation characterised by an 
increase in neutrophil CD62L expression (or rather a decreased shedding from the 
cell surface) is again indicative of an anti-inflammatory effect (Takahashi et al., 
2013). It is also important to note that frequent exacerbators had an improvement 
in CD62L expression to the baseline levels observed in infrequent exacerbators 
suggesting a potential role of pulmonary rehabilitation in restoring inflammatory 
markers to ‘normal’ levels. In contrast, neutrophil CD11b and CD66b, which are 
upregulated when neutrophils are activated (Fortunati et al., 2009), were not 
affected further showing that pulmonary rehabilitation does not exacerbate resting 
inflammation. Study 4 suggested that CD62L was significantly decreased following 
an acute exercise bout, suggesting increased neutrophil activation (Takahashi et 
al., 2013), at the beginning of pulmonary rehabilitation in frequent exacerbators 
only, providing indications of differing immune responses to acute exercise between 
frequent and infrequent exacerbators. Non-significant increases in CD11b & CD66b 
were also observed post-exercise in frequent exacerbators further adding to the 
notion of an increased neutrophil activation post-exercise.  
The utilisation of flow cytometry for the measuring of neutrophil activation came with 
numerous complications which is reflected by the small sample size. Firstly, flow 
cytometers comprise technical equipment including lasers and fluidics for the 
analysis of cellular populations using a high throughput (Ibrahim & van den Engh, 
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2007). Due to the multiple dependents (e.g. lasers, fluidics, vacuum) involved in the 
analysis of these cellular populations, the machine used for analysis in this thesis 
was susceptible to breakdown. Such limitations impacted on the sample size. 
Secondly, and a point that has wider significant importance were the issues 
surrounding the lack of expression of CD16b on neutrophils in the populations 
studied in this thesis (Figure 8.2). CD16 has been, and still is, considered a valid 
and important marker for identifying neutrophils (Lakschevitz et al., 2016). 
Manufacturers highly recommend the use of CD16 for the identification of 
neutrophils. There is very little in the literature to explain the phenomenon observed 
in subsets of COPD patients which was ruled out as a disease specific effect when 
similar observations were made in healthy smokers and healthy never smokers. 
Ultimately, this led to the withdrawal of these techniques for the follow-up study 
(Study 5). The assessment of literature suggested two potential reasons for the lack 
of expression of CD16b. One paper suggested a very rare hereditary deficiency of 
CD16 which could be due to genetic defects (Wagner & Hansch, 2004). Given the 
rarity, the current observations in this thesis would not plausibly align with these 
suggestions. A second observation was that elevated levels of ADAM17 can lead 
to the shedding of CD16b on neutrophils (Jing et al., 2015). ADAM17 has been 
suggested to be elevated in COPD (Stolarczyk & Scholte, 2018), potentially 
providing an area worthy of investigation, however similar observations in healthy 
comparators somewhat effect the clarity of this. This phenomenon of low CD16b 
was discussed with many leading experts in neutrophil biology with no conclusions 
for the underlying causes being reached. However, subsequent searching of 
unpublished sources (e.g. public research forums such as researchgate.net) 
identified that this issue is more widespread with several academics suggesting that 
CD16b may not be an advisable marker for the consistent identification of 
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neutrophils. Therefore, research or guidance is required around the suitability of 
CD16b as a marker to assess neutrophils. Studies 2 & 4 did suggest that neutrophil 
CD62L was a promising marker for further investigations with exercise in COPD. 
However, preliminary evidence presented in studies 2 & 4 suggest that there are 
minimal changes in neutrophil expression of CD11b and CD66b in the context of 
pulmonary rehabilitation. 
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Figure 8.2. Example of a COPD patient pre- (A) and post-rehabilitation (B) with 
neutrophils identifiable by CD16bhigh. Another example of a COPD patient pre- (C) 
and post-rehabilitation (D) with CD16blow neutrophils. These examples were from 
analyses performed on the same day (for pre- and post-rehabilitation) utilising the 
same batch of antibodies for the given day.  
 
8.2.3.5 Neutrophil maturity 
The utilisation of the aforementioned neutrophil activation markers also allowed for 
the novel assessment of neutrophil maturity. This approach was adopted based on 
previous research identifying neutrophil subsets (Cortjens et al., 2017). This 
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approach was exploratory in nature and allowed for further insight into neutrophil 
dynamics and responses to exercise. For the first time, Studies 2 & 4 demonstrated 
the impact that acute and chronic exercise can have on neutrophil maturity in 
patients with COPD. In Study 2, pulmonary rehabilitation was shown to reduce the 
amount of progenitor neutrophils, a subset which is very immature in its function. 
Study 4 showed increases in immature neutrophils following an acute bout of 
exercise which has been previously observed with acute exercise in healthy 
individuals (Risoy et al., 2003). This further shows that exercise, in the context of 
pulmonary rehabilitation, has the potential to alter neutrophils in a similar pattern to 
healthy individuals. However, given the inflammatory state commonly observed 
with COPD, further research is required to confirm these responses with exercise, 
determining the clinical implications of such changes. Studies 2 & 4 demonstrate 
the potential of adopting the neutrophil phenotyping approach in exercise 
immunology.  
8.2.3.6 Corticosteroid responses 
When assessing immune functions in response to exercise, it is important to assess 
both pro- and anti-inflammatory mechanisms whereby exercise is considered to 
exert effects on both (Flynn, McFarlin & Markofski, 2007). It is important to establish 
a balance between pro- and anti-inflammatory responses to fully understand the 
effects of exercise on inflammation.  
With this is mind, Study 3 adopted an exploratory and novel approach of assessing 
responses of anti-inflammatory genes. This approach involved the assessment of 
gene expression in PBMC’s in response to treatment with a corticosteroid, a 
commonly used therapy in the treatment and management of COPD (Park, Man & 
Sin, 2012). The utilisation of this approach has never been adopted in the context 
of pulmonary rehabilitation and was based on previous research using an 
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established experimental model of assessing the effectiveness of corticosteroids in 
PBMC’s and epithelial cells of COPD patients (Kelly et al., 2012; Newton & Holden, 
2007). Study 3 demonstrated the potential effects that pulmonary rehabilitation may 
have on enhancing the action of corticosteroids in COPD by upregulating anti-
inflammatory genes. The effects of non-pharmacological interventions, such as 
pulmonary rehabilitation, on the effectiveness of pharmacological treatments is an 
area vastly underexplored in all populations. The work undertaken on 
pharmacological therapies in pulmonary rehabilitation mainly revolves around 
bronchodilators whereby the use of these devices has been shown to assist with 
exercise training, allowing patients to train at higher exercise intensities (ZuWallack, 
2008), and reduce dyspnoea during rehabilitation programmes (Maltais et al., 
2005). Therefore, there is very little understanding with regards to the mechanistic 
effects on potentially enhancing the effects of pharmacological treatments. The 
findings presented in Study 3 should be investigated further utilising different 
cellular populations (e.g. airway epithelial cells) which may represent a more 
meaningful model of response to inhaled treatments (Ito et al., 2000). Future 
research should also assess a whole range of genes related to inflammatory 
mechanisms in COPD to determine further potential unknown anti-inflammatory 
effects of pulmonary rehabilitation, but these early findings certainly hold a lot of 
promise. 
 Daily respiratory symptoms 
Study 1 demonstrated the ability of pulmonary rehabilitation to reduce daily 
respiratory symptoms (E-RS™) and recall of respiratory symptoms (CRQ). Within 
Study 4, attempts were also made to assess inflammatory responses to acute 
exercise alongside respiratory symptom monitoring to provide insights into the 
clinical impact of acute inflammatory responses to exercise in COPD. In healthy 
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populations, acute bouts of strenuous exercise have been observed to trigger 
elevations in respiratory symptoms (Walsh et al., 2011). In frequent and infrequent 
exacerbators of COPD, no changes were observed with respiratory symptoms 
following commencement of pulmonary rehabilitation, despite elevations in 
inflammatory markers following exercise. In fact, the respiratory symptoms almost 
appeared to improve following commencement of the pulmonary rehabilitation 
programme. This is of potential benefit as it could be argued that if elevated total 
leukocyte and neutrophil counts following exercise corresponded to increased 
respiratory symptoms, then this could increase the likelihood of a patient suffering 
from an exacerbation, which is a common factor for poor completion of pulmonary 
rehabilitation (Keating, Lee & Holland, 2011). These findings also appear to 
disagree with qualitative studies whereby patients have reported that they avoid 
exercise due to a fear of worsening their dyspnoea symptoms  (Fischer et al., 2007; 
Harris, Hayter & Allender, 2008; Taylor et al., 2007; Young et al., 1999). However, 
the beginning of pulmonary rehabilitation tends to be of a lower intensity of exercise 
to ‘ease’ COPD patients into the programme, potentially explaining the findings 
presented in Study 4. Future research should make attempts to assess respiratory 
symptoms, over a period of days following a controlled acute bout of exercise, 
alongside inflammatory responses to determine the clinical relevance of short-term 
elevations in inflammatory markers.  
 Implications 
8.4.1 Implications for practice 
The overall aim of this thesis was to examine the role of the frequent exacerbator 
phenotype in pulmonary rehabilitation. The evidence presented in this thesis show 
that non-pharmacological treatments such as pulmonary rehabilitation have an 
important role in the COPD frequent exacerbator phenotype. This is characterised 
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by significant improvements in traditional clinical outcomes with pulmonary 
rehabilitation accompanied by reductions in inflammation. Some inflammatory 
mediators and clinical outcomes were also observed to be significantly improved in 
infrequent exacerbators showing that pulmonary rehabilitation should be inclusive 
to all COPD patients. However, the lower completion rates in frequent exacerbators 
is concerning and efforts should be made to target interventions towards tackling 
this.  
The findings presented throughout this thesis may also result in the consideration 
of how pulmonary rehabilitation is implemented into COPD treatment 
pathways/algorithm. As expected, frequent exacerbators presenting to pulmonary 
rehabilitation met the criteria to be defined as GOLD grade D. Currently the 
treatment algorithm suggests triple therapy (LABA/ICS and LAMA) as a first-choice 
therapy for COPD patients in this category. Alternative options include combination 
therapies such as: LABA/LAMA, LABA/ICS and PDE4 inhibitor, or LAMA and PDE4 
inhibitor (GOLD, 2019). Also, the majority of infrequent exacerbators presenting to 
pulmonary rehabilitation met the GOLD B criteria. Currently treatment guidelines 
suggest that the first line of treatment for these patients should be LABA or LAMA. 
The alternative option is the use of a combination of LABA and LAMA (GOLD, 
2019). The NICE, (2018) guidelines suggest that pulmonary rehabilitation is a 
fundamental part of care and should be offered to patients who are breathless 
before starting inhaled therapies. The results presented in this thesis support these 
guidelines and suggest that anti-inflammatory benefits can be obtained with 
pulmonary rehabilitation supporting the need to repeat pulmonary rehabilitation in 
those who are most breathless and have recurrent exacerbations. This is 
particularly apparent in the GOLD D category, where anti-inflammatory treatments 
are considered to only be obtained from pharmacological therapies.  
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This thesis (Studies 1-4) was centred around a ‘real-world’ pulmonary rehabilitation 
intervention delivered to COPD patients as part of standard care. This intervention 
was not manipulated in any way by the design of these studies meaning that the 
findings represent evidence based on a standard clinical intervention which is 
commonly delivered as part of standard care. This has the potential to be of clinical 
relevance as opposed to attempting to apply findings from a study mimicking 
pulmonary rehabilitation but does not reflect a ‘real world’ setting. Resultantly, a 
wide variation of COPD patients, in terms of disease severity, were included in the 
studies comprising the make-up of this thesis meaning the findings are 
generalisable to other UK pulmonary rehabilitation services. Despite this, these 
studies did implement exclusion criteria to attempt to control for potential 
confounders suggest as other underlying inflammatory diseases which could 
influence the outcomes of the thesis.  
In the literature review, a systematic review was also performed which has 
implications for practice. The findings of the review build upon those proposed by 
Moore et al. (2016) where pulmonary rehabilitation was shown to reduce the risk of 
hospitalisation. The review demonstrated the role supervised maintenance exercise 
programmes following pulmonary rehabilitation can have on enhancing the effect 
of reduced hospital admissions and exacerbations of COPD compared to that of 
pulmonary rehabilitation alone (Jenkins et al., 2018). These findings highlight the 
importance of providing/promoting longitudinal supervised exercise programmes 
for patients with COPD and efforts should be made to provide this as an effective 
way of exacerbation/hospital admission avoidance.  
Practical guidance for the management of frequent exacerbators in the pulmonary 
rehabilitation setting –  
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• Pulmonary rehabilitation is equally, if not more important to frequent 
exacerbators and completion should be encouraged 
• Ensure optimisation of pharmacological therapies and consider repeating 
pulmonary rehabilitation  
• Reiterate the benefits of pulmonary rehabilitation in the management of 
COPD and exacerbations  
• Improve self-management pathways and utilise physical activity 
interventions to encourage frequent exacerbators to reduce sedentary 
behaviours  
• Provide/promote supervised maintenance options for COPD patients to 
continue exercising following pulmonary rehabilitation as an effective way of 
reducing the risk of exacerbation/hospital admission  
8.4.2 Implications for research  
The experimental evidence presented in this thesis brings numerous implications 
for consideration in future research. In Study 1, although completion rates were 
found to be significantly lower in frequent exacerbators of COPD, larger sample 
sizes are commonly required to provide confidence in this effect. Therefore, future 
larger scale studies, or audits of services, are required to confirm these findings. 
Confirmation of these findings could have significant implications on research and 
assessing the various phenotypes presented in pulmonary rehabilitation. The scope 
of this would result in research attempting to tailor interventions to specific subsets 
of patients (e.g. frequent exacerbators) to assist in completion.  
Secondly, Studies 2 & 3 highlight the potential anti-inflammatory benefits, in terms 
of modulation of both pro- and anti-inflammatory mediators, of pulmonary 
rehabilitation on resting systemic inflammation (Table 8.1). With future research, 
the clinical impact of this could be of huge significance and have the potential to 
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change how pulmonary rehabilitation is marketed, which could indirectly have 
knock-on effects for completion rates. For example, if the efficacy and mechanisms 
of  pulmonary rehabilitation on exacerbations or hospitalisations and enhancing 
pharmacological therapy are confirmed, this might be deemed a more attractive 
therapy for COPD patients and commissioners. Especially given that a recent paper 
found that COPD patients valued exacerbations as the most important outcome 
(Zhang et al., 2018). However, trials assessing inflammatory responses in the 
airways are also warranted to support observations seen in the systemic 
compartment. 
It is too early to interpret the clinical effects of these systemic inflammatory 
responses to exercise in COPD. However, Study 4 was the first study in COPD to 
attempt the monitoring of daily respiratory symptoms and inflammatory responses 
to exercise in COPD (Table 8.1). This highlighted that respiratory symptoms did not 
appear to increase in response to inflammation with exercise. It has been 
suggested that exercise training may reduce the acute inflammatory response to 
exercise (Turton et al., 2002). This was not observed in Study 4 with similar 
inflammatory responses to exercise at the end of pulmonary rehabilitation 
compared to beginning. It is important to note that the exercise regimens were not 
controlled, and the progressive nature of the pulmonary rehabilitation programme 
may in part explain the lack of reduction in the acute inflammatory response to 
exercise. Future trials should assess acute inflammatory responses to exercise, in 
both the airway and systemic compartments, in COPD in a more controlled manner, 
but it is important to not undermine the evidence presented here which represents 
‘real-world’ evidence within the context of a usual pulmonary rehabilitation 
programme. The continual assessment of respiratory symptoms alongside this is 
also encouraged if a correlation is to be established between acute inflammatory 
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responses to exercise and exacerbations. Establishing these links are important 
because if acute inflammatory responses to exercise in COPD are linked to 
exacerbations, then it will provide further emphasis on the decisions regarding the 
intensity of exercise used in pulmonary rehabilitation programmes. It is also 
important to note that the evidence presented in this thesis assessed markers of 
systemic inflammation, which are considered surrogate markers of exacerbation 
risk, as a key mechanism of the frequent exacerbator phenotype. However, whilst 
beyond the scope of this thesis, it would be prudent for future research to assess 
other mechanisms such as susceptibility to viral infections. 
Table 8.1. Summary of inflammatory responses to chronic and acute exercise 
Parameter COPD patients Frequent Exacerbators 
Chronic Acute Chronic  Acute 
Fibrinogen ↓ - ↓ - 
CRP - - - - 
Total leukocyte count - ↑ ↓ ↑ 
Total neutrophil count - ↑ ↓ - 
Neutrophil CD11b - - - - 
Neutrophil CD62L - - - ↓ 
Neutrophil CD66b - - - - 
Mature neutrophils - - - - 
Immature neutrophils - ↑ - ↑ 
Suppressive neutrophils - - - - 
Progenitor neutrophils ↓ - ↓ - 
MKP-1 - N/A - N/A 
GILZ - N/A - N/A 
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Finally, Study 5 further highlighted the ever-increasing topic of interest in terms of 
the profile of COPD patients following completion of pulmonary rehabilitation. This 
pilot study showed that frequent exacerbators may adopt more inactive lifestyle 
habits. Despite this, it was unclear whether these inactive habits corresponded to 
an increase in systemic inflammation. There is a need for future research to assess 
physical activity in frequent exacerbators of COPD alongside inflammatory 
parameters suggested in this pilot study. This will help to determine whether 
frequent exacerbators need targeting with physical activity interventions. 
Research priorities for exercise and inflammation in frequent and infrequent 
exacerbators of COPD –  
• A large prospective cohort study of pulmonary rehabilitation compliance in 
frequent and infrequent exacerbators of COPD without limiting inclusion 
criteria (e.g. other co-morbid respiratory and/or inflammatory conditions). 
• Designing and developing interventions tailored to help frequent 
exacerbators complete pulmonary rehabilitation. 
• Further explore the effects of exercise programmes on systemic 
inflammation in COPD, utilising biomarkers such as fibrinogen, total 
leukocyte counts, neutrophil counts, neutrophil CD62L expression, and 
neutrophil phenotypes (mature, immature, suppressive, progenitor).  
• Examine the effects of acute and chronic exercise on airway inflammation in 
comparison to systemic observations. 
• Assess acute inflammatory responses to controlled exercise bouts in COPD, 
utilising total leukocyte and neutrophil counts, and determine whether 
progressive exercise training programmes (e.g. pulmonary rehabilitation) 
can dampen any acute inflammatory responses. It would be prudent to 
investigate daily respiratory symptoms alongside these inflammatory 
 227 
 
responses to draw correlations between exercise-induced elevations in 
markers and patient reported symptoms.  
• Further explore the effects (acute and chronic) of exercise training in COPD 
on the effectiveness of corticosteroids and other pharmacological  therapies 
purported to have direct or synergistic effects on inflammation (e.g. LABA) 
utilising different genes (e.g. RGS family) and assessments at a protein level. 
• Design interventions to target daily physical activity (e.g. step counts and 
time spent in light activity) and sedentary behaviour in frequent 
exacerbators.  
 Summary  
In conclusion, this thesis provides convincing evidence that pulmonary 
rehabilitation provides clinical benefits to COPD patients with frequent 
exacerbations but they may require improved support in order to complete 
programmes or to be physically active post-rehabilitation. This thesis also provides 
the proof of concept that pulmonary rehabilitation can have anti-inflammatory 
effects in these patients. However, more research is needed to fully understand the 
frequent exacerbator phenotype and how inflammatory responses to exercise 
relate to respiratory symptoms and exacerbation frequency. 
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Appendices 
Appendix A: Systematic Review Protocol 
Efficacy of supervised exercise following pulmonary 
rehabilitation on health status 
Alex Jenkins, Holly Gowler, Ffion Curtis, Arwel Jones 
Review question(s) 
To assess the efficacy of continued supervised exercise training following 
completion of pulmonary rehabilitation on COPD-related health status  
Searches 
Searches of systematic review databases will be conducted; Cochrane, DARE 
and PROSPERO. The following databases will be searched for completed and 
ongoing trials: MEDLINE, EMBASE, CINAHL, Cochrane Central Register of 
Controlled Trials (CENTRAL), Web of Science, ClinicalTrials.gov, PEDro, and 
Current Controlled Trials. We will also search the British Library (ETHOS) and 
Conference Papers Index as well as other library services within our institution for 
obtaining non-published data. Database searches will impose a restriction on 
articles translated into English, with searches encompassing all time points from 
inception to present.  
Key search terms to be used to search trials registers and databases are terms 
related to chronic obstructive pulmonary disease (COPD), pulmonary 
rehabilitation, and exercise maintenance. Database searches are to be 
supplemented with internet searches (e.g. Google Scholar), contact with study 
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authors, experts and research groups, forward and backward citation tracking 
from included studies and systematic reviews.   
Types of study to be included 
Papers will only be included if they adhere to the following study designs: 
Randomised Controlled Trials, Cluster Randomised Controlled Trials, Cross-over 
randomised trials (data up to point of cross-over only) or Quasi-randomised 
Controlled Trials.  
Condition or domain being studied  
Chronic Obstructive Pulmonary disease (COPD) is defined as a preventable and 
treatable disease characterised by airflow limitation that is not fully reversible 
(GOLD, 2010). COPD is now the third leading cause of mortality worldwide 
(British Thoracic Society, 2006). The main cause for hospitalisations in COPD is 
exacerbations of respiratory symptoms (World Health Organisation, 2012).  
Participants / population   
Patients who have completed pulmonary rehabilitation and taken part in 
supervised exercise training. 
Intervention(s), exposure(s) 
Trials to be included will have patients randomised to a supervised exercise 
training programme or any other form of care/non-exercise pathway following 
pulmonary rehabilitation.   
Supervised exercise training will be defined as “supervised and prescribed 
exercise by an individual not partaking in the intervention”. 
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Exercise is defined as “a type of physical activity consisting of planned, structured 
and repetitive bodily movement done to improve or maintain one or more 
components of physical fitness. (Caspersen, Powell, & Christenson, 1985).”   
Comparator(s) / control  
Concurrent control group receiving any care post-pulmonary rehabilitation.  
Outcome(s) 
Primary outcomes 
Hospital admissions (respiratory cause) 
Exacerbations requiring treatment with short course of antibiotics or oral 
corticosteroids or both 
Mortality 
Secondary outcomes 
Length of hospital stay 
All-cause hospital admissions 
Outpatient visits 
GP visits 
Data extraction, (selection and coding)  
Selection of studies  
Titles and abstracts will be independently screened by two reviewers in line with 
the inclusion criteria. Full text papers will be requested and assessed by two 
reviewers when studies are not excluded based on title or abstract. Any 
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discrepancies between the two reviewers will be resolved with the inclusion of a 
third reviewer.  
Data extraction and management 
Data extraction will take place using an adapted Cochrane Data Extraction 
Template including elements adapted from a Taxonomy form used previously 
(Lamb et al., 2011) for randomised controlled trials. Data extraction will be 
undertaken by one reviewer for each study, with cross checking taking place via a 
second reviewer. Papers will be compiled using Endnote referencing software. 
The following study characteristics will be extracted: 
Methods: Date/title of study, aim of study, study design, unit of allocation, duration 
of study, duration of intervention, primary outcome, other outcomes, and funding 
source.  
Participants: Population description, demographics, inclusion criteria, exclusion 
criteria, method of recruitment of participants, total number randomised, clusters, 
baseline imbalances, withdrawal and exclusions, subgroups reported.  
Intervention: Group name, number randomised to group-sample size, description, 
venue numbers/locations, duration and frequency of maintenance exercise 
training period, delivery, providers, co-interventions, compliance/adherence, and 
defined parameters of usual care. 
Comparison: Usual care defined as a referral back to the patient’s primary care 
provider for continued medical care with recommendations for post-pulmonary 
rehabilitation self-management at home.  
Outcomes: Outcome name, outcome type, outcome definition, person 
measuring/reporting, unit of measurement, scales (upper and lower limits), is 
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outcome/tool validated?, imputation of missing data, assumed risk estimate, level 
of power.  
One reviewer will independently analyse the extracted data using RevMan and 
then the data will be cross-checked by a second reviewer for accuracy purposes, 
yet again if there are any discrepancies in the reported data, a third party will be 
involved.  
Risk of bias (quality) assessment 
Assessment of risk bias in included studies 
Two reviewers will independently assess risk of bias in included studies using the 
Cochrane Risk of Bias Table with the following domains: Random sequence 
generation, allocation concealment, blinding of participants, blinding of assessor, 
blinding of personnel, incomplete outcome data, selective outcome reporting, and 
other bias. These domains will be categorised as a high, low or unclear risk of 
bias. The Cochrane Risk of Bias assessment tool is designed to assess studies 
for accuracy of key quality issues such as randomisation, blinding and follow up. 
Each domain will be classified as adequate, unclear or inadequate with risk of 
bias for each study to be classified using the following criteria: (a) low risk of bias 
(all criteria are deemed adequate), (b) moderate risk of bias (one criterion graded 
as inadequate or two graded as unclear), and (c) high risk of bias (more than one 
criterion is deemed inadequate, or more than two graded unclear). Disagreements 
between reviewers over risk of bias in particular studies will be resolved through 
further discussion with the potential use of a third party. As it is not possible to 
blind participants to this intervention, the issue of blinding will only apply to 
outcome assessors and personnel. 
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Strategy for data synthesis 
We will create narrative synthesis of the findings from the included studies, 
structured around the type of intervention, target population characteristics, type 
of outcome and intervention content. Due to a range of different outcomes 
measured and reported across the small amount of existing trials there may be a 
limited scope for meta-analysis. However, where studies overlap in terms of 
outcome measures, we will bring these data together using a random-effects 
meta-analysis, with mean differences for continuous outcomes, rates as rate 
ratios, and dichotomous data as risk ratios. Data will not be pooled if 
heterogeneity is moderate (I2 statistic greater than 30%). If heterogeneity is 
identified, potential causes will be explored (e.g. clinical and/or methodological 
diversity). We will try to clarify heterogeneity via subgroup analysis, but if it cannot 
be explained (i.e. if there is considerable variation in the results, particularly 
inconsistency in the direction of the effect), then a narrative approach will be taken 
and a meta-analysis will not be performed.  
Sensitivity analyses will be carried out on the included studies displaying a low 
risk of bias in accordance with the Cochrane Risk of Bias Table.  
We plan to carry out subgroup analysis on the primary outcomes using the 
following: 
• Supervised exercise alone versus supervised exercise and education 
• Outpatient exercise vs. community exercise 
• Frequency of exercise: <2 per week vs. ≥ 2 per week 
• Supervised exercise compliance  
• Impact of supervisor (e.g. qualifications) 
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Dissemination plans 
This review is to be published in a peer-reviewed journal.  
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Appendix B: Systematic Review Supplementary Materials 
 
Figure S1. Trial-level data, effect estimates and forest plot of comparison for the 
risk of all-cause hospital admission. 
 
Figure S2. Trial-level data, effect estimates and forest plot of comparison for the 
risk of GP visits. 
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Table S1. Example search strategy of a bibliographic database (CINAHL) 
 Search Term Field 
1 Lung diseases, obstructive MH (explode) 
2 Lung diseases, interstitial MH (explode) 
3 Pulmonary fibrosis MH (explode) 
4 COPD TX 
5 Chronic obstructive pulmonary disease TX 
6 COAD TX 
7 COBD TX 
8 emphysem* TX 
9 chronic bronchitis TX 
10 cystic fibrosis TX 
11 Pneumoconiosis TX 
12 Sarcoidosis TX 
13 Asthma TX 
14 Bronchiectasis TX 
15 Alveolitis TX 
16 Histiocytosis TX 
17 Granulomatosis TX 
18 Bagassosis TX 
19 asbestosis OR byssinosis OR siderosis OR silicosis OR berylliosis OR 
anthracosilicosis   
TX 
20 Scleroderma TX 
21 1 OR 2 OR 3 OR 4 OR 5 OR 6 OR 7 OR 8 OR 9 OR 10 OR 11 OR 12 OR 13 OR 
14 OR 15 OR 16 OR 17 OR 18 OR 19 OR 20 
 
22 Exercise therapy MH (explode) 
23 Activities of Daily Living MH (explode) 
24 Rehabilitation research MH  
25 Physical and rehabilitation medicine  MH (explode) 
26 Physical fitness MH 
27 Exercise Movement Techniques MH (explode) 
28 Telerehabilitation MH 
29 Rehabilitation within 2 of: pulmonary OR respiratory OR physical OR early TI, AB 
30 exercis* within 3 of: supervi* OR training OR maintenance OR program* TI, AB 
31 physical activit* TI, AB 
32 Maintenance within 2 of: intervention OR group OR exercise OR program* OR 
training 
TI, AB 
33 22 OR 23 OR 24 OR 25 OR 26 OR 27 OR 28 OR 29 OR 30 OR 31 OR 32  
34 Randomised TI, AB 
35 Randomized TI, AB 
36 Randomly TI, AB 
37 Trial TI, AB 
38 Controlled TI, AB 
39 34 OR 35 OR 36 OR 37 OR 38  
40 21 AND 33 AND 39  
Searches encompassed other chronic lung conditions as part of a wider review. 
 
